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SUMMARY
Forty-two non-diabetics whose glycated haemoglobin levels could 
not be explained by their levels of fasting glycaemia or glucose 
tolerance were identified as part of the Islington Diabetes Survey. 
Mean glycated haemoglobin levels that were high relative to their 
blood glucose levels (HIGH GLYCATORS) were found in 22 subjects 
whilst 20 subjects had low relative levels (LOW GLYCATORS).
A repeat glucose tolerance test in 13 of the 42 subjects (7 high and 
6 low glycators) showed that they remained categorised in the two 
groups four years after the discrepancy was identified. Mean blood 
glucose levels calculated from two 5-point d iurnal profiles also 
failed to explain the glycated haemoglobin levels in the two groups.
Further b iochem ica l and haem ato log ica l tests  revealed tha t 
glycated albumin showed a better relationship with blood glucose 
levels than did glycated haemoglobin. Intra-erythrocyte glucose 
concentrations were significantly lower than the plasma glucose in 
the low g lyca to rs , w h ils t the leve ls  of e ry th rocy te  2,3- 
d ip h o sp h o g lyce ra te  (a known ca ta lys t of g lyca tio n ) were 
sign ificantly higher in the high glycators. These findings may 
partially explain the original discovery of low and high glycators.
The effects of high fibre/low glucose and high glucose/low fibre 
diets on glycated proteins were studied in normal subjects. Only 
glycated albumin levels changed significantly, probably due to small 
changes in plasma glucose occurring on each diet, which were not 
mirrored by similar changes in the erythrocyte.
When another group of normal subjects received 1 g vitamin C daily 
for three months, s ignificant reductions in glycated albumin and 
glycated haemoglobin were observed, with the former being reduced 
to a greater extent. This suggests that vitamin C has the potential 
of being used therapeutically to reduce glycation.
In conclusion, for normal subjects, glycated albumin is a more 
re liab le  ind ica to r of b lood g lucose con tro l than g lycated 
haemoglobin.
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C H A P T E R  1  
I N T R O D U C T I O N
1
1.1. GLYCATION (GLYCOSYLATION)
G lycation is a non-enzym ic post-trans la tiona l m odification of 
p rote ins which may be re levant not only to the long-term  
complications occurring in diabetes meliitus (Vlassara et ai., 1986), 
but also to the normal process of ageing (Cerami et al., 1987).
1.2. DISCOVERY OF GLYCATED PROTEINS
Haemoglobin was the first protein- to be discovered to undergo the 
process of glycation. In 1955 Kunkel and Wallenius reported the 
presence of both slow-m oving (HbA2 ) and fast moving minor 
fractions when haemoglobin samples were subjected to starch-gel 
electrophoresis. Aiien, Schroeder and Balog in 1958 employed a 
cation-exchange column to separate from HbA a heterogeneous fast 
moving fraction (HbA-i). By modifying the. conditions, the fast 
fraction was resolved into three minor components, H b A ia, HbAi b 
and HbAic- HbA-|C was found to be present in the greatest relative 
amount, comprising 5 - 7% of the total haemoglobin.
The independent discovery that HbA-j (in particular HbA-ic) was 
increased two to three fold in diabetic subjects (Huisman and Dozy, 
1962; Rahbar et al., 1969) led to extensive investigations into 
establishing the structure, biosynthesis and kinetics of formation of 
H bA ic and the other minor components.
1.3. STRUCTURAL ANALYSIS OF H b A i ^ ANP THE OTHER MINOR 
COMPONENTS
In 1966 Holmquist and Schroeder demonstrated that the a -a m in o  
groups of the valine residues of the (3-chains of H bA ic were blocked 
by a small molecule held by a Schiff base or sim ilar linkage. 
Subsequently, Bookchin and Gallop (1968) identified these as being 
hexoses and showed that two were bound per tetramer. Bunn et al., 
(1975) showed that glucose reacted with the amino terminal valines 
of the (3-chains in H b A ic . Periodate studies dem onstra ted a 
ketoamine linkage rather than an aldim ine linkage between the 
glucose and the amino group. They proposed a two-step reaction 
scheme for the formation of H b A ic (see Fig. 1.1). Initially a Schiff 
base is formed (aldimine) between glucose and the (3-te rm ina i 
valines followed by an Amadori rearrangement (Hodge, 1955) to form
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a ketoam ine. Further studies have confirm ed an Am adori 
rearrangem ent occurs subsequent to S ch iff base fo rm ation 
(Fluckiger and Winterhalter, 1976; Koenig et ah, 1977; Bunn et al., 
1979).
As well as the a-amino groups of the (3-chains, other amino groups 
of the haemoglobin molecule have been shown to be glycated in vitro 
and in v iv o . These include the amino termini of the a-chains and 
various e-amino groups of both the a -  and (3 -chains (Bunn et al., 
1979). It is estimated that approximately 8 - 9% of haemoglobin in 
non-diabetic subjects is glycated through the e-amino groups of 
lysyl residues of both chains (Bunn et a l., 1979). As with HbA-|C, 
glycation of these other sites has also been shown to be increased in 
diabetic subjects (Gabbay et al., 1979).
The structure of the other minor haemoglobins have also been 
studied. HbA-ja has been shown to be further resolved into HbA-|ai 
and H bA ia2 (McDonald et al., 1978). HbA iai proved to have the N- 
terminal p-valine linked to fructose 1,6-diphosphate and possibly 
other red blood cell phosphates (Haney and Bunn, 1976) and HbA-ja2 
with giucose-6-phosphate (Haney and Bunn, 1976; McDonald et al.,
1978). The structure of HbAi b has still not been elucidated, 
although it has been shown to be a covalent modification of the p - 
chains (Krishnamoorthy et al., 1977) and does not contain phosphate 
(McDonald et al., 1978). The HbA-ia-|, HbA-|a2 and HbA-jb fractions 
comprise 0.2, 0.2 and 0.4 percent of the total haemoglobin 
respectively in normal subjects. Levels of HbA-|a-|, H bA ia2 and HbAib 
are not increased in diabetes (McDonald et al., 1978).
1.4. BIOSYNTHESIS AND KINECTICS OF FORMATION O F  
GLYCATED HAEMOGLOBIN
The biosynthesis of HbAi (and HbA-jC) has been extensively studied 
both in vitro and in v iv o .
1.4.1. IN VITRO STUDIES
Haney and Bunn (1976) and others subsequently (Bunn et al., 1976; 
Shapiro et al., 1979) incubated purified human haemoglobin (HbA0) 
with glucose and other sugars (mannose, lactose and galactose) for 
varying times and sugar concentrations. They showed that the 
sugars reacted with HbA0 to form H bA ic, which was identical with 
naturally occurring H b A ic isolated from erythrocytes of normal and
diabetic subjects (Koenig et al., 1977; Stevens et al., 1977 and 
MacDonald et al., 1978). Spicer et al., (1979) showed that HbA-| c 
increased linearly with time of incubation, glucose concentration 
and temperature of intact red cells in v itro .
The non-enzymic nature of the glycation process was indicated by 
the fact that red cell haemolysates and pure HbAo incubated with 
g lucose or labelled glucose form ed H b A ic at identical rates 
(Fiuckiger and Winterhalter, 1976). Also, L-[14C]-glucose and D- 
[ i 4C]-glucose reacted similarly (Bunn et al., 1979).
The biokinectics of formation of the ketoamine H b A ic , through a 
labile and reversible aldim ine form has received intensive study. 
The initial rate for the aldim ine condensation is very sim ilar in 
several reports (Higgins and Bunn, 1981; Svendsen et al., 1981; 
Weykamp and Penders, 1982; Mortensen and Christophersen, 1983). 
It is formed very rapidly within a few hours of incubation of HbA0 
with glucose (for rate constants, see Fig. 1.1). In contrast, the 
formation of the more stable ketoamin§ is negligible during this 
time. The rate of the Amadori rearrangement has been calculated to 
be 1 /60th the of the rate of dissociation of the aldimine back to 
glucose and haemoglobin. Bunn et al., (1979) incubated p 4C2- 3H]- 
glucose with HbA0 and used the 3H to 14C ratio in H bA ic to measure 
accurately the Amadori rearrangement. After six days some 60% of 
the new ly syn thesized  H b A ic had undergone the Am adori 
rearrangement and an estimated 91% after 22 days.
The form ation of the ketoam ine had been considered to be 
irreversible (Bunn et al., 1975). Graf et al. (1978) found a 50% 
conversion of haem oglobin to H b A i^  in v itro  and predicted a 
saturable system of 23% glycation in v ivo  for severe states of 
glycaemia. However, prolonged saline incubation of pure HbAi c 
(ketoamine) revealed a progressive decrease in HbA-|C concentration 
with the concomitant formation and increase in HbA0 (Mortensen and 
Christophersen, 1983; Mortensen et al,, 1984). The degradation of 
HbA-tc to the Schiff base was 12% of the rate of its formation.
1.4.2. IN VIVO STUDIES
The biosynthesis of HbA-|C was followed in humans after an injection 
of [59Fe] transferrin into a human volunteer (Bunn et al., 1976). The 
specific activity of HbA-jc increased slowly and at day 60 started to 
exceed that in HbA0 . It was concluded that HbA-|C is formed 
continuously at a slow rate over the 120 day lifespan of normal 
human red blood cells. In agreement with these findings, young red
cells separated by density gradient, have lower concentrations of 
H b A ic than do old cells (Fitzgibbons et al., 1976).
By injecting labelled reticulocytes into diabetic and normal mice, 
Koenig and Cerami (1975) showed that the rate of synthesis of HbAic 
was much faster in diabetic mice. This is in agreement with Rahbar 
(1969) who found increased levels of HbAic in diabetic subjects.
So, in summary, the formation of HbAic is a two-stage process. The 
initial reaction to form the aldimine is rapid. Once formed it can 
either proceed by an Amadori rearrangement to form the ketoamine, 
or proceed to reverse libe ra ting  free g lucose should the 
concentration of blood glucose decrease,
1.5. GLYCATION OF OTHER HAEMOGLOBINS
Normal haemoglobins other than HbA0, HbA2 and HbF also undergo 
g lycation in humans (Bernste in , 1987). G lycation of fe ta l 
haem oglobin, HbF becomes particu la rly  s ign ifican t in d iabetic 
pregnancy. Similarly glycation of variant haemoglobins C, D, E, G and 
S have also been reported (Bernstein 1987).
1.6. GLYCATION OF OTHER PROTEINS
Follow ing the d iscove ry  and extensive  study of g lyca ted  
haemoglobin, it became evident that due to the non-specific nature 
of the glycation reaction, a wide variety of proteins with reactive a 
-amino or e -amino groups in their composition could undergo 
variable degrees of glycation.
Glycation has since been demonstrated for many proteins ranging 
from those with short to very long half-lives. They have been found 
to be sim ilarly raised in diabetic subjects compared to normal 
ind iv idua ls .
1.6.1. SHORT-LIVED PROTEINS
A number of plasma proteins have been shown to be glycated in vitro 
and in v iv o , however, glycated albumin has received most attention 
mainly because it is the most abundant of the plasma proteins (70 - 
80% of the total) (Peters, 1985).
G lycation of horse serum albumin was firs t reported in 1956 
(Bernstein, 1987). However, it was not until the phenomenon of 
human haemoglobin giycation was well accepted that glycated
albumin was found to be a normal constituent of human blood and 
also to be elevated in diabetic subjects (Day et al., 1979(a); Dolhofer 
and Wieland, 1979(b); Guthrow et al., 1979; Dolhofer and Wieland, 
1980; Ney et al., 1981),
Experim ents in v itro  demonstrated that glycation occurred by the 
same mechanism as for glycated haemoglobin, with the initia l 
formation of a Schiff base followed by a rearrangement to form a 
ketoamine (Day et al., 1979(a); Dolhofer and Wieland, 1979(b)). The 
biokinectics of albumin glycation studied with radioactive glucose 
(Baynes et al., 1984) indicated that the incorporation of glucose into 
the labile Schiff base was complete in 1 - 2 hours. Some 2% of the 
albumin contained the glucose bound in this form under physiological 
conditions (5.5mM glucose, pH 7.4, 37°C). From the kinectic 
constants involved in the formation and dissociation of the aldimine 
and its Amadori rearrangem ent product, an estim ate of 29% 
glycation by the radiochemical procedure was found (Baynes et al., 
1984). This is in close agreement with the value of 28% based on 
the furosine assay which measures lysine-bound, glucose (Schleicher 
and W ieland, 1981). The in v iv o  glycation of 8% reflects the 
■considerable b ind ing capac ity  of a lbum in fo r endogenous 
metabolites, such as bilirubin and exogenous substances, such as 
drugs (Harding, 1985).
The e-amino groups of lysine have been shown to be the main sites 
of glucose attachment in albumin (Dolhofer and Wieland, 1979; 
Garlick and Mazel, 1983). The principal site of glycation of human 
plasma albumin in vivo is lysine-525 (Garlick and Mazer, 1983; Iberg 
and Fluckiger, 1986). This differs from the main site found in v itro  
which is lysine-199 (Day et al., 1979(a)).
Other plasma proteins have been shown to be glycated in vivo and in 
v itro . These include transferrin (Kemp et al., 1984), fibrinogen and 
fibrin (Brownlee et al., 1983) and lipoproteins in particular low- 
density lipoproteins (Gonen et al.,. 1981; Schleicher et al., 1981; 
Harding, 1985). Glycation of erythrocyte membrane proteins have 
also been studied (Bailey et al., 1976; Harding, 1985). Glycation of 
insulin has been achieved in v itro  (Dolhofer and Wieland, 1979(a)) 
and numerous enzymes have also been shown to be glycated in vitro 
(Coradello et al.,1981; Dolhofer et al.,1982).
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1.6.2. LONG LIVED PROTEINS
The glycation of structural and tissue proteins have also been shown 
in v itro  and in v iv o , including lens crystallins (Monnier et al., 1979; 
Chiou et al., 1981; Mandel et al., 1983; Harding, 1985), collagen 
(Hamlin et al., 1975; Schneider and Kohn, 1981; Kohn and Schneider, 
1982) and nerve proteins (Vlassara et al., 1981).
1.7. CHEMISTRY OF GLYCATION AND FACTORS AFFECTING THE 
REACTION
Non-enzymic glycation has been shown to be a reaction occurring in 
two phases (Bunn et al., 1975). The initia l step involves a 
nucleophilic attack by an unprotonated amino group contributed by a 
free amino acid or protein, on the open chain, carbonyl form of a 
reducing sugar. This is a rapid, reversible reaction resulting in the 
formation of a labile Schiff base or aldimine. The Schiff base will 
be in equilibrium  with the glycosylam ine (Dixon, 1972). This 
in te rm e d ia te  p roduct subsequen tly  undergoes an Am adori 
rearrangement (Hodge, 1955) to form a 1-am ino-1-deoxyfructose 
derivative (ketoamine or fructosamine) which in turn can cyclize to 
a ring structure (Fischer and Winterhalter, 1981).
The rate and extent of the Schiff base form ation depends 
predominantly on the concentration of the two reactants. Since the 
concentration of the protein in v iv o  remains fa irly stable, the 
glucose concentration together with the time of exposure of the 
protein to an increase in glucose concentration (i.e. degree and 
duration of hyperglycaemia) are the major determinants of the level 
of glycation j_n v iv o .
The ha lf-life  of the protein w ill be an im portant factor in 
determining the extent of glycation in v iv o . A reduction in the half- 
life of a protein can decrease the extent of glycation even without a 
change in the corresponding blood glucose levels. For example, there 
is a decreased content of glycated haemoglobin in the erythrocytes 
of patients with haemolytic anaemia and shortened red cell lifespan 
and also in normal subjects who have sustained an acute blood loss 
(Bunn et al., 1976). Conversely, polycythaemia as seen in smokers 
(Smith and Landaw, 19798) leads to an increase in glycated 
haemoglobin (Graham et al., 1980).
8
The perm eability and availab ility  of glucose in d ifferent tissues 
will clearly influence the extent of glycation of proteins. Higgins et 
al., (1982) showed that the permeability of erythrocytes to glucose 
was an important factor in affecting the glycation of haemoglobin.
Bunn and Higgins (1981) studied the reaction of various sugars with 
haem oglob in  in v itro  and showed that the rate of glycation is 
directly dependent on the extent to which the sugar exists in the 
open-chain form. The latter has been shown to be influenced by pH, 
with a decrease in the open-chain, reactive form occurring with 
decreasing pH (Cantor and Peniston, 1940). Also, aldose sugars such 
as glucose and galactose react more rapidly than ketose sugars, such 
as fructose. This is probably because the aldehyde carbonyl groups 
are relatively more electrophilic than ketone groups, making them 
more susceptible to nucleophilic attack by an unprotonated amino 
group (Bunn and Higgins, 1981). Stevens et al., (1977) showed that 
phosphorylated sugars react with haemoglobin more rapidly than 
g lucose, inc lud ing g lucose-6 -phospha te , fruc tose -6 -phospha te , 
fru c to se -1 ,6 -d ip h o sp h a te , r ibose-5 -phospha te  and ribu lose -5 - 
phosphate. The rate of glycation of haemoglobin by g!ucose-6- 
phosphate was twenty times the rate with glucose. This is partly 
due. to the fact that glucose-6-phosphate exists to a greater extent 
than glucose in the straight-chain form and partly due to the 
cata lytic effect of the phosphate group (W atkins et al., 1987). 
Although non-enzymic glycation can involve these different sugars 
and despite glucose being present in the-low est percentage of the 
reactive stra igh t-cha in  form (0.002%  com pared to 0.02% for 
galactose and 0.7% for fructose) (Higgins and Bunn, 1981), it 
remains the major sugar involved in glycation in normal humans 
because of its relatively greater concentration.
There are circum stances where sugars other than glucose are 
pathologically raised and contribute to a greater extent to glycation. 
For example, in galactosaemia, glycation by galactose occurs to a 
considerable degree due to the increased rate of reaction of 
galactose as a result of the greater proportion of galactose that 
exists in the open-chain form (Urbanowski et al., 1982). Recently, 
g lycation  by fructose has received a tten tion  since fructose 
accumulates in organs where the sorbitol pathway is active (Suarez 
et al., 1989). This metabolic shunt mediates the conversion of 
g lucose to fructose  with the form ation of sorb ito l as an 
intermediate (Gabbay, 1975). In conditions of increasing glucose 
supply such as diabetes, the level of fructose in the lens may rise 
23-fold becoming twice as concentrated as glucose (Suarez et al., 
1989). Also, the rate of Schiff base formation between amino
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groups of haemoglobin is 7.5 times higher for fructose than for 
glucose (Higgins and Bunn, 1981).
As well as the concentration of the reducing sugar present in the 
reactive form, the initial Schiff base formation depends on the pKa 
of the amino group and steric factors affecting its accessibility. 
The terminal amino acid residues ( a-amino groups) and intra-chain 
lysine residues ( e -amino groups) which titrate with low pKa values
are likely sites for Schiff base formation. The pH will clearly
influence the formation of the Schiff base. However, its effect on 
the glycation reaction is extremely complex (Higgins and Bunn, 
1981; Lowrey et al., 1985) and several mechanisms are probably 
involved. Although a decrease in pH will result in an increase in 
protonation of free amino groups and therefore a decrease in their 
reactivity, an increase in hydrogen ion concentration also catalyses 
the initial dehydration step. A decrease in pH also decreases the 
amount of glucose in the reactive open-chain form by affecting its
tautomeric equilibrium (Cantor and Peniston, 1940). The overall
effect is an increase in Schiff base formation with increasing pH.
The initial reaction between glucose and a protein may also be 
affected by other ketones and aldehydes which also react with a - 
and e -amino groups. These may compete with glucose for binding 
and therefore may inhibit glycation.
Acetaldehyde is produced by the metabolism of alcohol in the liver 
and has been shown to react with amino groups on proteins in v itro  
and in vivo in a manner analogous to that of glucose. The reaction of 
acetaldehyde with haemoglobin in v itro  yields five adducts which 
can also be identified in vivo and are raised in alcoholics compared 
to controls (Stevens et al., 1981; Hoberman, 1983).
The major cofactor of vitamin B6, pyridoxal-5-phosphate also forms 
a Schiff base with protein amino groups through its reactive 
aldehyde functional group (Dempsey and C hristiansen, 1962; 
Srivastava et al., 1972). Therefore, it should compete with glucose 
for binding to protein amino groups. Shepherd et al., (1985) showed 
that pyridoxal-5-phosphate inhibited the glycation of human serum 
albumin, ribonuclease A, lysozyme, human haemoglobin, human IgG 
and bovine myelin based protein in v itro . Pyridoxylated haemoglobin 
has also been demonstrated in vivo (Srivastava et al., 1972). Other 
metabolites of vitamin B6, such as pyridoxal and pyridoxic acid have 
also been shown to react with haemoglobin (Benesch and Benesch,
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1981) and albumin (Stevens et al., 1985) in v it ro , but pyridoxai-5- 
phosphate appears to be the most effective inhibitor of glycation.
Carbamylation of proteins by cyanate has long been recognised by 
food chemists and has been shown to occur in vitro  and in vivo (see 
Fig. 1.2). Cyanate can react with both a -  and e -amino groups of all 
proteins. In haemoglobin the a -amino groups are preferentially 
carbamylated, partly due to their low pKa (Kilmartin and Rossi- 
Bernardi, 1971). Cyanate'is formed from urea in vivo as follows:
NH
I 2
r = n  -------------  N H = C  =  0 +  NH_
V U ---------------------------------  3
NH
2
UREA CYANATE AMMONIA
Cyanate levels are increased in uraemia and an increase in the level 
of carbamylated haemoglobin has been shown in patients with renal 
failure (Fluckiger et al., 1981).
Aspirin has also been shown to modify the structure of a number of 
plasma proteins by a transacetylation reaction (see Fig. 1.3). 
R ad ioactiv ity  from aspirin labelled in the acety l group is 
incorporated into plasma proteins in vivo and in vitro  (Defuria et al., 
1973; Bridges et al., 1975). In haemoglobin the principal sites of- 
acetylation are p -iys-59, p -lys-144 and a -lys-90 (Shamsuddin et 
al., 1974). Patients on high doses of aspirin may have 200 j i M of 
acetyisaficylic acid in their plasma and approximately 5% of their 
haemoglobin may be acetylated (Bridges et al., 1975). The principal 
acetylation site on human serum albumin is tys-199 (Walker, 1976.) 
and acetylation alters its drug-binding properties. Acetylsalicylic 
acid has been shown to inhibit the glycation of haemoglobin and 
albumin both in v ivo  and in v itro  (Day et al., 1979; Rendeli et al.,
1986). The glycation of haemoglobin is far less susceptible to 
inhibition than is albumin glycation. This correlates well .with the 
fact that the major glycation site on haemoglobin is the amino 
terminus of the p-chains whereas aspirin reacts preferentia lly at 
the e-amino groups. In constrast to haemoglobin the reaction of 
glucose and albumin occurs mostly at the e -amino residues. Also
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FIGURE 1.2. THE REACTION OF CYANATE WITH
PROTEIN AMINO GROUPS
NH o
II n
P r - N H  + c ---------- > P r N H - C - N H .
I II
H 0
PROTEIN AMINO
GROUP CYANATE CARBAM YLATED PROTEIN
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FIGURE 1.3. ACETYLATION OF PROTEIN AMINO
GROUPS BY ASPIRIN
Pr NH
P r N H  — COCH.
ASPIRIN ACETYLATED PROTEIN
( ACETYLS ALICYU C
ACID;
hydrolysis of acetylsalicylic acid occurs rapidly in the bloodstream 
with further hydrolysis occurring during membrane transport. The 
hydrolysis product, sa licylic acid does not react with proteins. 
Therefore, haemoglobin in the erythrocyte is likely to be exposed to 
lower concentrations of acetylsalicylic acid than albumin in the 
plasma.
Dehydroascorbic acid, one of the oxidation products of ascorbic acid 
is another compound known to react with amino acids and proteins. 
This was first described by Dulkin and Friedeman in 1956 and has 
since been extensively studied by food chemists (Ranganna and 
Setty, 1974; Kurata and Fujimaki, 1976). The carbonyl group at the 
2-position (see Chapter 5) is thought to undergo a nucleophilic 
reaction with both a- and e-amino groups to form a Schiff base, 
which is probably reversible under physiological conditions. Stolba 
et al. (1987, 1988) have shown that both dehydroascorbic acid and 
ascorbic acid can affect the glycation of bovine serum albumin and 
collagen in v itro . They found that ascorbic acid inhibited glycation 
whilst dehydroascorbic acid appeared to enhance the incorporation 
of glucose into proteins. Khatami et al., (1988) on the other hand 
showed that ascorbic and dehydroascorbic acid both inhibited the 
glycation of bovine serum albumin in v itro . When insulin-dependent 
diabetic subjects were treated with 1.5g of ascorbic acid daily for 
three weeks, a significant decrease in the plasma fructosamine 
concentration occurred (Stolba et al., 1988).
Instead of compounds competing with glucose for binding to amino 
groups on proteins, free amino acids can react with glucose and may 
themselves compete with reactive amino groups on proteins for 
glucose attachment. Sensi et al., (1989) recently reported the 
inhib ition of g lycation of proteins by D-iysine in v i t r o . They 
investigated the effect of varying concentrations of D-lysine on 
glucose incorporation and ketoam ine form ation on short-lived 
proteins, such as albumin and immunoglobulin G and long-lived 
proteins, such as collagen and glomerular basement membrane. They 
found that under physiological conditions, inhibition of glycation of 
all the proteins increased linearly with increasing concentrations of 
D-iysine and that the degree of inhibition was greater with high 
concentrations of glucose.
The most important factor affecting the rate of conversion of the 
Schiff base to the ketoamine is its m icroenvironment within the 
protein (Watkins et al., 1987). The main determ inants being the 
structure of the protein and ionic influences in the direct vicinity of
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the Schiff base. A number of physiological factors have been shown 
to influence the extent of Amadori rearrangement both in v itro  and 
in v iv o . The effect of pH on the kinetics of formation of glycated 
haemoglobin has been studied in vitro (Smith et al., 1982; Lowry et 
al., 1985). The rate of formation of the stable ketoamine was found 
to increase with decreasing pH, which is in agreement with Hodge 
(1955) who showed that the Amadori rearrangem ent was acid 
catalysed. Also, Shapiro et al., (1989) reported that the glycation of 
lysine residues in haemoglobin occurs on lysines in the vicinity of 
carboxyl groups on the protein surface. They suggested that the 
latter may act as a local catalyst of glycation. They did not find a 
direct correspondence between the pKa of the amino group and the 
extent of glycation, suggesting that the kinetics of the Amadori 
rearrangement rather than the pKa of the amino group may be rate- 
limiting in determining the sites of glycation on the protein. Iberg 
and Fluckiger (1986) also noted that the lysine residues glycated in 
albumin were frequently located in sequences of basic amino acids. 
They suggested that ‘clusters’ of these basic amino acids in proteins 
may act as ne ighbouring group ca ta lys ts  of the Am adori 
rearrangement on adjacent lysine residues.
Watkins et al. (1987) investigated the effects of phosphate on the 
kinetics and specificity of glycation of various proteins in v i t r o . 
They had previously found that reactive lysine residues involved in 
the glycation of RNAase were located in or near the phosphate region 
of the active site, a fairly basic region of the protein, rich in lysine, 
histidine and arginine residues (Watkins et ai., 1985). • They found 
that both inorganic and organic phosphates not only increased the 
g lycation of all p rote ins studied by cata lysing the Am adori 
rearrangement, but also apparently directed the specificity of the 
reaction. Incubation of the proteins in d iffe rent buffers with 
varying concentrations of phosphate lead to a significant increase in 
glycation, which occurred ih a concentration-dependent fashion. The 
pattern of glycation of am ino-acid residues was different in the 
presence of phosphate. Haemoglobin was studied in greater detail, 
in particular to examine the effect of 2,3-diphosphoglycerate on 
glycation. The glycation of haemoglobin has been shown previously 
to be enhanced by 2,3-diphosphoglycerate in v itro  (Smith et al., 
1982; Lowry et al., 1985). Both inorganic phosphate and 2,3- 
diphosphoglycerate increased the overall extent of glycation of both 
valine and lysine residues, but the relative extent of glycation of 
valine residues was greater, particularly in the presence of 2,3- 
diphosphoglycerate. Phosphate is thought to increase the glycation 
of proteins by affecting both phases of the reaction. Phosphate is 
known to increase the proportion of the open-chain, reactive form of
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reducing sugars in solution (Burton and McWeeny, 1963) and 
therefore w ill promote the initial Schiff base form ation. Also, 
since its pKa is near neutral pH, phosphate can also serve as an acid- 
base catalyst of the Amadori rearrangement under physiological 
conditions. The effect of phosphate on the specificity of glycation 
is though t to be due to its b ind ing to un ique basic 
microenvironments in the protein (see Fig. 1.4), where it catalyses 
the rearrangement reaction. Thus, the preferential glycation of 
lysines in or near the active site of RNAase and the [3 -cha in  
terminal valines in haemoglobin can be explained by the binding of 
phosphate in the active site and allosteric sites of these proteins 
respective ly .
The pronounced effect of 2,3-diphosphoglycerate on both the overall 
kinetics and the specificity of glycation of haemoglobin in v itro  
suggests that the binding of organic phosphate is probably also 
significant in determining the rate and pattern of glycation of the 
protein in v iv o . Several investigators have described a strong 
positive correlation between 2,3-diphosphoglycerate concentration 
and the kinetics of formation of glycated haemoglobin in vitro and in 
v ivo  (Smith et al., 1982; Roberts et al., 1984; Lowry et al., 1985). 
The enhanced rate of glycation of haemoglobin found under anaerobic 
conditions (Smith et al., 1982) is probably explained by the 
increased affinity of haemoglobin, for 2,3-diphosphoglycerate under 
these conditions, which in turn will catalyse glycation.
The catalysis of the Amadori rearrangement by local amino acid 
residues and/or the binding of phosphate or other buffering ions 
probably explains the apparent preferential glycation of various 
residues in a given protein, it may also explain the fact that some 
proteins become more glycated than others and that there are 
differences between the sites and order of prevalence of glycation 
occurring in vivo versus in v itro . For example, although the amino 
group of the terminal valine of the (3-chain of haemoglobin is the 
most reactive group in vivo and in v itro , several other sites on the 
(3-chain as well as on the a-chain can be modified (Bunn et a!., 
1979). Incubation of purified HbA0 with [14C]-glucose followed by 
ion-exchange chromatography and two-dimensional peptide mapping 
allowed identification of the major sites of glycation occurring j_n 
v it r o . These were (3.-val-1, a-iys-16, (3 -iys-66, (3 -lys-17, a -
val-1, a-lys-7 and (3-lys-120. In contrast, the major sites of 
glycation occurring in v ivo  were identified as p-val-1, [3 -Iys-66, 
a -  lys-61, p -lys-17 and a -val-1 (Shapiro et al., 1980).
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The sites of glycation of albumin have also been studied in vitro and 
in v iv o . Preliminary experiments in vitro and in vivo suggested that 
just the e -amino groups of lysine residues were glycated (Dolhofer 
and Wieland, 1979; Day et al., 1979; Garlic and Mazer, 1983). 
However, recently Robb et al., (1989) showed that the N-terminal
amino acids of albumin may also be glycated in vivo and in v itro , in
v itro  incubations of human (Day et al., 1979) and rat (Day et al.,
1979) serum albumin with glucose suggested that the principal site 
of glycation was lysine-199. However, in vivo studies showed that 
approxim ately 40% of g lycation of serum albumin occurred at 
lysine-525 (Garlic and Mazer, 1983; iberg and Fluckiger, 1986). It 
was suggested that this difference may be due to the accessibility 
of a particular lysine e -amino group. In v i t r o , the glycation of 
human serum albumin is enhanced when the fatty acids are removed 
from the albumin prior to incubation with glucose (Mereish et al.,
1982). It is possible that in vivo the e -amino group of lysine-199 is 
covered by a ligand, such as a fatty acid so that is is not accessible 
to glucose in v iv o . For in v itro  experiments a. portion or all of the 
masking ligand may be lost in the purification process, uncovering
the reactive e-amino group, namely lysine-199.
The rate of non-enzymic glycation of human serum albumin in v ivo 
appears to be markedly greater than that of human haemoglobin. In 
non-diabetics, serum albumin has a half-life of approximately 19 
days and is 10 - 12% glycated whereas haemoglobin has a half-life 
of 120 days and is 5 - 7% glycated. Olufemi et al., (1987) 
investigated the relative extent of glycation of haemoglobin and 
albumin in v ivo . They found that the e-amino groups on albumin were 
more extensively modified than those on haemoglobin. They 
concluded that the average rate of reaction of lysyl residues in 
albumin is markedly faster than in haemoglobin, possibly due to acid 
catalysis by neighbouring aspartic acid and glutam ic acid side- 
chains, which are abundant in albumin.
So, in summary, although the main determinants of the extent and 
rate of glycation of a given protein in v ivo  are the availability of 
reactive amino groups and the concentration of glucose in its 
reactive form, there are other important factors which may directly 
or indirectly influence one or both phases of the glycation reaction.
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1.8. CLINICAL IMPLICATIONS OF PROTEIN GLYCATION
The process of glycation occurs continuously at a slow rate in 
normal subjects, but in diabetes mellitus due to the continual 
exposure to long periods of hyperglycaemia, glycation of proteins 
occurs at a faster rate and to a greater extent (Koenig and 
C eram i,1975).
The discovery that proteins were glycated in a time-related fashion, 
dependent mainly on the circulating glucose concentration (Bunn et 
al.,1976), resulted in extensive evaluation of glycated proteins, in 
particular glycated haemoglobin (GHb) and glycated albumin (GA) as 
monitors of integrated glycaemia in diabetes.
The most intriguing aspect of glycation is the possibility of linking 
hyperglycaemia to the chronic complications occurring in diabetes 
mellitus (Brownlee et al.,1984).
Glycation may also play a role in the tissue changes associated with 
normal ageing (Cerami et al.,1987). The effect of diabetes on many 
organs and tissues is often described as accelerated ageing. Several 
of the complications that occur in people with d ia be tes ,. including 
cataracts, jo in t stiffness and atherosclerosis are identical with 
disorders that develop in the elderly. They merely develop earlier. 
If excess glucose does hasten the onset of these complications in 
people with diabetes, normal amounts of glucose could conceivably 
play a role in the slower onset seen in non-diabetics as.they age.
Before discussing the pathophysiological effects of g lycation, a 
brief outline of the history, classification and diagnosis of diabetes 
will be given together with a more detailed discussion of insulin and 
the use of glycated proteins in both the diagnosis and monitoring of 
blood glucose control.
1.9. DIABETES MELLITUS
1.9.1. DEFINITION (OLEFSKY, 1985)
D iabetes m ellitus is a heterogeneous prim ary d iso rder of 
carbohydrate metabolism  with m ultiple ae tio log ic  factors that 
generally involve absolute or relative insulin deficiency or insulin 
resistance or both. It is characterised by chronic hyperglycaemia 
and is often associa ted w ith the deve lopm ent of . specific  
microvascular complications, especially in the eye and kidney, and
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an increased frequency of macrovascular disease, such as peripheral 
coronary artery disease.
1.9.2. HISTORY
Many books, outline the history' of diabetes and report on the 
investigations showing the association between insulin and diabetes 
(Oakley et al., 1975; Faris, 1982; Bennett, 1983).
The term of diabetes mellitus was originally used to describe a 
disorder characterised by the passage of sweet urine, excessive 
urination, thirst, excessive weight loss and hunger which over the 
course of several months resulted in death.
Over 100 years ago, it was recognised that the disease appeared in 
at least two distinct forms. One affected mainly obese adults and 
the other being more frequent in younger people, often children who 
were usually thin at the time of diagnosis.
Following the discovery of the role of the pancreas in regulating 
blood sugar and the demonstration that pancreatectomy resulted in a 
syndrome of hyperglycaemia, ketosis and death, it was assumed that
the diabetes was the result of pancreatic disease. It was found that
persons who died from diabetes had atrophy of the Islets of 
Langerhans and pancreatic fibrosis. Many attempts were made 
between 1890 and 1922 to dem onstrate that extracts of the 
pancreas were effective in relieving the symptoms of diabetes. In 
1916, Sharpey-Shafer concluded that the Islets of Langerhans must 
secrete a substance which regulates carbohydrate metabolism and 
proposed the name of insulin for this substance.
It was not until 1921 when Banting and Best isolated and purified
insulin from pancreatic extracts that the firs t really effective 
preparation of insulin was produced for the treatment of diabetes.
Although insulin has led to increased . life expectancy of diabetics, 
after years of exposure to high glucose levels and high insulin 
levels, standard treatment of insulin, diet or oral hypoglycaemic 
drugs does not prevent the development of chronic complications 
affecting the eyes, kidneys, nerves and arteries (Brownlee and 
Cerami, 1981). In the eye, retinal capillary damage and cataract 
formation eventually leads to blindness. Capillary damage in the 
glomerulus, associated with basement membrane thickening leads to 
chronic renal failure with proteinuria. In the diabetic peripheral 
nerve, axonal dw ind ling and segm ental demyelination are
associated with a very high prevalence of motor, sensory and 
autonomic dysfunction. Increased atheromata in the medium and 
large arteries leads to coronary heart disease and peripheral 
arterial disease.
1.10. INSULIN
Since the discovery and isolation of insulin, extensive research has 
been carried out to. e lucidate its structure, b iosynthesis and 
secretion from the pancreas and its mechanism of action.
1.10.1. STRUCTURE
The chemical sequence of insulin was determined in 1955 (Brown et 
al., 1955; Ryle et al., 1955). The human insulin molecule consists of 
two polypeptide chains. The A-chain contains 21 residues, whilst 
the B-chain is longer with 30 residues. The chains are held together
by two inter-chain disulphide bonds. There is also a disulphide
bridge within the A-chain.
In 1967 it was discovered that the hormone was synthesized in the 
pancreatic p-ceils as pro-insulin, which is subsequently converted 
enzymatically to insulin in the storage vesicle (Steiner and Oyer, 
1967). This cleavage reaction leads to the production of insulin and
also a connecting peptide, C-peptide. The insulin and C-peptide are
stored together in the p-granule until released into the intercellular 
space in response to an insulinotropic stimulus by the process of 
exocytosis (Lacy, 1961).
1.10.2. SYNTHESIS AND SECRETION
The regulation of the biosynthesis and secretion of insulin has 
recently been reviewed by Howell and Bird, (1989). The major 
physio logical determ inant of secretion in mammals is glucose, 
although a large number of physiological and pharmacological agents 
can also act as secretogogues. These can be divided into two groups. 
The first group are initiators, which are agents that are capable of 
provoking insulin release alone such as glucose and certain amino 
acids. The second group are potentiators which are agents that are 
effective alone, but will increase the insulin released in response to 
glucose or amino acids. The latter include glucagon and gastric- 
inhibitory polypeptide (GIP). The autonomic nervous system is also 
thought to affect insulin secretion.
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The events leading to the secretion- of insulin are not fu lly 
understood, but calcium is thought to play an essential role in the 
stim ulus-secretion coupling in the pancreatic p -cells (reviewed by 
Wollheim and Sharp, 1981). The action of calcium to affect insulin 
secretion is thought to be via the calcium regulating protein, 
calmodulin (Sugden et al., 1979). Calmodulin has been implicated in 
a number of activities in the [3-cells, but its major effects are 
probably produced via activation of plasma calm odulin-responsive 
protein kinase activity (McDonald and Kowlune, 1982), following 
which several proteins are specifica lly  phosphoryiated. Two 
possible target proteins are the microtubule subunit, tubulin and 
myosin light chains, with the implication that calmodulin-dependent 
phosphoryla tion may m odulate granule m ovem ent leading to 
exocytosis (Howeil, 1984).
1.10.3. RECEPTORS AND MECHANISM OF ACTION
Insulin exerts its metabolic actions by binding to specific receptors, 
which are found mainly on insulin-sensitive cells. Houslay and 
Siddle (1989) have recently reviewed the current knowledge on the
structure and activity of the receptor.
The insulin receptor consists of two alpha subunits of approximately
135,000 Daltons and two beta subunits of approxim ately 90,000 
Daltons held together covalently by both inter- and intra- subunit 
disulphide bridges (Czech, 1985). The alpha subunit provides the 
binding site for insulin and is wholly extracellular. The beta subunit 
is a transm embrane entity with globular domains at both the 
extrace llu lar and cytosolic surfaces. It is assumed that the 
intracellular signai(s) elicited by the insulin receptor arise from the 
activ ity  of the cytoso lic  domain of the beta-subun it a fter 
activation via conformational changes transmitted through the alpha 
subunit and the external domain of the beta-subunit. Evidence 
suggests that insulin action is mediated by reactions initiated by 
activation of an insulin receptor tyrosyl kinase. Many putative 
substrates have been suggested for the receptor kinase, however the 
most readily demonstrated substrate is the receptor itself. This
autophosphorylation may be to enhance and prolong the activity of 
the kinase towards other cellular substrates involved in signalling 
pa thw ays.. Alternatively, the phosphorylation of the receptor may 
regu la te  its in te raction  with other p rote ins which are not
themselves phosphoryiated, but might nevertheless be important in 
signal transduction. However, experim ents have shown that 
autophosphorylation and . kinase activity are not the only mechanisms 
involved in signalling the metabolic response of insulin (Houslay and
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Siddle, 1989). Insulin receptors have also been shown to interact 
with so called, G-proteins (Guanine-nucleotide binding regulatory 
prote ins) which m odulate cyclic-AM P concentra tions and may 
control the production of inositol glycans. Cyclic-AMP and inositol 
glycans have been implicated as secondary messengers involved in 
exerting the metabolic effects of insulin along with calcium, cyclic- 
GMP and diacylglycerol. However, none of the mechanisms studied so 
far appear to exclusively mediate insulin action, but may be involved 
in controlling different aspects of its action.
Insulin has many actions. As well as lowering blood glucose 
concentrations, it lowers plasma amino acids, non-esterified free 
fatty acids and potassium levels by stimulating glycogen formation,, 
trig lyceride synthesis and protein synthesis. It also exerts an 
inhibitory effect upon gluconeogenesis and glycogenolysis.
Any disturbance in the secretion or action of insulin as occurs in 
d iabetes m ellitus, has profound effects on fat, protein and 
carbohydrate metabolism.
1.11. CLASSIFICATION OF DIABETES MELLITUS
The classification adopted by the WHO expert committee on diabetes 
mellitus in 1980 has since been revised by the committee in 1985 
(WHO Report, Geneva, 1985) and is shown in Table 1.1. The most 
important change from the previous classification is the appearance 
of m alnutrition-related diabetes as a major clin ical subclass. So 
there are four major subclasses; insulin-dependent type, non- 
insulin-dependent type, malnutrition-related type and other types.
1.11.1. INSULIN-DEPENDENT DIABETES MELLITUS (SDDM)
IDDM is usually characterised by the abrupt onset of symptoms, 
insulinopenia, proneness to ketoacidosis and dependency on injected 
insulin to prevent ketosis and to sustain life. While classically the 
disease occurs in juveniles, it may appear at any age. Genetic 
determ inants are believed to be important as evidenced by the 
association of this entity with increased and decreased frequencies 
of certain histocompatibility antigens (HLA). Islet cell antibodies 
are frequently present at the time of diagnosis. Autoimmune 
disorders are probably responsib le for the disease in some 
instances, while evidence of a likely viral aetiology for some cases 
has been demonstrated.
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TABLE 1.1 CLASSIFICATION OF DIABETES MELLITUS AND 
ALLIED CATEGORIES OF GLUCOSE TOLERANCE
A. CLINICAL CLASSES
(1) Diabetes mellitus (DM)
(a) Insulin-dependent diabetes mellitus (IDDM)
(b) Non-insulin-dependent diabetes mellitus (NIDDM)
(i) Non-obese
(ii) Obese
(c)Mainutrition-reiated diabetes mellitus (MRDM)
(d)Other types of diabetes associated with certain conditions and 
syndromes: (i) pancreatic disease; (ii) disease of hormonal aetiology; (iii) 
drug-induced or chemical-induced conditions;
(iv) abnorm alities of insuiin or its receptors; (v) certain genetic 
syndromes; (vi) miscellaneous
(2) Impaired glucose tolerance (IGT)
(a) Non-obese
(b) Obese
(c) Associated with certain conditions and syndromes
(3) Gestational diabetes mellitus (GDM)
B. STATISTICAL RISK CLASSES
(SUBJECTS WITH NORMAL GLUCOSE TOLERANCE BUT SUBSTANTIALLY 
INCREASED RISK OF DEVELOPING DIABETES)
(1) Previous abnormality of glucose tolerance
(2) Potential abnormality of glucose tolerance
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1.11.2. NO N-INSULIN  DEPENDENT D IABETES M ELLITUS 
(NIDDM)
NIDDM is the term employed for subjects who are not insulin- 
dependent or ketosis-prone, although insulin may be used or required 
for the correction of symptomatic hyperglycaemia. Although not 
ketosis-prone under normal circumstances, they can develop ketosis 
under certain circumstances such as infection or other stress. The 
majority of the subjects with NIDDM are adults at the time of onset 
and are obese, but the disease can occur in children and non-obese 
adults. Evidence suggests there is a strong genetic basis for this 
type of diabetes. NIDDM is further characterised by the absence of 
islet-cell antibodies and is not associated with the HLA-types seen 
in IDDM. Nevertheless, the typical vascular complications seen in 
IDDM also frequently develop in persons with NIDDM.
1.11.3. MALNUTRITION-RELATED DIABETES MELLITUS
In tropical developing countries, young diabetics often present with 
a history of nutritional deficiency and a constellation of symptoms, 
signs and metabolic characteristics which fail to meet the criteria 
used to classify IDDM and NIDDM. Specific environmental factors 
interacting with genetic make-up are suspected to be involved in 
causing this type of diabetes. It is associated with damage of the 
pancreas caused by toxic substances and probably of inadequate 
protein intake.
1.11.4. OTHER TYPES
This group contains those forms of diabetes previously known as 
secondary diabetes, where the disease has an established aetiology 
or where it is part of a well-defined condition or syndrome (see 
Table 1.1). These cases of diabetes are in the minority.
1.11.5. IMPAIRED GLUCOSE TOLERANCE (IGT)
IGT is the term used to describe those persons whose glucose 
tolerance is neither unequivocally normal nor sufficiently abnormal 
to be diagnostic of diabetes. IGT is still the subject of research to 
determine its mechanisms and prognostic implications. A recent 
study by Kadowaki et al. (1984) suggested that Japanese patients 
with IGT have a higher risk of developing diabetes if they have low 
plasma insulin levels 30 minutes after the adm inistration of a 
glucose load. This is independent of the two other positive
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predictive factors which are high fasting and/or high post-load 
blood glucose concentration and the degree of adiposity.
1.11.6. GESTATIONAL DIABETES (GDM)
GDM denotes glucose intolerance that has its onset or is first 
recognised during pregnancy. As relatively mild degrees of glucose 
intolerance during pregnancy are associated with increased risk of 
perinatal mortality and morbidity, it is important to recognise its 
presence and provide appropria te  m anagem ent. Follow ing 
parturition, the glucose tolerance may revert to normal, remain as 
IGT or persist as diabetes mellitus.
1.11.7. STATISTICAL RISK CLASSES
These are subjects who have had an abnormality of glucose tolerance 
in the past or who, by virtue of their genetic relationship with a 
diabetic or other characteristic, have an unusually high risk of 
developing diabetes. These are classified into two categories: 
previous and potential abnormality of glucose tolerance.
1.11.7.1. Previous Abnormality of Glucose Tolerance
These persons have had in the past diabetes, IGT or GDM. They are at 
risk of developing glucose intolerance if subjected to appropriate 
stresses.
1.11.7.2. Potential Abnormality of Glucose Tolerance
This is a group of people with normal oral glucose tolerance, but 
who have a statistically increased risk of developing diabetes.
1.12. DIAGNOSIS OF DIABETES MELLITUS
1.12.1. CLINICAL AND BIOCHEMICAL DIAGNOSTIC CRITERIA
The finding of the classical symptoms of diabetes such as thirst, 
polydipsia, pofyuria, loss of weight and tiredness together with 
marked, glycosuria (with or without ketonuria) and a random blood 
sugar of more than 10 mmol/L is diagnostic of diabetes mellitus 
(WHO Report, 1985). However, in many cases, particularly .those 
with NIDDM, who have few symptoms and where glycosuria is 
frequently discovered by chance, the diagnosis is less obvious and an 
oral glucose tolerance test will be required.
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1.12.2. ORAL GLUCOSE TOLERANCE TEST (OGTT)
The OGTT is the most important tool in the diagnosis of diabetes and 
is carried out according to the procedure recommended by the WHO 
Report (1985).
The test should be carried out in the morning after an overnight fast 
of 10 - 16 hours, during which water may be drunk. The test should 
be proceeded by at least three days of unrestricted carbohydrate 
intake (at least 150g) and usual physical activity. Outpatients 
should rest for at least half an hour before starting the test. They 
should also remain seated and refrain from smoking during the test. 
After collection of a fasting blood sample, the subject drinks 75g of 
glucose in 250 - 300mls of water over the course of five minutes. 
Another blood sam ple is co llected after the test load. If 
appropriate, samples may also be taken every half-hour during this 
period. The glucose concentration is measured in either the whole 
blood or plasma of the collected samples in either venous or
capillary blood. For the interpretation of the results see Table 1.2.
A number of factors should be taken into account when interpreting 
the results from the OGTT (Rifkin, 1983). The age of the patient
will affect the results as there is a gradual decrease in glucose
tolerance with increasing age (although not usually into the diabetic 
range). This is due to a decreased, capacity of tissues to metabolize 
glucose. Also, a number of drugs can affect glucose tolerance. 
C h ron ic  g lu co co rtico id  a d m in is tra tio n , ora l d iu re tic s , the 
contraceptive pill (oestrogen) and nicotinic acid can all raise blood 
glucose and may give rise to false positives. Conversely, some drugs 
can lower blood glucose including salicylates, alcohol, monoamine
oxidase inhibitors and propranolol. Ideally the patient should be off 
all medication when tested, to eliminate any possible influence upon 
the results. There are also a number of non-diabetic causes of an 
abnormal OGTT (see Table 1.3), which should be taken into account if 
diabetes is not conclusive.
1.12.3. GLYCATED PROTEINS
Glycated proteins have so far all proved to be insuffic iently 
sensitive in the diagnosis of diabetes. A large number of studies of 
GHb in patients referred for OGTT have been carried out ( Dods and 
Bolney, 1979; Dunn et al., 1979; Frazer and Shepherd et al., 1985; 
Forrest et al., 1987). The sensitivity of GHb in diagnosing patients 
with abnormal OGTT have varied from 20 - 80%. The vast range of
27
T A B L E  1 . 2  D I A G N O S T I C  V A L U E S  F O R  T H E  G L U C O S E  
T O L E R A N C E  T E S T  ( W H O , 1 9 8 5 )
WHOLE BLOOD WHOLE BLOOD PLASMA PLASMA
(VENOUS) (CAPILLARY) (VENOUS) (CAPILLARY)
GLUCOSE GLUCOSE GLUCOSE GLUCOSE
(mmoi/ l )  (mmol/ l )  (mmol/ l )  (mmol/ l )
DIABETES
MELLITUS-
FASTING >6.7 >6.7 >7.8 >7 .8
DIABETES 
MELLITUS- 
2HR POST
GLUCOSE >10.0 >11.1 >11.1 >12.2
IMPAIRED
GLUCOSE
TOLERANCE-
FASTING < 6.7 <6.7 <7.8 <7.8
IMPAIRED 
GLUCOSE 
TOLERANCE- 
2HRS POST
GLUCOSE 6.7-(0.0 7.8-U.I < 7 .8 -|l.{ 8 r?-12.2
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T A B L E  1 . 3  M A I N  N O N - D I A B E T I C  C A U S E S  O F  
A B N O R M A L  O R A L  G L U C O S E  T O L E R A N C E  T E S T S
C L I N I C A L  S T A T E
Liver ceil disease
Chronic iiiness; prolonged 
physical inactivity;bed 
confinem ent
“Acute stress” : fever, trauma, 
major surgery, myocardial 
in farction, stroke
Starvation; under nutrition
Potassium depletion (oral 
diuretics; alcoholism, ureamia, 
m alnutrition, primary 
a ldosteron ism )
Chronic renal disease
Other disease of the endocrine 
glands:
Active acromegaly 
Cushing’s syndrome or 
glucocorticoid therapy (in 
potential diabetics only) 
Primary aldosteronism 
(secondary to potassium 
deple tion)
Insulinom a
Glucagonoma
Phaeochromocytoma
T h yro tox icos is
F A S T I N G  H Y P E R G L Y C A E M I A  
Absent
Absent
Often present for a few days 
after onset
Absent
May be present 
Absent
Present in about 25%
Present
May be present 
Absent
May be present 
May be present
Only in prediabetic or diabetic
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results corresponds to differences both in the criteria  used for 
defining abnormal OGTT and in definition of an abnormal GHb 
concentra tion.
The first clinical assessment of glycated plasma proteins in the 
form of fructosam ine (see Section 1.13.2.) suggested that the 
sensitivity was better than for GHb (Baker et al., 1983). A more 
recent comparison of GHb and fructosamine found however, that 
although fructosam ine was slightly more sensitive than GHb in 
borderline diabetes, there was no difference in the sensitivity of 
patients with clearly abnormal OGTT, being 67% for both tests 
(Salemans et al., 1987).
Therefore, blood glucose measurement either with or w ithout a 
proceeding glucose load remain the basis for the diagnosis of 
diabetes mellitus or impaired glucose tolerance.
1.13. MONITORING GLYCAEMIC CONTROL USING GLYCATED  
PROTEINS
The regular monitoring of blood glucose concentration is used not 
only to assess the response of diabetic patients to hew treatments, 
but also most studies have suggested that better glycaemic control 
is associated with the amelioration or less frequent development of 
long-term com plications (Tschobroutsky, 1978; Eschwege et al., 
1979; White et al., 1982).
Assessment of glycaemic control has depended upon sporadic blood 
glucose determinations, spot urine testing for glucose and 24 hour 
measurement of urine glucose. All these m easurements are 
cumbersome, laborious and not always accurate or very reliable.
On the basis that the glycation of proteins occurs continuously 
during their lifespan and .depends mainly on the prevailing glucose 
concentration, it was proposed that the measurement of glycated 
proteins should provide an objective means of quantitating the 
average blood glucose concentration in a tim e-re lated fashion, 
depending on the half-life of the protein involved (Bunn et al., 1976).
The circulating proteins in the blood were the obvious choice due to 
their easy accessibility and relative ease of measurement.
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1.13.1. GLYCATED HAEMOGLOBIN
Haemoglobin was the first protein shown to be glycated in vivo and 
to be raised in diabetes mellitus. Bunn et al. (1976) showed that 
haemoglobin was glycated continuously throughout the lifespan of 
the erythrocyte (120 days) and that the extent of glycation depended 
on the glucose concentration within the erythrocyte. Due to the 
s ligh t revers ib ility  o.f the g lycation reaction (M ortensen and 
Christophersen, 1983; Mortensen et al., 1984), the measurement of 
GHb therefore reflects the oscillations of glucose concentration in 
the erythrocyte over the preceeding 4 - 6 weeks (Berstein, 1987).
Most investigators have reported a correlation of HbAi or HbAi c 
levels with various parameters of glycaemic control in population 
studies employing both IDD or NIDD subjects. Random HbAi or HbA-jc 
levels have been found to correlate to variable degrees (r = 0.6 - 0.9) 
with fasting blood glucose, mean daily blood glucose during the 
preceeding three months,, maximum glucose concentration in the area 
under an OGTT curve, the highest mean blood glucose occurring 
during twelve hours of continuous glucose monitoring and 24 hour 
urine glucose obtained 4 - 1 2  weeks previously (Koenig et al., 1976;
Gabbay et al,, 1977; Gonen et al., 1977; Paisey et al., 1980; Boucher
et al., 1981; Svendsen et al., 1982; Verillo et al., 1983).
The strongest correlations between levels of glycaemia and levels 
of GHb are found in NIDD subjects (Nathan et al., 1984). This is 
probably due to the relative stability of the blood glucose levels in 
NIDD subjects. In NIDDM the blood glucose concentrations remain 
fairly stable. There is little variability in fasting levels and close 
corre lations are found between fasting and 24 hour integrated 
values (Holman and Turner, 1980; Paisey et ai., 1980). In IDDM on 
the other hand considerable alterations of blood glucose may occur 
in minutes to hours, so the level at any time point may be misleading 
as to the integrated level of glycaemia. GHb levels and levels of 
glycaemia are often discrepant in IDDM. Kennedy et al. (1984) found
that GHb and post-prandial plasma glucose levels in 302 IDD
subjects, measured over a period of 9 - 12 months were only 
concordant in 40% of those studied. Schleicher et al., (1984) 
similarly found discrepancies between GHb and blood glucose levels 
in ten IDD subjects observed over a year.
Kennedy and Lyons (1989) suggest that regular monitoring of GHb is 
very useful in IDDM, but debatable in NIDDM, particularly in those not 
receiving insulin and should perhaps only be measured infrequently.
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The time-relation between changes in glycaemic control and GHb 
levels have been studied in several longitudinal investigations. 
Studies assessing improved control have found GHb levels to lag 3 - 
10 weeks behind achievement of improved diabetic control as judged 
by urine glucose excretion or mean daily blood glucose levels (Koenig 
et al., 1976; Gabbay et al., 1977). This variability probably reflects 
differences in individual rates of GHb formation, red blood cell 
destruction and also in pre-GHb (Schiff base) formation that follows 
acute changes in blood glucose concentrations (Widness et al., 1980). 
Many methods for GHb measurement quantitate both the labile Schiff 
base and the more stable ketoamine, which may give a falsely 
elevated GHb reflecting the blood glucose concentration at the time 
of sampling.
Boden et al., (1980) carried out in vivo studies that suggested that 
the rate of formation of GHb was considerably faster than the rate 
of its disappearance. They concluded that GHb is not suited to 
detect rapid m etabolic improvements, but is useful to monitor 
rapidly deteriorating control.
There are certain clinical situations where the measurement of GHb 
will not be an accurate reflection of blood glucose concentration. 
This may occur in haemoiytic anaemias (decreased erythrocyte 
s u rv iv a l) ,  h a e m o g lo b in o p a th ie s , c h ro n ic  re n a l d ise a se  
(carbam ylation of haemoglobin), alcoholism (acetaldehyde reacts 
with haemoglobin) and during the ingestion of certain drugs (e.g. 
asp irin ).
So, although the regular determination of GHb levels has proved to be 
a useful index of metabolic control in diabetes (in particular IDDM), 
in certain instances it may give an unrepresentative measure of 
average giycaemia. Also, it cannot be used to monitor changes in 
glycaemia occurring in the short-term (i.e. week to week), which 
may be particularly important to assess the immediate response to 
new treatments and for the monitoring of diabetic pregnancies.
1.13.2. GLYCATED PLASMA PROTEINS
The measurement of glycated plasma proteins, especially glycated 
albumin have received much attention as monitors of short-term 
glycaemia due to their rapid turnover as compared to haemoglobin 
within the erythrocyte.
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Although total glycated plasma proteins have been shown to be a 
sensitive indicator of hyperglycaem ia (McFarland et al., 1979; 
Dolhofer and Wieland, 1980), the measurement of individual glycated 
plasma proteins is preferred due to problems in interpreting total 
glycated plasma proteins. The latter is a heterogeneous mixture of 
proteins with d iffe rent half-lives, d ifferent numbers of reactive 
amino groups and competitive binding of particular proteins to other 
molecules.
Most attention has been devoted to glycated albumin (GA), which is 
the most abundant plasma protein (approximately 70-80% of the 
total) and has a half-life of about 20 days (Peters, 1985).
The correlations of GA with various indices of glycaemia are varied 
and depend particularly on the group of patients studied. This is due 
mainly to the d ifferences in stab ility  of blood glucose levels 
between NIDD and !DD subjects (as described, in previous section on 
glycated haemoglobin). In all groups of subjects (including norma! 
subjects) it has been found that GA correlates the strongest with 
the mean blood glucose level calculated from frequent daily blood 
glucose m easurements (Dolhofer and W ieland, 1980; Ziel and 
Davidson, 1987).
A sign ificant corre lation is generally found between GHb and 
GA/total plasma glycated proteins in diabetic subjects (McFarland 
et a l., 1979; D o lho fe r and W ie land , 1980; Jones et 
a l.,1983;M urtiashaw  et al., 1983; Ziel and Davidson, 1987). 
Although, Guthrow et al., (1979) found a poor correlation between 
GHb and GA in both normals and diabetics. This finding may be partly 
due to the wide group of subjects studied, which included both NIDD 
and IDD subjects, with duration of diabetes ranging from 3 - 20 
years and also normal subjects. All the diabetic subjects were 
defined as being poorly controlled, therefore the short-term changes 
in glycaemia may not mirror the long term changes in these patients. 
So, the lack of correlation between GA and GHb was probably due to 
the d ifferent half-lives of the proteins, thus detecting' d ifferent 
periods of glycaemia.
The main advantage of measuring GA is that it appears to be a much 
more sensitive ind icator of short-term  changes in glycaem ia. 
Several studies have been performed following the rate of change of 
GA and GHb with the .start of therapy in newly diagnosed or poorly 
stabilized diabetics (Dolhofer and Wieland, 1980; Kennedy et al., 
1981; Jones et al., 1983). The percentage decrease in GA was much 
greater than in GHb and occurred more rapidly (within the first week
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of treatment). So, changes in glycaemia in response to treatment 
can be monitored more closely with GA than with GHb.
Another important difference found between GA and GHb is the lack 
of overlap found between diabetic and non-diabetic subject groups 
when average glycaemia is assessed by GA (McFarland et al., 1979; 
Guthrow et al., 1979; Schleicher et a!., 1984; Ziel and Davidson,
1987). This probably reflects both the shorter half-life of albumin 
and its greater tendency to become glycated (Olufemi et al., 1987), 
so that it detects smaller changes in blood glucose than GHb.
Despite GA having several advantages over GHb in the monitoring of 
blood glucose concentrations, GHb (e ither HbA-j or H bA ic) is 
genera lly used, probably reflecting m ethodologica l d iffe rences 
between the two proteins. Assays for GA are fairly laborious and 
lack automation, whereas GHb can be measured by one of several 
simple and relatively easily automated procedures. However, a 
d iffe rent type of assay for the measurement of total glycated 
plasma proteins was developed by Johnson et al., (1982), the so- 
called fructosamine assay. It has since been automated (Lloyd and 
Marples, 1984) and has been shown to be cheap, precise and simple 
to perform. However, as well as having many methodological 
difficulties, it has been shown that only 50% of the fructosamine 
activity measured is due to glycated proteins (Howey et al., 1987; 
Schleicher et al., 1988). The nature of the other 50% is unclear but 
does not appear to be albumin associated and differs from patient to 
patient (Howey et al., 1987). Fluckiger et al., (1987) showed that 
the re  was vast in tra - in d iv id u a l va ria tion  in fruc tosam ine  
concentration that was not accounted for by correction for protein 
concentration, suggesting that other factors must be responsible for 
th is va riab ility .
Despite these findings, numerous clinical studies have shown that 
the fruc tosam ine  concen tra tion  co rre la tes s ig n ifica n tly  w ith 
various indices of glycaem ia and with other glycated proteins 
(Johnson et al., 1982; Lloyd and Marples, 1984; Baker et al., 1985; 
Mosca et al., 1987). Dominczak et al., (1988) followed fructosamine 
and GHb for 8 - 18 weeks in both IDD and NIDD subjects and found 
both tests of glycation to be useful monitors of glycaemic control. 
They concluded that the fructosamine and GHb assays should be used 
as complementary rather than alternative tests. Jerntorp et al.,
(1988) on the other hand found that in a group of diabetics, whilst 
only 4% had normal GHb levels, 39% had normal fructosamine 
concentrations. Also, after two weeks of treatment, fructosamine
and GHb both decreased, but after six weeks, although GHb had 
decreased further fructosamine remained unchanged.
So, although giycated plasma proteins when measured by specific 
assays (i.e. GA) have significant advantages over GHb for the 
monitoring of blood giucose levels, plasma giycated proteins as 
measured by the fructosamine assay does not appear to accurately 
reflect changes in blood glucose, probably due to a variable 
contribution made by a non-specific ungiycated component.
Other plasma proteins studied as monitors of short-term  blood 
glucose control, include transferrin which has a half-life of 8 days. 
Kemp et al., (1984) followed GA and giycated transferrin in 73 
diabetic children. After 10 days of careful control mean GA fell 
from 16.4 to 14.6% and mean glycated transferrin feil from 8.2 to 
6.7%.
1.14. PATHOPHYSIOLOGICAL EFFECTS OF GLYCATION
There are two mechanisms as to how non-enzymic glycation might 
lead to or contribute to the chronic complications of diabetes and 
perhaps also to the normal process of ageing. The first concept is 
that glycation might involve a site which is crucial to the specific 
functioning or normal metabolism of a protein. This might be 
particularly relevant for relatively short-lived proteins with highly 
specialised functions. The second concept is that glycation leads to 
an alteration in structure or physical properties of a protein. This 
would be especially relevant to long-lived tissue proteins.
1.14.1. SHORT-LIVED PROTEINS
1.14.1.1. Haemoglobin
The amino-termina! of the (3-chain of haemoglobin to which giucose 
attaches is also the site where 2,3-diphosphoglycerate binds. 2,3- 
d iphosphoglycerate  in fluences the a ffin ity  of haem oglobin for 
oxygen through its ability to bind to deoxyhaemoglobin. When the 
amino-terminals of the (3-chains are covalently linked to glucose, 
the a va ila b ility  • of these s ites  for in te ra c tio n  w ith 2,3- 
diphosphoglycerate are compromised (Bunn and Briehl, 1970). Hence, 
GHb exhibits greater oxygen affinity than unglycated haemoglobin in 
the presence of 2 ,3-d iphosphoglycerate  (D itzel et al., 1975; 
McDonald et al., 1979). When GHb is increased in diabetic red blood 
cells, the oxygen affinity of these cells in the presence of 2,3-
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diphosphoglycerate is slightly greater than that of red ceils from 
non-diabetic subjects (Arturson et al., 1974). Whether the minor 
shift in the haemoglobin-oxygen dissociation curve arising from 
increased GHb in diabetics has a major impact is unclear. Ditzel 
suggested that it promotes hypoxia, which in turn could contribute 
to diabetic complications (Ditzel & Standi, 1979; Ditzel et al., 1979; 
D itzel, 1980). However, th is in te rp re ta tion  rests on the 
extrapolation of in v itro  data to in v ivo  situations. Ditzel et al., 
(1975) did find an increased oxygen affin ity in the blood from 
diabetic children and it is possible that an increased GHb coupled 
with low red cell 2,3-diphosphoglycerate in diabetes (Standi and 
Kolb, 1973) might result in tissue hypoxia.
However, haemoglobinopathies produce greater shifts in the oxygen- 
d isso c ia tio n  curve  w ith o u t d e le te rio u s  e ffe c ts  on tissue  
oxygenation, which makes it unlikely that the minor change in 
oxygen a ffin ity  associated with an increase in g lycation of 
haemoglobin in diabetes significantly alters oxygen transport (Bunn 
et al., 1979).
1.14.1.2. Albumin
Although glycation of albumin does not affect its circulating half- 
life  or m etabolism  (Day et al., 1979(b)), it can induce a 
conform ational change in the protein altering its ligand binding 
properties (Shaklai et ah, 1984). W illiams (1981) showed that 
glycated albumin was taken up more avidly than native albumin by 
endothelia l cells in v i t r o . Other experiments have shown that 
g lycated album in and other c ircu la ting  g lycated prote ins in 
uncontrolled diabetes could increase transendothelial transport and 
contribute  to increased cap illa ry perm eability  associated with 
diabetes (Williams & Solenski, 1984; Williams & Segal, 1985). In 
support of this concept is the finding that the passage of glycated 
album in through the g lom eru lar filtra tion  barrie r is enhanced 
relative to that of normal albumin in diabetic patients with and 
without m icroalbuminuria as well as in normal people. McVerry et 
al., (1980) reported that the intravenous in jection of glycated 
plasma proteins produces glomerular basement membrane thickening 
in non-diabetic mice. However, Nathka et a l.(1984) performed a 
sim ilar experim ent and found no thickening of the g lom erular 
basement membrane.
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1.14.1.3. Lipoproteins
Glycation of low-density lipoproteins (LDL) has been implicated in 
the increased incidence of macrovascular disease associated with 
diabetes.
Initial in v itro  studies showed that the binding and degradation of 
glycated LDL by cultured human fibroblasts and by umbilical vein 
endothelial cells was diminished compared to ungiycated LDL and 
that the degree of reduction in degradation was greater with 
increased glycation (Kim & Karup, 1982; Saski & Cottam, 1982; 
Gonen et al., 1981 and Lorenzi et al. 1984).
However, it has since been argued that those in v itro  studies used 
glycated LDL that had been reduced with sodium borohydride and 
hence represented unphysiological conditions. Schleicher et al. 
(1985) examined the effect of non-reductive glycation on the- uptake 
and degradation of LDL in fibroblasts, hepatocyte macrophages and 
endothelial cells and found that glycation (1.8 - 4.6 glycated lysine 
residues per m olecule of apo lipoprote ins) did not a lter the 
interaction of LDL with its high affinity receptor. Only more heavily 
glycated LDL (more than 12 glycated lysine residues per molecule of 
apolipoproteins) or reduced glycated LDL exhibited reduced receptor- 
mediated internalisation and degradation by human fibroblasts.
The internalization and degradation of LDL from patients with IDDM 
and poor metabolic control is decreased compared to that of LDL 
isolated from normal subjects or from IDDM with good control 
(Lopez-V irella et al. 1982). There is little doubt that excess 
glycation of LDL occurs in v ivo  in diabetic patients with poor 
metabolic control, but whether glycated LDL plays an important role 
in the development of macrovascular disease is still equivocal.
1.14.1.4. Coagulation Proteins
Several pathophysiological consequences of excess glycation of 
factors involved in blood clotting have been suggested.
Increased glycation of lysine residues in fibrinogen may interfere 
with its function. However, in v itro  studies showed that glycation 
of fibrinogen to a level of 3.8mol glucose/mole protein had no effect 
on clotting time nor factor VIII crosslinking of fibrinogen (Ney et 
al., 1985). Further in v itro  studies showed that the glycation of
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fibrin reduced its susceptib ility  to degradation by the enzyme 
plasmin (Brownlee, Vlassara & Cerami, 1984).
Antithrombin ill is a coagulation-regulatory factor that binds to 
heparin and inhibits thrombin mediated cleavage of fibrinogen. 
Heparin binds at the £-amino groups of lysine and is crucial to its 
function. In v itro  glycation resuits in significant dim inution of its 
throm bin-inhib itory activity (Brownlee, Vlassara & Cerami, 1984). 
Antithrombin III activity has also been shown to be reduced in 
patients with insulin-dependent and non-insulin dependent diabetes, 
the extent of the reduction correlating with fasting blood giucose 
concentrations and the GHb levels (Banerjee et al. 1974; Sowers et 
al. 1980). G lycation induced interference with antithrom bin HI 
activity could explain the accelerated disappearance of fibrinogen 
that is normalized by improving giycaem ic contro l in diabetic 
patients (Jones & Peterson, 1979).
This inhib ition of antithrom bin 111 activ ity in conjunction with 
glycation induced changes in susceptibility of fibrin to degradation 
could play a role in the accumulation of fibrin reported to occur in 
severa l d iabetic  tissues affected by long-term  com plica tions 
.(Brownlee et al.,1984).
Glycation may also alter platelet function. Although there is little 
information as to whether any of the changes described in diabetes, 
such as increased platelet adhesiveness and aggregation, derive 
from glycation of platelet proteins, there is evidence that glycation 
of collagen increases its aggregating potency (Le Pape et aL, 1983).
1.14.1.5. Enzyme and Hormones
Even one firs t step in the glycation reaction, the reversib le 
formation of the Schiff base could significantly alter the catalytic 
properties of certain types of enzymes. The most likely inactivation 
mechanism would involve the giucose attachment to a lysine e- 
amino group essential for normal function of the active site.
In Ribonuciease A, for example, the loss of a single lysine at 
position 41 is known to cause total loss of enzyme activity.
Incubation of the enzyme with glucose for 24 hours results in 50% 
loss of initial enzyme activity associated with glycation of two
lysine residues per molecule (Brownlee et al.,1984).
Another study found that glycation of cathepsin B, an enzyme
involved in proinsulin cleavage, partially inhibits the ability of the
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enzyme to convert proinsulin to insulin in v itro  (Coradello et al. 
1981).
In v itro  g lycation of N -acetyl-D -g lucosam in idase resulted in a 
reduction in its activity (Dolhofer et al., 1982). This enzyme
participates in the catabolism  of glycosam inoglycans which are 
in tegra l constituents  of connective  tissues and extrace llu la r
matrices. Its activity is decreased in kidney and other tissues in 
d iabetes. • However, since the glycosam inogtycan content of 
basement membranes is reportedly decreased rather than increased 
in diabetes (Parathasarathy and Spiro, 1982; Cohen & Surma, 1984), 
it is unlikely that non-enzymic glycation of the enzyme in v ivo  is 
involved in the pathogenesis of diabetic basement membrane lesions.
In v itro  evidence of insulin glycation has been reported (Dolhofer & 
Wieland, 1979). Glycation diminished the hormone’s effect on the
oxidation of [14C]-glucose by adipose tissue, reduced its ability to
stim ulate lipogenesis in isolated adipocytes and decreased its 
antilipolytic activity. However, since insulin has a relatively short 
half-life, it is not clear whether in v ivo  .glycation of the hormone 
would be to a sufficient extent to have impact on biologic function.
1.14.2. LONG-LIVED PROTEINS
The effect of glycation on the physical properties and structure of 
long-lived proteins is more complex than for the shorter-lived 
proteins and probably has more profound effects on their function.
G lycation of proteins resulting in the formation of the Amadori 
product is only the. first step in a series of non-enzymjc reactions 
long known to food chemists as the Maillard or Browning reaction 
(Hodge, 1953; Reynolds, 1963; Reynolds, 1965). The products of such 
reactions are highly cross-linked , inso lub le , p igm ented and 
fluorescent carbohydrate-protein polymers called melanoidins.
Maillard browning involves three phases, which were clarified over 
25 years ago by Hodge (1953). Formation of the colourless 
deoxyketose derivative (Amadori compound) via the Schiff base 
intermediate is the first step and is sometimes referred to as the 
.‘early Maillard reaction’. The next phase involves the removal of 
amino groups via 1,2- or 2,3-enolization reactions followed by 
dehydra tion , cyc liza tion  and fiss ion  reactions tha t generate 
secondary products such as hydroxym ethylfurfura l, reductones, 
aldehydes and • dicarbonyls. In the third phase, polymerization 
reactions occur, y ie ld ing n itrogen-free brown pigm ents if the
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complexing secondary phase products' derive from the sugar moiety 
of the Amadori compound and nitrogen-containing polymers when 
secondary products react with amino groups (Finot, 1982) to form 
aldimines and ketimines. The first phase is relatively fast, whilst 
the second and third phases occur very slowly.
The formation of the Amadori product is well recognised and the 
evidence is overwhelming that it occurs in vivo . It is only recently 
tha t the poss ib ility  of advanced M aillard reactions w ith the 
formation of post-Amadori products might also occur in v ivo  and 
that they may be linked with both the pathogenesis of chronic 
com plications occurring in diabetes and also with the norma! 
process of ageing (Brownlee et al., 1984; Pongor et al. 1984).
The term now being adopted for substances which result from the 
fu rthe r m od ifica tion  of the Am adori p roduct is ‘Advanced 
Glycosylation End (AGE) Products’. These AGE products form very 
slowly and irreversibly and may accumulate over many years, thus 
the biological half-life of the protein will be especially important 
in determining the extent to which these products form.
AGE products have been shown to be present in lens crystallin where 
they may result in cataract formation (Stevens et al. 1978; Monnier 
& Cerami, 1981) collagens where they may contribute to both micro 
and macro vascular disease ( Brownlee et al., 1986), nerve tubulin 
and m yelin a ffec ting  axop lasm ic  tran sp o rt and the re fo re  
contributing to diabetic neuropathy (Williams et al., 1982) and also 
DNA (Bucala et al., 1984). The accumulation of AGE products on DNA 
may be responsible for age-dependent changes in the genetic 
material that include chromosomal aberrations, DNA stained breaks 
and a decline in DNA repair, replication and transcription. The 
amount of AGE products increases with age in normal subjects 
(Monnier et al., 1981). Diabetic individuals have a greater amount of 
AGE products relative to non-diabetics of similar age. This suggests 
that ageing of long-lived proteins is accelerated in subjects with 
diabetes.
The structure of one of the AGE products has been characterised, 2- 
furoyl-4(5)-(2-furanyl) 1H-im idazole (FFI) (Pongor et al., 1984). 
However Njoroge et al. (1988) have recently shown that FFI can also 
form from the acid hydrolysis of Amadori products in v itro  and may 
therefore be an artefact.
Prelim inary evidence for the form ation of a d iffe rent type of 
compound, protein-bound pyrolles during the glycation of proteins jn
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v itro  has been reported by Ghiggeri et al., (1985). Hayase et al.
(1989) developed two different types of immunoassays to one of 
these glucose-derived pyroiies, called pyrrailine and found it to be 
present on albumin from both normals and diabetics and to a greater 
extent on diabetic albumin. They speculate that these pyroiies 
might also be involved in ageing and diabetic complications.
Evidence has also been presented for the existence of two 
alternative pathways for the Amadori product that do not involve 
Maiiiard browning (Ahmed, 1986 and Ahmed, 1988) (see Fig. 1.5). 
Incubation of N-form yi-fructose lysine, an analogue of glycated 
lysine residues in proteins, under physiological conditions in v itro  
resulted in the formation of either carboxymethyi-iysine (CML) and 
erythronic acid or lysino-iactic acid (LL) and D-g!yceric acid as a 
result of oxidation. Both CML and LL have been detected in human 
lens protein and in human urine suggesting that they are also formed 
in v ivo by degradation of glycated proteins. They are described as 
non-browning pathways of the Maiiiard reaction and appear to 
compete with the browning reactions. These products are relatively 
inert compared to cross-linked products, such as FFi and may limit 
the consequences of protein glycation in the body. Differences in 
rates of browning versus non-browning pathways among individuals 
may be im portant in determ ining their relative susceptib ility  to 
tissue damage from these reactions. This may explain why some 
individuals develop complications more rapidly compared to others, 
despite having the same levels of glycaemia.
So, there is much evidence to suggest that hyperglycaemia-induced 
glycation of proteins is involved in the development of chronic 
com plications in diabetes both through early M aiiiard reactions 
mainly affecting short-lived proteins and with the formation of AGE 
products on long-lived proteins.
The inhibition of the glycation reaction at any stage in the sequence 
of reactions may help to alleviate or prevent the development of 
these complications. Brownlee et a l.(1986) have shown that a 
nucieophilic  hydrazine com pound, am inoguanid ine reduces the 
formation of fluorescent AGE’s and the formation of glucose-derived 
collagen cross-links in v iv o . The administration of aminoguanidine 
to diabetic rats prevented the accumulation of fluorescent AGE in 
aortic connective tissue; and also inhibited the increase in collagen 
cross-link ing  seen in aortic  tissue from untreated anim als 
suggesting a potential role for aminoguanidine in the prevention and 
treatment of. chronic diabetic complications.
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FIGURE 1 . 5 .  PROPOSED P A T H W A Y S  FOR F U R T H E R  
METABOLISM AND DEGRADATION O F  N O N - E N Z Y M A T I C  
GLYCATION PRODUCTS AND HYPOTHETICAL ROLES I N  
THE FO RM ATIO N  O R  PR EVENTIO N OF C H R O N I C  
DIABETIC COMPLICATIONS
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1.15. BACKGROUND AND AIMS OF THESIS
Between 1983 and 1985 a two-phase screening survey for diabetes 
was conducted in North London, the so-called Islington Diabetes 
Survey (Forrest et a!., 1986; Forrest et al., 1987).
A random sample of non-diabetic patients over the age of 40 
registered with a single group practice were selected for study and 
1084 of the 1644 eligible subjects (65.9%) were examined in phase 
i. They underwent a simplified glucose tolerance test consisting of 
a 75g glucose load taken in the form of lucozade in the morning after 
an overnight fast and a capillary blood sample taken 2 hours later 
for the estim ation of glucose (2HBG) and GHb measured by 
electrophoresis without removal of the Schiff base. In phase II of 
the stt*dy~ a stratified sample of those originally examined were 
selected biased towards subjects with more marked degrees of 
glucose-intolerance. There were 347 subjects recalled and 223 
(64.3%) were examined. The recall examination comprised a full 
OGTT with venous blood samples being taken at fasting, 1 hour and 2 
hours after the glucose load for the measurement of glucose and for 
the assay of GHb by four different methods on the fasting and 2 hour 
samples. GHb was measured by agar gel electrophoresis, with and 
w ithout the removal of the Schiff base, isoelectric focusing and 
affin ity chrom atography.
To overcome the problem of the use of capillary blood at screening 
and venous blood at recall, and by the different ranges for the 
various assays of GHb, all 223 subjects examined at recall were 
classed into centile rankings of 2HBG at screening and recall, and of 
GHb at screening and by each assay method both fasting and 2 hour- 
post glucose at recall. The mean centile ranking for 2HBG and GHb 
were then calculated.
An interesting observation in this study was the unusually poor 
correlation found between the mean GHb and the mean 2HBG (r =
0.51, see Fig. 1.6(a) and (b)). The relationship was the same between 
2HBG at recall or screening and any of the individual GHb assays. 
There were 42 subjects (non-diabetics) in whom the mean 2HBG 
ranking differed by at least 30 centiles from their mean ranking for 
GHb (see Fig. 1.7). Twenty had a mean ranking for GHb exceeding 30 
centiles higher than for 2HBG (HIGH GLYCATORS) and twenty-two had 
a mean GHb ranking more than 30 centiles lower than for 2HBG (LOW 
GLYCATORS). There was no difference in age, gender, body mass
43
FIGURE.1.6.(a) MEAN GENTILE RANKINGS OF TWO, 
HOUR BLOOD GLUCOSE AND OF ALL THE ASSAYS FOR 
GLYCATED HAEMOGLOBIN AT SCREENING AND RECALL
The line of agreement is indicated.
The corresponding levels of blood glucose, and of two-hour post-load 
assays of glycated haemoglobin are indicated.
Total GHb - agar-gel electrophoresis without the removal of the 
Schiff base
Stable GHb - agar-gel electrophoresis with prior removal of the 
Schiff base
Aff - affinity chromatography 
IEF - isoelectric focusing
Screen ing 3  4
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FIGURE.1.6.(b) ARITHMETIC MEAN LEVELS O F  TWO- 
HOUR BLOOD GLUCOSE AND ALL OF THE ASSAYS FOR 
GLYCATED HAEMOGLOBIN
High glycators represented as ( •  ) and low giycators as ( a ).
Mean 1 5 -
glycated
haemoglobin -14..
0/ '
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FIGURE.1.7 MEAN CENTILE RANKINGS OF TWO-HOUR 
BLOOD GLUCOSE AND OF ALL OF THE ASSAYS FOR 
GLYCATED HAEMOGLOBIN AT SCREENING AND RECALL 
SN THE HIGH AND LOW GLYCATORS
The line of agreement is indicated.
The corresponding levels of blood glucose, and of two-hour post-ioad 
assays of glycated haemoglobin are indicated.
High glycators represented as ( •  ) and low glycators as ( ± ).
Abbreviations as for Figure 1.6.
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index or haemoglobin level between the high and low glycators (p > 
0.1). Nine of the high (45%) and four of the low (18%) were cigarette 
smokers. Seven of the high glycators and five of the low glycators 
were taking medication; two high and one low glycator were taking 
non -steroidal anti-inflammatory drugs; two high glycators were on 
thiazides; one high and one low glycator were on nitrites and one 
high and one low glycator on digoxin; and one each was taking 
benzodiazepines (high), antacids (high), p-blockers (high), thyroxine 
(low) and aminophylline (low).
Due to the unphysiological nature of the OGTT the high and low 
glycators were also classed into rankings of fasting blood glucose 
(FBG) (see Fig. 1.8). There was a less marked difference between 
median rankings of GHb and of glycaemia than when classified by 
2HBG, but the difference was still apparent. 18 out of 20 high 
glycators and 16 out of 22 low glycators remained in the same 
categories when classified by FBG.
The contribution of OGTT variability and of both assay and biological 
variability to the weakness of the relationship between GHb and 
glycaemia has also been assessed (Yudkin et al., in press), but were 
not found to be major determinants of the poor relationship.
So, the marked differences in individual levels of GHb found in this 
group of non-diabetics could not be explained by either fasting 
glycaemia or tolerance to a glucose load. Certain diets have been 
shown to have marked effects on both fasting glycaem ia and 
tolerance to an unphysiological glucose load. Thus, starvation or a 
carbohydrate-restricted diet causes intolerance to a glucose load 
(Wilkerson et al., 1960), whilst causing a reduction in fasting blood 
glucose and GHb (Ktorza et al., 1985). A high carbohydrate intake 
has been reported to improve glucose tolerance (Brunzell et al., 
1971). However, a high carbohydrate, high fibre diet may lower 
fasting blood glucose levels despite an increase in post-prandiai 
levels of blood glucose (Simpson et al., 1979).
So, a dietary survey was carried out by 25 of the subjects (60%) (12 
high glycators and 13 low glycators), a mean of 2.3 years after the 
original screening survey, to investigate whether differences in diet 
might explain the inappropriate levels of GHb relative to the degree 
of glycaemia (Yudkin et al., in press). Each subject was asked to 
record a 7-day food diary and then the daily intake of all nutrients 
were calculated from standard food tables. Table 1.4 shows the 
mean levels of nutrient intakes in the low and high glycators. There
s
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FIGURE.1.8 CENTILE RANKINGS OF FASTING BLOOD 
GLUCOSE AND MEAN CENTILE RANKINGS OF ALL THE 
ASSAYS FOR GLYCATED HAEMOGLOBIN AT SCREENING 
AND RECALL IN THE LOW AND HIGH GLYCATORS
The line of agreement is indicated.
High glycators represented as ( •  ) and low glycators as ( ^ ).
The corresponding levels of blood glucose, and of two-hour post-ioad 
assays of glycated haemoglobin are indicated.
Abbreviations as for Figure. 1.6.
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TABLE 1 . 4 .  DAILY NUTRIENT I N T A K E  I N  T H E  L O W  A N D  
HIGH GLYCATORS
Low glycators High glycators Significance 
(n=13) (n=12) of difference
(P)
Age 65.8 (13.0) 60.1 Q03) 0.24
BMI 25.0 (3.4) 26.4 (4.3) 0.37
Total Carbohydrate (g) 195.9 (40.5) 194.6 (58.0) 0.95
Starches & Dextrins (g) 111.6 (34.6) 108.5 (33.1) 0.87
Sugars (g) 75.1 (27.9) 76.0 (29.2) 0.94
Glucose Equivalents (g) 157.5 (35.2) 157.9 (48.4) 0.98
% Energy from Carbohydrates 41.7 (8.4) 38.8 (85) 0.39
Protein (g) 67.1 (18.7) 67.9 (18.3) 0.91
Vitamin B6 (mg) L15 (0.30) 135 (0.41) 0.19
Vitamin C (mg) 535 (36.6) 67.9 (32.4) 031
Total Fibre (g) 16.6 (5.7) 19.2 (9.4) 0.42
Soluble Fibre' (g) 7.3 (2.3) 8.2 (3.6) 0.49
Energy (Cals) 1806 (465) 1864 (429) 0.75
Alcohol (g) (median^ ange) 2.7 (0-36) 1.0 (0-57) 0.65
Values are shown as mean (SD) for normally distributed data and median (range) for skewed data 
which are so indicated. The former are compared using Student’s unpaired t-test and the latter by 
Mann-Whitney U-tesL
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was no significant difference in the intake of any of the major 
nutrients or of fibre between the two groups. In particular, the 
consumption of total carbohydrates, sugars, glucose equivalents, 
total fibre and soluble fibre were no different between high and low 
glycators. Also, no significant differences between the two groups 
could be identified when nutrient intake was expressed as a 
proportion of the total energy intake or as a percentage of body 
w e igh t Vitamin C and vitamin B6 were found to be marginally 
higher in the high glycators. However, again these differences were 
no longer significant when corrected for body weight or total energy 
intake. So, dietary patterns also failed to explain the difference in 
levels of GHb relative to glycaemia in the high and low glycators.
Therefore the aims of this thesis were divided into t h r e e  
main parts, as follows:
.1. INVESTIGATION OF THE HIGH AND LOW GLYCATORS
(a) Stability of the high and low glycators
This involved recalling the original 42 subjects and performing a 
repeat OGTT to determine whether they still remained classified in 
the same two groups, four years after the original screening survey.
(b) Measurement of ambient glycaemia in the low and high 
g ly c a to rs
Blood glucose profiles were performed on the two groups of 
subjects and the mean blood glucose calculated to determ ine 
whether ambient glycaemia was responsible for the differences in 
GHd
(c) Determination of the cause(s) of the high and low 
g ly c a t io n
A detailed biochemical and haematological analysis was carried out . 
on the two groups of subjects to investigate whether there may be 
determ inants other than glucose affecting the ir g lycation of 
haemoglobin.
2. INVESTIGATION OF THE EFFECT OF DIET ON GLYCATION
Although the d ietary survey failed to show any s ign ificant 
differences between the two groups of subjects, the imprecision and 
poor reproducibility of the dietary history as a means of assessing
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intake is well known (Burke, 1947; James et al., 1980). Therefore a 
study was undertaken to investigate the effect of specific dietary 
components, carbohydrate and fibre on glucose tolerance and 
glycation of proteins in a small group of healthy volunteers.
3. INVESTIGATION OF THE EFFECT OF VITAM IN C ON 
GLYCATION
Although the intake of another dietary component, vitamin C was 
not significantly different between the 2 groups it has been shown 
to specifically affect the glycation of proteins in v it ro , therefore a 
third study was carried out investigating the effect of oral vitamin 
C on the glycation of proteins in vivo in healthy, human volunteers.
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C H A P T E R  2  
E X P E R I M E N T A L  M E T H O D S
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2.0 INTRODUCTION
The methods described in this chapter were used for ail the analyses 
carried out in Chapters 3, 4 and 5.
Al! the reagents used were of Analar grade and obtained from BDH 
(BDH Limited, Poole, Dorset), unless otherwise stated.
2.1. GLYCATED HAEMOGLOBIN
Glycated haemoglobin was measured by three different methods, 
affinity chromatography (Gould et ai., 1982), isoelectric focussing 
(Mortensen, 1980) and agar-gel electrophoresis (Menard et ai.,
1980).
2.1.1. AFFINITY CHROMATOGRAPHY
2.1.1.1. REAGENTS
GLYCOGEL B - m-aminophenyiboronate agarose (Pierce and Warriner, 
Chester,- U.K.).
WASH BUFFER-200 mmol/l ammonium acetate
50 mmol/! magnesium chloride 
3 mmoi/l sodium azide
The pH was adjusted to 8.5 using 1M sodium hydroxide or 1M 
hydrochloric acid.
ELUTION BUFFER-200 mmol/i sorbitol
50 mmol/l disodium EDTA 
3 mmol/l sodium azide
100 mmoi/l tris (hydroxymethyl) methylamine
The pH was adjusted.to 8.5 using 1M sodium hydroxide or 1M 
hydrochloric acid.
REGENERATION SOLUTION- 0.01 M acetic acid.
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2.1.1.2. APPARATUS
Minicolumns were obtained from Biorad Laboratories Limited 
(Watford, Herts, U.K.) for the affinity chromatography.
The absorbances of the fractions were measured on a Uvikon 860 
Spectrophotometer (Kontron Instruments, Zurich).
2.1.1.3. PROCEDURE
100 pi of potassium EDTA packed erythrocytes was added to 2 mis of 
deionised water and vortex mixed to haemolyse the cells.5 mis of 
wash buffer at 20 ±1°C was added to the affinity columns each of 
which contained 1 ml of the gel, so that the latter equilibrated at 
the correct pH and temperature. When drained, the columns were 
placed onto 25 ml measuring cylinders, 100 pi of haemolysate added 
to the top of the gel and allowed to soak in. This was followed by 1 
ml and then a further 7 mis of wash buffer. Once this had drained 
through, the wash fraction collected in the measuring cylinder was 
made up to 15 mis with wash buffer.The columns were then placed 
onto 10 ml plastic tubes and the glycated haemoglobin eluted with 3 
mis of elution buffer at 20 ±1°C.The wash fraction was mixed by 
inversion and the elution fraction by vortexing.The absorbances of 
the two fractions was measured at 414 nm, using the wash buffer as 
a blank. The percentage of glycated haemoglobin was determined by 
the following equation:
GHb(%) = ■■-.......... ......... x 100
(Aw x 5)'+Ae
where Ae = Absorbance of elution fraction 
Aw « Absorbance of wash fraction
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2.1.2. ISO-ELECTRIC FOCUSING
2.1.2.1. REAGENTS
AMPHOLINE POLYACRYLAMIDE GELS for the determination of HbA1c 
were obtained from LKB (LKB Products, Bromma, Sweden).
0.9% sodium chloride
1M potassium cyanide
Carbon tetrachloride
ELUTION BUFFER - 0.05M Tris-HCI buffer, pH 8.3 containing 0.01 M 
potassium cyanide and 0.1 mM EDTA.
ELECTRODE SOLUTIONS - Cathode - 0.1 M sodium hydroxide
Anode - 0.04M glutamic acid
2.1.2.2. APPARATUS
LKB (Bromma, Sweden) Multiphor II electrophoresis unit (2117).
LKB Power supply
Uvikon 860 Spectrophotometer (Kontron Instruments, Zurich, 
Germany). ■
2.1.2.3. PROCEDURE
The instructions provided by LKB with their gels were used to carry 
out the measurement of HbA1c as follows:
Preparation of haem olvsate
100 jil of potassium EDTA whole blood was added to 1 ml of 0.9% 
sodium chloride and vortex mixed. After centrifugation at 3000 g 
(room temperature) for 5 minutes, the supernatant was removed 
taking care not to disturb the erythrocyte pellet. This was followed 
by the addition of 600 |il of 0.01 M potassium cyanide and 1 drop of 
carbon tetrachloride. After vortex-mixing, the sample was further 
centrifuged at 3000 g (room temperature) for 10 minutes. Then 0.5 
mis of the clear supernatant was pipetted into a new tube.
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Isoe lec tric  focus ing
1 5 - 3 0  minutes prior to electro-focusing, cold water was 
circulated in the cooling piate. A small volume of liquid paraffin 
was spread over the cooling piate to make a thin film. Then the gel 
was removed from the package and carefully lowered onto the 
cooling plate, avoiding getting air bubbles between the gei and the 
p late.
Each electrode strip (wick) was saturated with the appropriate 
electrode solution and the excess removed. These were then 
carefully laid onto the gel 1-2 mm from the edge on the correct 
sides for focusing (the strips should be cut to fit the gel length).
The electrofocusing lid was then put on, positioning the electrodes 
on the wicks. The electrofocusing unit was then connected to the 
power supply and the voltage set to 2000V, the power to 20W and 
the current to 50 mA.
The gel was first run without samples for 30 minutes. Then the 
power supply was switched off and the sample application pieces 
placed on the gel surface, about 1cm from the cathode electrode 
strip and 3 mm apart. Up to 30 samples could be applied per gel.
Then 15jul of each haemolysate was pipetted onto each sample 
application piece. Then the electrofocusing lid was replaced and the 
power switched on again. After 40 minutes the sample application 
pieces were removed and electrofocusing carried out for a further 
70 minutes.
When focusing was complete the power supply was switched off and 
each HbAic band cut out of the gel and put into 1 ml of eluting buffer. 
The H bA ic was eluted for 12 - 24 hours at 4°C with constant mixing. 
Total haemoglobin (HbA0) solutions were prepared by adding 15 jii of 
each haemolysate to 5 mis of the elution buffer and mixing well.The 
absorbance of the HbAic and HbA0 fractions were measured at 415 
nm and the percentage of H bA ic calculated as follows:
Absorbance o f  HbA \ r
% HbA 1 = ------------------ ------------------
5 x Absorbance o f  HbAQ
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2.1.3. AGAR-GEL ELECTROPHORESIS
Glycated haemoglobin (HbA-i) was assayed with and without the 
removal of the labile Schiff base using the Glytrak TM Kit obtained 
from Corning Medical Limited, Halstead, Essex, U.K.
2.1.3.1. REAGENTS (all supp lied  by C orn ing)
AGAR GEL PLATES - 2% (w/v) agar gel containing 4% sorbitol, 0.036M 
sodium citrate,.002M citric acid and 0.003M disodium EDTA pH 6.3.
GLYSOSYLATED HAEMOGLOBIN BUFFER - Supplied in vials each 
containing 27.9 g of citric acid trisodium salt dihydrate and 0.98 g 
citric acid. Each vial was made up to 11 with distilled water (0.1 M, 
pH 6.3).
HAEMOLYSING REAGENT - Supplied in 15 ml vials, each containing 
0.1% saponin and 0.05% EDTA in distilled water.
LABILE-REMOVING HAEMOLYSING REAGENT - Supplied in 15 mi vials, 
each containing 0.1% Saponin and 0.05% EDTA in potassium dithiolate 
bu ffe r.
2.1.3.2, APPARATUS (supp lied  by C orn ing)
Cassette electrophoresis cell (No. 470130)
Incubator/oven (No. 470041/40)
Variable Voltage Power Supply (No. 470024)
Densitometer (No. 475710/360)
2.1.3.3. PROCEDURE
The procedure employed was as described in the instructions 
provided by the manufacturer, which are as follows:
Sample Preparation
100 pi of potassium EDTA whole blood was added to 300 pi of iabile- 
removing haemolyzing reagent and also to 300 pi of the other 
haemolyzing reagent (measuring total HbA-j inclusive of. the Schiff 
base). The latter were vortexed mixed and then ready to use. The 
former samples were incubated at 37°C for 15 minutes prior to 
e lectrophoresis.
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E lectrophoresis
95 mis of buffer was placed in each chamber of the electrophoretic 
ceil. Then 10 pi of each haemolysate was added to each of the wells 
in the gel plate. The gel plate was then loaded securely into the 
cassette holder and placed in the electrophoretic cell.
Electrophoresis was carried out at 60V for 40 minutes. Then the gel 
plate was removed from the cassette holder and dried completely in 
the oven at 55 ±10°C (1 0 -2 0  minutes). The gel was then scanned at 
420 nm in the densitometer and the glycated haemoglobin (both total 
and with the labile removed) expressed as a percentage of the total.
2.2. GLYCATED ALBUMIN
Plasma glycated albumin was measured by first separating 
unglycated and glycated albumin by affinity chromatography, 
followed by the analysis of the albumin concentration. in the two 
fractions using rocket immunoelectrophoresis (John and Jones, 
1985).
2.2.1. AFFINITY CHROMATOGRAPHY
2.2.1.1. REAGENTS
GLYCOGEL B (Pierce and Warriner, Cheshire, U.K.)
WASH BUFFER - 250 mmoi/l ammonium acetate
50 mmol/l magnesium chloride 
3 mmol/l sodium azide
The pH was adjusted to 8.5 using 1M sodium hydroxide or 1M . 
hydrochloric acid.
ELUTION BUFFER - 200 mmol/l sorbitol
50 mmol/l disodium EDTA
100 mmol/l tris(hydroxymethyl)methylamine 
3 mmol/l sodium azide
The pH was adjusted to 8.5 using 1M sodium hydroxide or 1M 
hydrochloric acid.
REGENERATION SOLUTION - 0.01 M acetic acid.
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2.2.1.2. APPARATUS
Minicoiumns were obtained from Biorad Laboratories Limited 
(Watford, Hertfordshire, U.K.) for the affinity chromatography.
2.2.1.3. PROCEDURE
100 pi of lithium heparin plasma was diluted in 1.5 mis of distilled 
water. 150 pi of the diluted plasma was then applied to a 1 ml 
affinity column already equilibrated with 5 mis of wash buffer 
(temperature 20 ±1°C). 1 mi of wash buffer was then added and 
allowed to soak in, followed by a further 8 mis of wash buffer. The 
entire eluate containing the unglycated albumin was collected and 
freeze-dried. The giycated albumin was eluted from the column 
with 3 ml of elution buffer (temperature, 20 ±1°C), which was also 
freeze-dried. The unglycated albumin fraction was reconstituted in 
20 mi of distilled water and the giycated fraction in 0.5 ml of 
w a te r.
2.2.2. ROCKET IMMUNOELECTROPHORESIS
This was carried out according to Laurell (1966).
2.2.2.1. REAGENTS
ELECTROPHORESIS BUFFER - 0.06M Barbitone buffer, pH 8.6 
0.9% sodium chloride 
1% agarose
50% polyethylene, glycol
COOMASSIE BLUE STAIN - 1 g of Coomassie Brilliant Blue C (Sigma 
Chemical Co., Poole, Dorset, U.K.) was dissolved in 50 ml ethanol. 20 
ml of glacial acetic acid and 130 ml of deionised water was added. 
Then it was left overnight and filtered before use.
DESTAIN SOLUTION - .50 ml methanol
100 ml glacial acetic acid 
850 ml deionised water
ANTISERUM - Guildhay (Antisera Limited, Guildford, Surrey, U.K.) 
Sheep anti-human albumin
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2.2.2.2. STANDARD
Human albumin SPS01 (Sheffield Protein Reference Unit, Yorkshire, 
U.K.). 40 g/l diluted in 0.9% saline to produce a range of standards 
2.5 - 40 mg/l.
2.2.2.3. APPARATUS
Glass plates 21 x 10 cm
Electrophoresis tank (Shandon Southern Products Limited, Runcorn, 
Cheshire, U.K.)
Power-pack SAE 2761 (Shandon Southern Products Limited)
2.2.2.4. P rocedure  
P reparation of gel
22.4 ml of molten agarose was added to 1.6ml of 50% polyethylene 
glycol (PEG) 6000, mixed thoroughly and warmed to 56°C. Then 40jil 
of anti-albumin antisera was added to the agarose/PEG solution.
After mixing well, the mixture was drawn quickly into a warmed 30 
ml syringe and smoothly injected into a mould (2 glass plates 21 x 
10 cm clamped together). The gel was allowed to solidify and stored 
at 4°C in a moisture chamber at least overnight.
E lectrophoresis
When required the glass plates were carefully separated and any air 
bubbles removed from under the gel. A row of 30 wells were cut 
into the gel using a 4 mm punch (0.6 cm apart and 1.5 cm from the 
lower edge).
The gel on the glass plate was then placed in the electrophoresis 
tank (which was kept cooled on a cold tray) in contact with filter 
paper (3 mm) wicks. A small voltage (5 - 10V) was applied across 
the gei whilst 10 jil of the standards and samples were quickly 
applied. The voltage was then set to 100V and left to run overnight 
(approximately 16 hours).
At the end of electrophoresis the gel was removed from the tank and 
compressed with a heavy weight. After 20 - 30 minutes, the gel 
was dried with a hair-dryer. The gel was then stained, destained 
and dried again. The peak heights of the rockets were measured and
60
the concentration of albumin in each fraction calculated by 
comparison with the standards.
The percentage of glycated albumin of the total albumin was 
calculated as follows:
[ GLYCATED ALBUMIN ]
7 ;  F- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - x  1 0 0
[ GLYCATED ALBUMIN + 4 0 [ UNGLYCATED ALBUMIN ]
where G.A. =GLYCATED ALBUMIN
2.3. FRUCTOS AMINE
• Plasma fructosamine was measured using the method of Johnson and 
Baker (1982) adapted onto the Cobas Bio Centrifugal analyser (Lloyd 
and Marples, 1984).
2.3.1. REAGENTS
0.25 mmol/l nitroblue-tetrazolium (Sigma Chemical Company, Poole, 
. Dorset, U.K.) prepared in 0.1 M carbonate buffer, pH 10.35.
150 mmol/l sodium chloride
40 g/l human albumin solution (Centrai blood products laboratory 
authority, Hertfordshire, U.K.) prepared in 150 mmol/l sodium 
ch loride.
2.3.2. STANDARD
A 40 mmoi/l stock solution of 1 -deoxy-1 -morpholinofructose 
(Sigma Chemical Company, Poole, Dorset, U.K.) was prepared in the 
human albumin solution. This was diluted in the human albumin 
solution to produce a series of standards 0 - 4 mmol/l.
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2.3.3. APPARATUS
Cobas Bio Centrifugal Analyser (Roche Diagnostics Limited, Welwyn 
Garden City, Hertfordshire, U.K.).
Cobas Bio sample cups, rotors and reagent trays (Roche Limited).
2.3.4. PROCEDURE
500 pi of plasma was pipetted into the sample cups in the sample 
rotor, which was then loaded onto the Cobas Bio, the reagent and 
standards were pipetted into the reagent rack which was also loaded 
onto the analyser.
The parameter listing for the fructosamine assay was as shown in 
Table 2.1.
6.2
TABLE 2.1 PARAMETER LISTING 
FOR THE FRUCTOSAMINE ASSAY
1 UNITS m m o l/ l
2 CALCULATION FACTOR 0
3 STANDARD 1 CONC. 1
4 STANDARD 2 CONC. 2
5 STANDARD 3 CONC. 4
6 LIMIT 1 0
7 TEMPERATURE(°C) 37
8 TYPE OF ANALYSIS 5
9 WAVELENGTH(nm) 530
1 0 SAMPLE VOLUME(pl) 20
1 1 DILUENT VOLUME(pl) 50
1 2 REAGENT VOLUME(pl) 200
1 3 INCUBATION TIME(secs) 0
1 4 START REAGENT VOLUME(pl) 0
1 5 TIME OF FIRST READING(secs) 600
1 6 TIME INTERVAL (secs) 300
1 7 NUMBER OF READINGS 2
1 8 BLANKING MODE 1
1 9 PRINTOUT MODE 1
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2.4. GLUCOSE
Plasma and whole blood glucose were measured on a Cobas Bio using 
a hexokinase kit (Roche Diagnostics, Limited). Intra-erythrocyte 
glucose was calculated from the whole blood and plasma 
measurements using the following formula: •
[GLUCOSE ] e = [ GLUCOSE 1 -  [GLUCOSE ] -  [ GLUCOSE ] WB
HcT
where E, P and WB are the erythrocyte, plasma and whole blood 
glucose concentrations respectively and Hot is the haematocrit 
(Higgins et al., 1982).
Glucose was also measured on capillary blood spots collected onto 
1% boric acid impregnated filter paper using a glucose oxidase kit, 
(Boehringer Mannheim, Lewes, Sussex, U.K.) on the Cobas Bio (Burrin 
and Price, 1984).
2.4.1. WHOLE BLOOD AND PLASMA HEXOKINASE METHOD
2.4.1.1. REAGENTS
0.6M Perchloric acid (ice-cold)
0.9% sodium chloride
ASSAY REAGENT - supplied with kit
2.4.1.2. STANDARD
A 200 mmol/l stock solution of glucose was prepared in deionised 
water. This was diluted to produce a range of standards, 5, 10 and 
20 mmol/l. These three standards were then diluted 1 in 4 with 
0.6M perchloric acid, so that there were at the same pH and dilution 
as the samples.
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2.4.1,3. APPARATUS
See section 2.3.2.
2.4.1.4. PROCEDURE
Sam pia preparation
200 pi of whole blood or plasma were added to 800 pi of ice-cold . 
0.6M perchloric acid and vortexed thoroughly. The samples were 
then centrifuged at 3000 g (at room temperature) for 10 minutes. 
The supernatants were then used for the assay.
The plasma and whole blood extracts were pipetted into the sample 
cups on the sample rotor which was then loaded onto the Cobas Bio. 
The reagent and standards were pipetted into the reagent tray which 
was also loaded onto the analyser. The parameter listing for the 
hexokinase assay is shown in Table 2.2.-
To take into account the protein content of the plasma and whole 
blood the final results were multiplied by 0.94 for plasma (Cannon et 
al., 1974) and 0.85 for whole blood (Bergmeyer, 1984). These 
figures were then entered into the equation to calculate the 
erythrocyte glucose concentration. The water content of the 
erythrocyte is 71% (Hald and Eisenman, 1937) however 
approximately 15% of this is unavailable and is adsorbed onto 
haemoglobin (Drabkin, 1950). Therefore, the calculated intra­
erythrocyte glucose concentration was divided by 0.60 which is the 
fraction of water available in the erythrocyte.
2.4.2. BLOOD SPOT GLUCOSE OXIDASE METHOD
2.4.2.1. REAGENTS
1% boric acid
2.5% trichloroacetic acid
0.9% sodium chloride
31 ET chromatography paper (Whatman Limited, Maidstone, Kent, 
U.K.).
ASSAY REAGENT (supplied in kit).
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2.4.2.2. STANDARDS
A 200 mmol/l glucose stock solution was prepared in 0.9% saline. 
This was used to prepare a range of standards 5, 10 and 20 mmol/l. 
These were diluted 1 in 50 with 2.5% trichloroacetic acid, so that 
they were at the same pH and dilution as the glucose in the eluant 
from the blood spots. '
2.4.2.3. APPARATUS
See Section 2.3.3.
2.4.2.4. PROCEDURE
Preparation of Chromatography Paper
The chromatography paper was soaked in 1% boric acid for 5 - 10 
minutes and then dried at 37°C.
Collection of Blood Spot
Each sample of capillary blood was collected in one large spot on the 
boric acid impregnated filler paper and then thoroughly dried at 
room temperature. These were stored at -20°C for 1 - 3 months.
EMion & Assay ot Glumae. in BJaari -Smt
A 6 mm (10 pi) disc of each blood spot was punched out and eluted in 
500 pi of 2.5% trichloroacetic acid for 30 minutes. The eluants, 
standards and reagent were loaded onto the Cobas Bio and assayed 
for glucose using the parameter listing shown in Table 2.3.
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TABLE 2 . 2  P A R A M E T E R  L I S T I N G  
FOR H E X O K I N A S E  A S S A Y
1 UNITS m m o l/l
2 CALCULATION FACTOR 0
3 STANDARD 1 CONC. 5
4 STANDARD 2 CONC. 1 0
5 STANDARD 3 CONC. 20
6 LIMIT 33
7 TEMPERATURE(°C) 37.0
8 TYPE OF ANALYSIS 5
9 WAVELENGTH(nm) 340
1 0 SAMPLE VOLUME(mJ) 6
1 1 DILUENT VOLUME(jil) 50
1 2 REAGENT VOLUME(jil) 200
1 3 INCUBATION TlME(secs) 0
1 4 START REAGENT VOLUME(jil) 0
1 5 TIME OF FIRST READiNG(secs) 120
1 6 TIME INTERVAL (secs) 1 20
1 7 NUMBER OF READINGS 2
1 8 BLANKING MODE 1
1 9 PRINTOUT MODE 1
T A B L E  2 . 3 .  P A R A M E T E R  L I S T I N G  
F O R  G L U C O S E  O X I D A S E  A S S A Y
1 UNITS m m o l/ l
2 CALCULATION FACTOR 0
3 STANDARD 1 CONC. 5
4 STANDARD 2 CONC. 1 0
5 STANDARD 3 CONC. 20
6 LIMIT 22
7 TEMPERATURE(°C) 30.0
8 TYPE OF ANALYSIS 4
9 WAVELENGTH(nm) 500
10 SAMPLE VOLUME(nl) 25
1 1 DILUENT VOLUME(jil) 25
1 2 REAGENT VOLUME(jil) 200
1 3 INCUBATION TIME(secs) 0
1 4 START REAGENT VOLUME(jil) 0
1 5 TIME OF FIRST READING(secs) 10.0
1 6 TIME INTERVAL (secs) 60
1 7 NUMBER OF READINGS 2
1 8 BLANKING MODE 1
1 9 PRINTOUT MODE 1
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2.5. INSULIN
Plasma insulin was measured by radioimmunoassay using an ‘in 
house’ reference method of St. Luke’s Hospital Biochemistry 
Department, Guildford, Surrey.
2.5.1. REAGENTS
0.04M phosphate buffer, pH 7.4.
ASSAY BUFFER- 0.5% bovine serum albumin (Sigma Chemical 
Company, Poole, Dorset, U.K.) prepared in the 0.04M phosphate buffer.
Normal Guinea-pig serum (Guildhay Antisera Limited)
CHARCOAL-STRIPPED SERUM - obtained from colleagues in the 
Biochemistry Department at Guildford.
LABEL - A stock solution of iodinated insulin (I125) obtained from 
Amersham, Bucks., U.K. was diluted 1 in 80 with assay buffer to 
produce the working label.
15% Polyethylene glycol 6000(dissolved in deionised water)
FIRST ANTISERUM - Guinea-pig anti-insulin antibody was supplied by 
Guildhay Antisera Limited in lyophiiised form. Each vial contained 
0.5 ml of diluted antiserum which was sufficient for either 100 or 
1000 tubes with diluting the vials in 20.5 ml or 201 ml of assay 
buffer respectively. Normal guinea-pig serum was added to the first 
antiserum at a dilution of 1 in 500. Normal guinea-pig serum was 
also added to a small volume of assay buffer at a dilution of 1 in 
500 for inclusion in the non-specific binding tubes.
SECOND ANTISERUM - Neat donkey anti-guinea pig antiserum supplied 
by Guildhay Antisera Limited was diluted 1 in 32 with the 15% 
polyethylene glycol solution.
2.5.2. STANDARD
A vial containing 1000 mU/i of insulin was obtained from Wellcome 
Diagnostics Limited, Dartford, Kent, U.K. This was diluted with 
charcoal-stripped serum to give a top standard of 200 mU/l. This
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was used to prepare a working range of standards by double dilution 
in the stripped serum - 3.13, 6.25, 12.5, 25, 50 and 100 mU/l.
2.5.3. APPARATUS
J6B Centrifuge (MSE Scientific Instruments, Sussex, U.K.)
1260 Multigamma II gamma counter (LKB Wallac., Finland).
2.5.4 PROCEDURE
50 pi aliquots of stripped serum for non-specific binding (NSB) and 
zero standard tubes, standard sera, control sera or sample sera were 
pipetted into LP3 tubes (Luckham Limited, Burgess Hill, Sussex,
U.K.). 200 pi of assay buffer containing the normal guinea-pig 
serum was added to the NSB tubes. To all the tubes, except the NSB 
and total tubes, 200 pi of working first antiserum was added, 
followed by 200pl of the working label to all of the tubes.
The tubes were vortex-mixed and incubated overnight (16 - 24 
hours) at room temperature. Then 200 pi of the second antiserum 
working solution was added to all of the tubes except the totals.
The tubes were vortex-mixed and incubated for a further two hours 
at room temperature.
Then all the tubes were centrifuged (except the totals) at 2500 rpm 
for 30 minutes at 4oC in the refrigerated J6B centrifuge (see 
apparatus). The supernatants were then aspirated off and the pellets 
counted in a gamma counter for 100 seconds.
2.5.5. CALCULATION OF RESULTS
The counts of the duplicates were meaned. and the NSB counts 
subtracted from all the standard curve means, except the total. The 
mean NSB counts from each sample was subtracted from the sample 
mean counts. Then the percentage of the total counts bound was 
calculated from each mean i.e.
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% BOUND 
(OF TOTAL)
A standard curve was constructed of the % bound versus the 
concentration of unlabelled insulin. The test samples were then 
read off the standard curve.
2.6. INORGANIC PHOSPHATE
Plasma and whole blood inorganic phosphate were measured on the 
Cobas Bio using a kit obtained from Roche Diagnostics Limited, the 
method of which is based on that of Daly and Ertingshausen, 1972.
Intra-erythrocyte inorganic phosphate was calculated from the 
whole blood and plasma inorganic phosphate measurements using 
the same formula as for intra-erythrocyte glucose (see section 2.4).
2.6.1. REAGENTS
10% trichloroacetic acid 
ASSAY REAGENT (supplied with kit)
2.6.2. STANDARD
A 1.5 mmol/l standard was supplied with the kit. This was diluted 1 
in 4 with 10% trichloroacetic acid so that it was at the same 
dilution and pH as the samples.
2.6.3. APPARATUS
See section 2.3.3.
2.6.4. PROCEDURE
200 jil of lithium heparin whole blood or plasma was added to 800 \ i \  
of 10% trichloroacetic acid and vortexed thoroughly. The samples •
= MEAN OBSERVED COUNTS -  MEAN NSB COUNTS 
MEAN TOTAL COUNTS
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were then centrifuged at 3000 g (at room temperature) for 10 
m inutes. t
The whole blood and plasma extracts together with the standard and 
reagent were loaded onto the Cobas Bio. The parameter listing used 
to measure the inorganic phosphate in the samples is shown in Table
2.4.
The plasma and whole blood inorganic phosphate results were 
corrected for the protein content as described for glucose in Section
2.4.1.4. and sim ilarly for the erythrocyte protein/water content in 
the calculation of the intra-erythrocyte inorganic phosphate 
concentra tion.
2 . 7 .  2 . 3 - P 1 P H O S P H O G L Y C E R A T E
A kit for 2,3-diphosphoglycerate was obtained from Boehringer 
Mannheim (U.K.) the principle of which is based on the method of 
Ericson and De Verdier (1972). This manual method was adapted 
onto the Cobas Bio.
2.7.1. REAGENTS 
0.6M perchloric acid (ice-cooled)
2.5M potassium carbonate
ASSAY REAGENTS A,B,C,D,E (supplied in kit) - Solutions A, B and C 
were mixed together in the proportions of 40:1:1 respectively 
(Reagent 1). Solutions D and E were mixed together in the 
proportions of 1:1 (Reagent 2).
2.7.2. STANDARD
A 8 mmol/l stock solution of 2,3-diphosphoglycerate (Sigma 
Chemical Company, Poole, Dorset, U.K.) was prepared in deionised 
water. This was double-diluted down to give a range of standards, 
1,2 and 4 mmol/l. These were then subjected to the same 
preparations as the samples (see below, Section 2.7.4.) so that they 
were at the same dilution and pH.
2.7.3. APPARATUS 
See Section 2.3.3.
\
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2.7.4. PROCEDURE
500 pi of lithium heparin whole blood was added to 2.5 mis of ice- 
cold 0.6M perchloric acid (within 5 minutes of collection). This was 
vortex-mixed and centrifuged at 2500 rpm at 4°C in the J6B (MSE 
Ltd.) centrifuge for 10 - 15 minutes.
To 2 mis of the supernatant, 250 pi of 2.5M potassium carbonate was 
added. This was vortex-mixed and then left on ice for at least 30 
minutes. Then it was centrifuged again at 3000 g (room 
temperature) for 10 minutes to remove the perchlorate precipitate. 
The supernatant was then used for the assay.
The sample and standard extracts together with reagent 1 (main 
reagent well) and reagent 2 (start reagent well) were loaded onto 
the Cobas Bio. The assay was carried out using the parameter 
listing shown in Table 2.5.
The final concentration obtained by the Cobas Bio was multiplied by 
100/haematocrit to give the 2,3-diphosphoglycerate concentration 
in mmol/l erythrocytes. *
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T A B L E  2 . 4 .  P A R A M E T E R  LISTING 
FOR I N O R G A N I C  P H O S P H A T E  A S S A Y
1 UNITS m m o l/l
2 CALCULATION FACTOR 0
3 STANDARD 1 CONC. 1.5
4 STANDARD 2 CONC. 0
5 STANDARD 3 CONC. 0
6 LIMIT 1 0
7 TEMPERATURE(°C) 25.0
8 TYPE OF ANALYSIS 5
9 WAVELENGTH(nm) 340
1 0 SAMPLE VOLUME(pl) 1 0
1 1 DILUENT VOLUME(nI) 30
1 2 REAGENT VOLUME(jil) 300
1 3 INCUBATION TIME(secs) 0
1 4 START REAGENT VOLUME(pl) 0
1 5 TIME OF FIRST READING(secs) 20.0
1 6 TIME INTERVAL (secs) 900
1 7 NUMBER OF READINGS 2
1 8 BLANKING MODE 1
1 9 PRINTOUT MODE 1
7 4
T A B L E  2 . 5  P A R A M E T E R  L I S T I N G  
F O R  2 , 3 - D I P H O S P H O G L Y C E R A T E  
A S S A Y
1 UNITS m m o l/l
2 CALCULATION FACTOR 15.40
3 STANDARD 1 CONC. 1
4 STANDARD 2 CONC. 2
5 STANDARD 3 CONC. 4
6 LIMIT 8
7 TEMPERATURE(°C) 25
8 TYPE OF ANALYSIS 6
9 WAVELENGTH(nm) 340
1 0 SAMPLE VOLUME(pl) 1 0
1 1 DILUENT VOLUME(pl) 05
1 2 REAGENT VOLUME(pl) 260
1 3 INCUBATiON TIME(secs) 300
1 4 START REAGENT VOLUME(pl) 05
1 5 TIME OF FIRST READING(secs) 10.0
1 6 TIME INTERVAL (secs) 600
1 7 NUMBER OF READINGS 2
1 8' BLANKING MODE 1
1 9 PRINTOUT MODE 1
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2.8. INTRA-ERYTHROCYTE PH
The pH inside the erythrocyte was measured using a method based on 
that described by Warth and Desforges (1978).
2.8.1. REAGENTS
5,5-d i methyl-12-"5 4 C ]oxazo!id ine-2,4-dione (Amersham 
International p.I.e., Bucks, U.K.)
10% trichloroacetic acid
Optiphase Scintillation fluid (LKB Ltd.,) Bromma, Sweden).
2.8.2. APPARATUS
1217 Rackbeta Liquid Scintillation Counter (LKB Wallac., Finland).
2.8.3. PROCEDURE
5 mis of venous blood was collected into a lithium heparin container. 
50 pi of 5,5-dimethyl[2-14C]oxazolid ine-2,4-dione was im mediately 
added to the blood, mixed well and incubated for 20 minutes at 37°C. 
The pH (pHe) of the incubated whole blood was then measured and 
noted. The haematocrit was also measured (see Section 2.11).
The blood was then centrifuged at 3000 g (room temperature) for 10 
minutes. From the resultant separated blood, 1 ml of plasma and 1 
ml of packed erythrocytes were each added to 1 ml of deionised 
water separately and mixed thoroughly. 0.5 mis of the diluted 
plasma and the haemolyzed erythrocytes were then deproteinised 
each with 1 ml of 10% trichloroacetic acid in duplicate. The 
samples were then centrifuged at 3000 g (room temperature) for 10 
- 15 minutes.
The two erythrocyte extracts and the two plasma extracts were then 
counted each in 10 mis of the Optiphase scintillation fluid using a p~ 
counter. Counts per minute were converted to disintegrations per 
minute (dpm) using a quench curve.
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2.8.4. CALCULATION
The plasma (external) dpm was converted to dpm/g of plasma water 
using 0.94 as the fraction of solvent water in plasma (Cannon et al., 
1974).. The erythrocyte (internal) dpm was also converted to dpm/g 
of erythrocyte water, utilizing 0.60 as the fraction of solvent water 
in the erythrocyte (Drabkin, 1950).
The dpm/g of plasma water and erythrocyte water were then entered 
into the following equation to calculate the intra-erythrocyte pH 
(Waddell and Beutler, 1959; Warth and Desforge, 1982):
pHi = pKa‘ -Hog (DMO)i (10  PHe-P Ka' + i ) - (D M 0)  
(DM0)e
where DMO = 5,5-d im ethyl[2 -i4C ]oxazo iid ine-2,4-d ione 
pHi = intra-erythrocyte pH 
pHe = whole blood pH 
DMOi = erythrocyte dpm/g water 
DMOe = plasma dpm/g water 
pKa’ » 6.13 for DMO (Waddell and Beutler,1959)
2.9. VITAMIN C
Plasma and intra-erythrocyte vitamin C were measured by a manual 
fluorometric method first introduced by Deutsh and Weeks (1959). 
This method was adapted for the measurement of vitamin C in 
physiological fluids by Brubacher and Vuilleumier (1974).
2.9.1. REAGENTS
0.9% saline
5% metaphosphoric acid
0.05M iodine solution
25% sodium acetate (trihydrate)(fIStered)
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SODIUM ACETATE-BORATE SOLUTION - 50 g of sodium acetate 
trihydrate and 20 ;g .o f boric acid dissolved in 200 mis deionised 
water and filtered.
0.1% o-phthaldehyde (prepared freshly before use and protect from 
lig h t) .
0.5M sodium thiosulphate
2.9.2. STANDARDS
A 1 mmol/l stock solution of ascorbic acid was prepared in 5% 
metaphosphoric acid. ' This was double diluted down to produce a 
range of standards, 0.125, 0.25, 0.50 andl.O mmol/l. These were 
then used to produce both plasma and erythrocyte standards as 
fo llo w s :
2.9.2.1. PIASMA STANDARDS
2 mis of plasma was deproteinised with 18 mis of 5% 
metaphosphoric acid. This was then centrifuged at 3000 g (at room 
temperature) for 15 minutes. Then 20 pi of each standard solution 
was added to each of 2 ml samples of the plasma supernatant. (20 pi 
of 5% metaphosphoric acid was added to two further 2 ml samples 
for blanks).
2.9.2.2. ERYTHROCYTE STANDARDS
2 mis of packed erythrocytes were deproteinised with 18 mis of 5% 
metaphosphoric acid and then centrifuged at 3000 g (room 
temperature) for 10 minutes. 20 pi of each standard solution was 
added to each of 2 ml samples of the erythrocyte supernatant. Two 
blanks were also prepared by adding 20pl of 5% metaphosphoric acid 
to each of two further 2 mi samples.
2.9.3. APPARATUS
Perkin Elmer LS-5 fluorimeter (Perkin Elmer Limited, 
Buckinghamshire, U.K.).
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2.9.4. PROCEDURE
2.9.4.1. Sam ple P repa ra tion
0.5 mis of plasma was deproteinised with 4.5 mis of 5% 
metaphosphoric acid and then centrifuged at 3000 g (at room 
temperature) for 10 - 15 minutes.
0.5 mis of packed erythrocytes were washed with 4.5 mis of 0.9% 
saline. After centrifuging (3000 g, 10 - 15 minutes) the supernatant 
was discarded and 4.5 mis of 5% metaphosphoric acid added. This 
was followed by mixing and centrifuging again at 3000 g for 10 
m inutes.
2.9.4.2. A n a lys is
To 2 mis of each deproteinised sample and each standard (both 
plasma and erythrocyte), 10 pi of 0.5M iodine solution was added 
followed by rapid mixing. After 10 seconds the excess iodine was 
destroyed by adding 5 pi of 0.5M sodium thiosulphate.
750 pi of each oxidized sample and standard was pipetted into two 
different tubes (one for the test and one as a blank). To all the test 
samples 750 jal of the sodium acetate solution was added and to all 
the blanks 750 pi of the sodium acetate-borate solution was added. 
These were all mixed well and then incubated in the dark at room 
temperature for 15 minutes.
Then 300 pi of the 0.1% o-phthaldehyde solution was added to all of 
the tubes which were then incubated for a further 15 minutes in the 
dark at room temperature.
The fluorescence of the test and blank of each sample and standard 
was then measured on the fiuorimeter, using an excitation 
wavelength of 348 nm and an emission wavelength of 423 nm.
Having subtracted the blank fluorescence from the test fluorescence 
for both the standards and the samples, a standard curve was 
constructed for the plasma standards and the erythrocyte standards 
which was used to obtain the concentration of vitamin C in the 
plasma and erythrocyte samples respectively.
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Both the plasma and erythrocyte vitamin C concentrations were 
expressed as pmol/l of water using the correction factors described 
in Section 2.4.14..
2.10. AMINO ACIDS
Plasma, urine and erythrocyte amino acids were analysed using a 
Waters Picotag System (Waters Associates, Milford, Massachusetts, 
U.S.A.). This utilized pre-column derivatisation with 
phenylisothiocyanate (PITC), reverse-phase high-performance liquid 
chromatography (HPLC) and ultra-violet detection at 254 nm 
(Heinrikson and Meredith, 1984).
2.10.1. REAGENTS
All reagents were of HPLC grade.
2.10.1.1. M obile  Phase
ELUENT 1- 0.07M sodium acetate trihydrate prepared in milliQ water 
pH 6.45 + 2.5% acetonitrile. The solution was filtered using a 0.45 M 
nylon membrane filter (Gelman Sciences Limited, Northampton, U.K.) 
and degassed before use
ELUENT 2 - 45% acetonitrile, 40% MilliQ water and 15% methanol.
The solution was degassed before use.
2.10.1.2. D rying S o lu tion  (Made up fresh)
2:2:1 (by volume) of methanol,1M sodium acetate (filtered) and 
tr ie th y la m in e
2.10.1.3. D e riva tis in g  S o lu tio n  (made up fre sh )
7:1 :1:1 (by volume) of methanol, triethylamine, milliQ water and 
PITC (Pierce and Warriner (U.K.) Limited, Chester, England).
2.10.2. STANDARD
Basic amino acids (2.5 jim ol/l ml) and acidic/neutral amino acids 
(2.5 pmol/ml) both from Sigma Chemical Co., Poole, Dorset, U.K. were 
diluted in milliQ water l:l:4.25 (acid/neutral:basic:water).
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This'standard solution was then mixed 1:1 with the internal 
standard (methionine suip.hone, 0.4 mM in 0.1 M hydrochloric acid). 
This resulted in a concentration of amino acids of 200 pmol/ I.
2.10.3. APPARATUS
All obtained from Waters Associates as part of the Picotag System:
Automatic Sampler Wisp TM Model 712
Two (model 510) HPLC pumps
Model 680 Automatic Gradient Controller
Model 440 Absorbance Detector
Column Heater, Model 710B
Picotag reverse-phase column - 30 cm x 3.9 mm 
Picotag Work Station for derivatization.
2.10.4. PROCEDURE
2.10.4.1. Sam ple P repa ra tion
PLASMA - 50 pi of plasma was mixed with 50 p! of the internal 
standard solution (methionine sulphate, 0.4 mM in 0.1 M hydrochloric 
acid).
Deproteinisation was carried out using a filtration device supplied 
by- Waters Associates with an ultrafiltration membrane (retention 
rating, 10,000 NMWL) (Millipore (U.K.) Limited, Harrow, Middlesex). 
The resultant filtrate was used for the analysis.
ERYTHROCYTES - 1 ml of packed erythrocytes were washed twice in 
0.9% saline and then deproteinised with 5 mis of ice-cold 0.6M 
perchloric acid. 50 pi of the extract was then mixed with 50 pi of 
the internal standard, which was then ready for analysis.
URINE - Urine was prepared by exactly the same procedure as for 
plasma.
2.10.4.2. D e n v a tis a tio n
25 pi of the standard or prepared sample were pipetted into small 
glass tubes (6 x 50 mm). These were placed in a reaction vial 
(Waters Associates) and then dried down under vacuum using the 
Picotag Work Station (30 - 40 minutes). Then 10 pi of the drying 
solution was added to each tube (samples and standard). These were 
then re-dried under vacuum (15 - 20 minutes). When thoroughly dry, 
20 p! of the derivatisation reagent was added to each sample and
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standard. After vortex-mixing, the tubes were replaced in the 
reaction vial and incubated at room temperature (20 - 25°C) for 20 
m inutes.
The reaction vial was then returned to the work station and all the 
tubes dried down under vacuum (30 - 45 minutes). To ensure the 
samples (and standards) were thoroughly dry, 10 pi of methanol was 
added to each tube and re-dried under vacuum (20 - 30 minutes).
2.10.4.3. H P IC  (ana lys is )
Each sample (and standard) was reconstituted with 100 pi of Picotag 
diluent and placed in the WispTM autosampler ready for analysis.
HPLC was carried out according to the manufacturer’s instructions 
using the Picotag fully-automated HPLC system.
The concentration of the individual amino acids in each sample was 
calculated from the peak areas, using the standard amino acid peak 
areas as a reference.
The plasma and erythrocyte amino acid concentrations were 
corrected for the protein content (see Section 2.4.1.4.) in plasma and 
erythrocytes respectively. The urine amino acid concentrations 
were expressed as pmol/24hr/mmol creatinine.
2.11. HAEMATOCRIT
A very small volume of potassium EDTA whole blood was taken up 
into a capillary tube (Boehringer Mannheim, U.K.) and centrifuged in a 
m icrohaematocrit centrifuge (MSE Scientific Instruments, Sussex, 
U.K.) for 5 minutes. The haematocrit(HCT) was calulated as follows:
H C T W  _ LENGTH OF PACKED ERYTHROCYTES (m m )_________  x 100
LENGTH OF PACKED ERYTHRQCYTES+PLASMA (mm)
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Plasma urea was measured on a Cobas Bio using a kit supplied by 
Roche Diagnostics Limited based on the method of Tiffany et al., 
(1972).
2.12.1. REAGENT
Assay reagent supplied with kit.
2.12.2. STANDARD
A standard urea solution of 7 mmol/l was supplied with the kit.
2.12.3. APPARATUS 
See Section 2.3.3.
2.12.4. PROCEDURE
The plasma samples, standard and reagent were loaded onto the 
Cobas Bio and the assay carried out according to the parameter 
listing shown in Table 2.6.
2.12. UREA
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T A B L E  2 . 6  P A R A M E T E R  L I S T I N G  
F O R  U R E A  A S S A Y
1 UNITS m mo I/I
2 CALCULATION FACTOR 0
3 STANDARD 1 CONC. 7
4 STANDARD 2 CONC. 0
5 STANDARD 3 CONC. 0
6 LIMIT 50
7 TEMPERATURE(°C) 37
8 TYPE OF ANALYSIS 4
9 WAVELENGTH(nm) 340
1 0 SAMPLE VOLUME(pl) 4
1 1 DILUENT VOLUME(pl) 20
1 2 REAGENT VOLUME(pl) 250
1 3 INCUBATION TIME(secs) 0
1 4 START REAGENT VOLUME (pi) 0
1 5 TIME OF FIRST READING (secs) 40
1 6 TIME INTERVAL (secs) 1 0
17 NUMBER OF READINGS 6
1 8 BLANKING MODE 1
1 9 PRINTOUT MODE 1
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2.13. CREATININE
Urine creatinine was kindly measured by the Clinical Biochemistry 
Department at St. Luke’s Hospital, Guildford, Surrey.
2.14. FREE FATTY ACIDS
Plasma free fatty acids were measured on a Cobas Bio using a kit 
obtained from Alpha Laboratories Limited, Hampshire, U.K., based on 
the method of Mulder et al., 1983.
2.14.1. REAGENT
Assay reagents supplied with the kit.
2.14.2. STANDARD
A standard free fatty acid solution of 1.0 mmol/l was supplied with 
the kit.
2.14.3. APPARATUS 
See Section 2.3.3.
2.14.4. PROCEDURE
The plasma samples, standard and reagents were loaded onto the 
Cobas Bio and the assay carried out using the parameter listing 
shown in Table 2.7.
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T A B L E  2 . 7  P A R A M E T E R  L I S T I N G  
F O R  F R E E  F A T T Y  A C I D  A S S A Y
1 UNITS m m o l/l
2 CALCULATION FACTOR 0
3 STANDARD 1 CONC. 1
4 STANDARD 2 CONC. 2
5 STANDARD 3 CONC. 3
6 LIMIT 1 0
7 TEMPERATURE(°C) 37.0
8 TYPE OF ANALYSIS 5
9 WAVELENGTH(nm) 530
1 0 SAMPLE VOLUME(pl) 20
1 1 DILUENT VOLUME(pl) 50
1 2 REAGENT VOLUME(pl) 200
1 3 INCUBATION TIME(secs) 0
1 4 START REAGENT VOLUME(pl) 0
1 5 TIME OF FIRST READlNG(secs) 600
1 6 TIME INTERVAL (secs) 300
1 7 NUMBER OF READINGS 2
1 8 BLANKING MODE 1
1 9 PRINTOUT MODE 1
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CHAPTER 3
INVESTIGATION OF HIGH AND LOW GLYCATORS
8 7
3.1. INTRODUCTION
The Islington Diabetes survey identified a group of non-diabetic 
sub jec ts , whose g lyca ted  haem oglob in  (GHb) leve ls were 
inappropriate relative to their tolerance to a glucose load. Twenty 
subjects had high GHb levels relative to the ir two-hour blood 
glucose (2HBG) levels (HIGH GLYCATORS) and twenty-two subjects 
had low relative levels of GHb (LOW GLYCATORS) (see Figure 1.7). 
B iological or assay variab ility  failed to account for the weak 
relationship found between GHb and 2HBG levels. Fasting glycaemia 
is the major determ inant of GHb levels in non-insulin dependent 
diabetics (Paisey et al., 1980). It is also more representative of 
ambient blood glucose levels than the response to an unphysiological 
glucose load. However, fasting blood glucose levels also did not 
explain the differences in GHb levels found in these subjects (see 
Figure 1.8.)
It is well proven that during a glucose tolerance test, the response 
to the glucose load is very dependent upon the basic nutritional 
status of the subject (i.e. previous diet) (Conn, 1940). However, 
analysis of the dietary patterns of the high and low glycators. found 
no significant differences between the two groups. This suggests 
that d ie t was not the causal facto r determ in ing the weak 
relationship between GHb and 2HBG. In general, the correlations 
found between GHb levels and glycaemia in non-diabetics are much 
weaker than those found in diabetic subjects (Boucher et al., 1981; 
Simon et al., 1985; John and Richardson, 1986), This may be partly 
because both assay and bio log ica l va riab ility  make a larger 
contribution to the variation at low levels of GHb and over the 
narrow range seen in non-diabetics.
Although correlation coefficients (r) of up to 0.98 have been found 
between GHb and blood glucose levels in diabetic subjects (Svendsen 
et al., 1982), there is considerable overlap of GHb levels between 
normal, impaired-giucose tolerant and diabetic individuals (Dunn et 
al., 1979; Verillo et al., 1983; Modan et al., 1988). This suggests the 
occurrence of sim ilar GHb levels with quite d iffe rent glucose 
tolerances. Also, two studies with diabetic subjects have shown 
unexplained discrepancies between GHb levels and blood glucose 
levels (Gonen et al., 1979; Verillo et al., 1983). This suggests that 
factors unrelated to blood glucose levels may result in differences 
in individual rates of glycation of haemoglobin. A number of
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different factors have been shown to affect the rate and extent of 
glycation of proteins both in vivo and in vitro (see Chapter 1).
If individual differences in the degree of glycation of proteins were 
physiologically significant, the identification of factors other than 
glucose determining the rate of glycation of proteins in v ivo  may 
have im portant im plications. In diabetic subjects, these factors 
may have bearing not only on the use of glycated proteins to monitor 
blood glucose control, but may also partly determ ine the rate of 
development of complications. Factors which can decrease glycation 
may help to a llev ia te  or prevent the occurrence of these 
complications and could possibly delay the normal ageing process.
Therefore, a detailed biochemical investigation of the high and low 
glycators identified in the Islington Diabetes survey was carried out 
to determine the cause(s) of the weak relationship found between 
GHb and blood glucose levels. The chapter is divided into two parts 
(A and B). The first part of the study (A) was to recall the 42 
subjects and to establish whether they remained classified in the 
two groups four years after the original screening survey. Then 
depending on the finding, the second part of the study (B) was to 
perform' a thorough biochemical and haematological examination to 
determine why the glycation of haemoglobin in these subjects was 
occurring at a level inappropriate to their blood glucose levels.
PART A - STABILITY OF THE HIGH AND LOW GLYCATORS
3.2. INTRODUCTION
The high and low glycators have been classified because of their 
inappropriate level of GHb relative to their 2HBG level. Despite the 
fasting blood glucose (FBG) level being more physiological than the 
response to a glucose load, this measure of glycaemia also did not 
explain the differences in levels of GHb between the high and low 
glycators. However, the most accurate and representative measure 
of ambient glycaemia in all subjects is probably the mean blood 
glucose (MBG) level calculated from multiple daily blood glucose 
measurements. Very high correlations have been found between GHb 
levels and MBG measurements (Paisey et al., 1980; Svendsen et al., 
1982).
Therefore, to investigate whether the high and low glycators had 
inappropriate levels of GHb relative to all measures of glycaemia,
daily blood glucose profiles were performed as well as repeat 
glucose tolerance tests.
3.3. METHODS
3.3.1. SUBJECTS
The high and low glycators were all patients of the St. John’s Way
Practice in Is ling ton , North London. In itia lly  the genera l
practitioners in the practice were approached to allow permission 
to recontact the subjects for further study.
The original 42 subjects had been reduced to 30; 4 had moved away, 
2 had died, 2 were unlocatable and 4 were too ill to take part in a 
further study. Therefore, 30 letters were sent out asking the 
subjects whether they would be interested in participating in a 
further study. Enclosed with each letter was a reply slip on which 
they could indicate whether they would agree to an informal visit,
for a more detailed explanation of what the study involved. A reply-
paid envelope was included in the letter.
Nineteen replies were received, of which 15 agreed to a home-visit 
to discuss the study. An appointment with each of the subjects was 
arranged by telephone. After the home-visits, 13 of the subjects 
agreed to take part in the study and letters were sent out later with 
appointment dates for both the daily blood glucose profiles and the 
glucose tolerance test.
The original letter was also re-sent to the 11 subjects who never 
replied in the first instance. Four more replies were received, of 
which 2 more subjects agreed to take part in the study. One further 
subject was contacted by telephone only and agreed to take part. So, 
a total of 16 subjects (38% of the original 42, or 53% of those
traced and eligible) agreed to take part in the study. There were 12
female and 4 male subjects, aged 45 - 81 years. Nine were high
glycators and 7 low glycators.
Before the start of the study the subjects were asked to fill in a 
brief questionnaire to check that physical activity, dietary habits 
and medication had not changed since the original screening survey.
3.3.2. GLUCOSE TOLERANCE TESTS
13 subjects participated in a full glucose tolerance test (7 high and 
5 low glycators The other 3 subjects who originally agreed to take
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part, were for various reasons not able to get to the clin ical 
investigation unit for the test.
Each subject visited the unit at the Whittington Hospital in North 
London separately to undergo the test. They were asked to fast for 
1 0 - 1 2  hours prior to the glucose tolerance test and to arrive at the 
unit between 9,30 - 10.00a.m.
Initially- a 30ml fasting venous blood sample was obtained. This was 
divided up into a number of d ifferent vessels containing either 
lithium heparin or potassium EDTA as the the anticoagulant, Most of 
this blood was collected for the measurement of a number of 
different analytes (see Part B). After consumption of a 75g glucose 
load dissolved in 200mls of water, further venous blood samples 
were collected at 30 minutes, 1 hour and 2 hours. At 30 minutes and 
1 hour, 5mls of blood was collected into lithium heparin. At 2 hours, 
10mls of blood was collected, 5mls into lithium heparin and 5mls 
into potassium  EDTA. L ith ium  heparin w hole  blood was 
deproteinised immediately at all time points for the measurement of 
glucose. The extracts were stored at 4 °C  for 24 hours prior to 
analysis of glucose. Glycated haemoglobin was measured on the 
potassium EDTA whole blood collected at fasting and 2 hours after 
the glucose load, by affinity chromatography, iso-electric focussing 
and agar-gel electrophoresis with and without the removal of the 
Schiff base. The blood was stored at 4°C for 1 week prior to 
analysis.
3.3.3. BLOOD GLUCOSE PROFILES
16 subjects (9 high and 7 low glycators) performed daily blood 
glucose profiles. None of the volunteers were prepared to do the 
profiles themselves at home, which would have provided the best 
indication of. their ambient blood glucose control. For this reason, 
they were invited to attend the clinical investigation unit at the 
Whittington Hospital from 8.30a.m. - 3.00p.m. in groups of 3 - 4 at a 
time. A 5-point profile was obtained employing finger-prick blood 
samples collected at 9.00a.m., 10.30a.m., 12.00p.m., 1.30p.m. and 
2.30p.m. representing the fasting, 1 hour post-breakfast, pre-lunch, 
1 hour and 2 hour post-lunch, blood glucose concentrations 
respectively. The capillary blood was collected onto filter papers 
impregnated with boric acid, which were thoroughly dried before 
being stored at -20°C. The blood spots were analysed for glucose 1 
month later.
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Each subject was offered a range of food for breakfast and lunch, 
and selected items which most closely represented the ir usual 
meals. They were also encouraged to follow their usual level of 
activity (as far as was possible).
The blood glucose profile was repeated on a second day during the 
subsequent 4 weeks in 14 of the subjects. The mean blood glucose 
from the two profiles was calculated.
3.3.4. ASSAY METHODS
Full details are given in Chapter 2.
3.3.5. STATISTICAL METHODS
Pearson’s correlation coeffic ien t (r) was used to express the 
relationship between GHb levels and levels of glycaemia, between 
the d iffe rent assays for GHb and also between the d ifferent 
measures of glycaemia in the low and high glycators. Groups were 
compared using Student’s t-tests. Unless otherwise stated, values 
are presented as mean (±SD).
3.3.6. CALCULATION OF THE RESULTS
In the Islington Diabetes survey, the 223 subjects examined at 
recall were classed into centile rankings for 2HBG at screening and 
recall, and of GHb at screening and by each assay method both 
fasting and 2 hours post-load glucose at recall. The mean of the two 
centile rankings for 2HBG and for all nine GHb measurements were 
calculated. The use of centiles was to overcome the problem posed 
by the use of capillary blood at screening and venous blood at recall, 
and by the different ranges for the GHb assays.
The 42 high and low glycators were so classified because their mean 
2HBG ranking differed by at least 30 centiles from their mean 
ranking for GHb. In order to reclassify the 13 subjects taking part in 
the present study, it was necessary to sim ilarily class them into 
centile rankings .for the various measurements of glycaemia (2HBG 
and FBG on the glucose tolerance test and MBG calculated from the 
profiles) and also for the four GHb measurements, for which the 
mean centile rank was calculated. The results for glycated 
haemoglobin and the different measures of glycaemia are also shown 
without the use of centiles.
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3.4. RESULTS
Although 16 subjects took part in the glucose profiles, only 13 
underwent the full glucose tolerance test with the measurements of 
GHb. Therefore, all the results presented are for these 13 subjects 
only.
3.4.1. CORRELATION OF GLYCATED HAEMOGLOBIN WITH BLOOD 
GLUCOSE LEVELS
3.4.1.1. Tw o-hour B lood G lucose
There was a stronger relationship between GHb and 2HBG levels in 
the subjects than found in the original study (see Fig. 3.1(a) 
compared to Fig. 1.6.). A change in grouping of the subjects has 
resulted in only one high and one low . glycator still having a centile 
ranking for 2HBG differing by at least 30 centiles from the mean 
centile ranking for GHb. However, 85% of the subjects remain on the 
correct sides of the unity line. Only two subjects (1 low and 1 high 
glycator) have changed groups. One of the low glycators (No. 6) has 
become diabetic (D) and two other subjects have impaired glucose 
tolerance (1 low and 1 high glycator, No. 9 and No. 2 respectively).
The subjects were sim iiarily distributed when the mean GHb and 
2HBG levels were plotted w ithout the use of centiles (see Fig. 
3.1(b)), although the discrepancy between the two parameters in 
general, was less obvious.
3.4.1.2. Fasting B lood G lucose
All the low glycators remained classified with the exception of the 
new diabetic, who had an unusually low FBG (see Fig. 3.2(a)). The 
centile ranking for GHb and FBG were ail at least 30 centiles apart 
for the . low glycators. However, three of the high glycators had 
crossed the line of unity and none of the high glycators had a centile 
ranking for GHb and FBG 30 centiles apart.
When plotted without the use of centiles (see Fig. 3.2(b)), a similar 
relationship was found between GHb and FBG for the low and high 
g lyca to rs .
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FIGURE.3.1(a) MEAN CENTILE RANKINGS OF ALL
ASSAYS FOR GLYCATED HAEMOGLOBIN AND CENTILE
RANKING OF TWO-HOUR BLOOD GLUCOSE
The line of agreement and the +30 and -30 centile lines are 
ind icated.
F I G U R E .  3.1 .(b) A R I T H M E T I C  MEAN O F  A L L  T H E  
ASSAYS F O R  G L Y C A T E D  H A E M O G L O B I N  A N D  T W O -  
H O U R  B L O O D  G L U C O S E  L E V E L
7 -
CQ
X
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<UJ
^  5
D
r=0.47
1 1 1 1 1 j  I 1 1 J------- 1 I J----- 1------- 1----------- 1---1 I 1 |
2 4 6 8 10 12
TWO-HOUR BLOOD GLUCOSE
(mmol/l)
(D » new diabetic)
High glycators are represented as (❖) and the low glycator as (□).
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FIGURE.3.2.(a) MEAN CENTILE RANKINGS OF ALL THE
ASSAYS FOR GLYCATED HAEMOGLOBIN AND CENTILE
RANKING OF FASTING BLOOD GLUCOSE
CENTILE OF FASTING BLOOD GLUCOSE
The line of agreement and the +30 and -30 centile lines are 
indicated.
FIG URE.3 .2 .(b) ARITHM ETIC MEAN OF ALL THE
ASSAYS FOR GLYCATED HAEMOGLOBIN AND FASTING 
BLOOD GLUCOSE LEVEL
4 _j----- ,------,----- 1------j----- 1----- 1----- 1----- 1
3 4 5 6 7
FASTING BLOOD GLUCOSE
(mmol/l)
(D=new diabetic)
High glycators are represented as (♦) and the low glycators as (□) .
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A very poor relationship was found between the MBG and GHb level 
(see Fig. 3.3(a) and (b)), The grouping of the high and low glycators 
on either side of the unity line (see Fig. 3.3(a)) more closely 
resembled the original classification pattern (see Fig. 1.6). Only the 
new diabetic had changed groups. All the low glycators with the 
exception of one (No. 4), has a centile ranking for GHb and MBG 30 or 
more centiles apart. Two of the high glycators were actually on the 
unity line, whilst the majority of the others had 20-30 centiles or 
more between their ranking for GHb and MBG. The discrepancy 
between GHb and MBG was greater for the low than the high 
glycators. This poor relationship between GHb and MBG was also 
shown when the results were plotted without the use of centiles 
(see Fig. 3.3(b)).
3.4.2. CORRELATION OF DIFFERENT ASSAYS FOR THE 
MEASUREMENT OF GLYCATED HAEMOGLOBIN
The correlation between levels of GHb when assayed by unrelated 
physiochemical methods was much stronger than between any of the 
glycaemic parameters and GHb level (see Table 3.1). The mean 
correlation coefficient (r) was 0.83.
3.4.3. CORRELATION BETWEEN DIFFERENT MEASURES OF 
GLYCAEMIA IN THE LOW AND HIGH GLYCATORS
The correlation between FBG and 2HBG was much improved when the 
new diabetic was omitted (r = 0.84 vs 0.64) (see Fig. 3.4(a)). The 
diabetic had a very low FBG level in comparison to a very high 2HBG 
level. Significant correlations were found between FBG and MBG (r = 
0.65) and between 2HBG and MBG (r = 0.63) (see Fig. 3.4(b) and (c)). 
The removal of the diabetic in the latter two situations made little 
difference to the correlations found.
The mean values for FBG, 2HBG and MBG were all higher for the low 
than the high glycators if the diabetic was omitted (see Table 3.2). 
Only the MBG calculated from the profiles was significantly greater 
for the low compared to the high glycators (p<0.01) and remained so 
whether the diabetic was included or omitted.
3.4.1.3. Mean Blood Glucose (Profiles)
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FIGURE.3 .3(a) MEAN CENTILE RANKINGS OF ALL
ASSAYS OF GLYCATED HAEMOGLOBIN AND CENTILE
RANKING OF MEAN BLOOD GLUCOSE (PROFILES)
CENTILE OF MEAN BLOOD GLUCOSE
The line of agreement and the +30 and -30 centile lines are 
indicated.
FIGURE.3 .3 .(b) ARITHMETIC MEAN OF ALL ASSAYS 
FOR GLYCATED HAEMOGLOBIN AND MEAN BLOOD 
GLUCOSE LEVEL(PROFILES)
CQr
o
Z
<
LU
2
7 -
6 -
5 -
D n r=-0.09
i j i i i i
5 6 7
MEAN BLOOD GLUCOSE(PROFILES) 
(mmol/I)
High glycators are represented as (♦) and the low glycators as (□) 
(D^new diabetic)
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TABLE 3.1 CORRELATION (r) OF DIFFERENT A S S A Y S  
FOR THE MEASUREMENT OF GLYCATED HAEMOGLOBIN
AFFINITY
CHROMATOGRAPHY(r)
AFFINITY
CHROMATOGRAPHY(r)
ISOELECTRIC
FOCUSING(r) 0.78
ELECTROPHORESIS-
TOTAL(r) 0.83
ELECTROPHORESIS-
STABLE(r) 0.94
ISOELECTRIC
FOCUSING(r)
0.78
0.72
0.78
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FIGURE.3.4 (a) CORRELATION BETWEEN FASTING
BLOOD GLUCOSE AND TWO-HOUR BLOOD GLUCOSE IN
THE LOW AND HIGH GLYCATORS
r=0.64(with diabetic)
2HOUR BLOOD GLUCOSE (mmol/l)
The regression line is indicated with r representing the correlation 
c o e ffic ie n t.
High glycators are represented as (❖) and the low glycators as (□) . 
(D= new diabetic)
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FIGURE.3.4.(b) CORRELATION BETWEEN FASTING
BLOOD GLUCOSE AND MEAN BLOOD GLUCOSE
(PROFILES) IN THE HIGH AND LOW GLYCATORS
r=0.49(with diabetic)
yyto
OO
(D
D S 
O o
q s
■ * c
flQ c L .
CD
sFco<
(mmol/l)
The regression line is indicated with r representing the correlation 
c o e ffic ie n t.
High glycators are represented as (❖) and the low glycators as (□) . 
(D= new diabetic)
1  0 0
FIGURE.3.4(c) CORRELATION BETWEEN TWO-HOUR
BLOOD GLUCOSE AND MEAN BLOOD GLUCOSE
(PROFILES) IN THE HIGH AND LOW GLYCATORS
5 6 7
MEAN BLOOD GLUCOSE(PROFILES)
(mmol/l)
r=0.54(with diabetic) 
r=0.63(without diabetic)
□ d
The regression line is indicated with r representing the correlation 
c o e ffic ie n t.
High glycators are represented as (❖) and the low glycators as (□) . 
(D=new diabetic)
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TABLE 3.2 FASTING, TWO-HOUR AND MEAN BLOOD 
GLUCOSE LEVELS IN THE HIGH AND LOW GLYCATORS
GLYCAEMIC
MEASUREMENT
HIGH
GLYCATORS
FASTING BLOOD 
GLUCOSE(mmol/l) 
+D1ABETIC 
-DIABETIC
4.82
4.82
(0.67)
(0.67)
TWO-HOUR BLOOD
GLUCOSE
(m m o l/l)
+DIABETIC
-DIABETIC
5.12
5.12
(1.60)
(1.60)
MEAN BLOOD
GLUCOSE
(m m o l/l)
+DIABETIC
-DIABETIC
5.45
5.45
(0.61)
(0.61)
LOW
GLYCATORS
SIGNIFICANCE
OF
DIFFERENCE(p)
4.80
5.06
(0.74)
(0.45)
NS
NS
6.45
5.44
(2.75)
(1.32)
NS
NS
6.75
6.78
(0.50)
(0.59)
<0.01
<0.005
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3.4.4. DAILY BLOOD GLUCOSE PROFILES
The mean blood glucose calculated from the daily blood glucose 
profiles was clearly separated in the high and low glycators (see 
Fig. 3.3(a) and (b)). Not only was the mean blood glucose 
significantly greater in the low glycators, but also the mean blood 
glucose at each tim e-point (except fasting) was significantly 
greater in the low compared to the high glycators (see Fig. 3.5 and 
Table 3.3).
3.4.5. COMPARISON OF GLYCATED HAEMOGLOBIN AND 
FASTING/TWO-HOUR BLOOD GLUCOSE LEVELS WITH THOSE 
VALUES OBTAINED AT RECALL ON THE ORIGINAL SCREENING 
SURVEY
There was no significant differences found in the FBG or 2HBG levels 
between screening and the present study. With the exception of iso­
electric focusing, all the methods for GHb were not significantly 
different four years after the original screening survey (see Table 
3.4).
3.4.6. QUESTIONNAIRES
The physical activity and the medication of the subjects had not 
changed during the four years between screening and the present 
study (except for the diabetic). Three of the subjects reported a 
change in diet. One of these was the diabetic and the other two had 
both changed to reducing diets (one low and one high glycator).
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F I G U R E . 3 . 5 .  MEAN B L O O D  G L U C O S E  L E V E L S  A T  EACH 
TIME POINT D U R I N G  T H E  P R O F I L E S  IN THE HIGH AND 
LOW G L Y C A T O R S  ( I N C L U D I N G  T H E  D I A B E T I C )
1 = 9.00 a.m.
2 = 10.30 a.m
3 « 12.00 p.m
4 = 1.30 p.m.
5 « 2.30 p.m.
The significance of the difference in mean blood glucose between 
the two groups, at each time point is indicated.
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TABLE 3.3 MEAN BLOOD GLUCOSE LEVELS AT EACH 
TIME POINT DURING THE PROFILES IN THE HIGH AND LOW 
GLYCATORS (INCLUDING THE DIABETIC)
TIME OF SAMPLE HIGH LOW SIGNIFICANCE
GLYCATORS GLYCATORS OF DIFFERENCE 
(m m o l/l)  (m m o l/l)  (p)
FASTING 4.58 (0.69) 5.03 (0.97) NS
ONE-HOUR POST
BREAKFAST 6.45 (1.48) 8.74 (1.10) <0.001
PRE-LUNCH 5.11 (0.88) 6.24 (1.04) <0.05
ONE-HOUR POST
LUNCH 5.81 (0.84) 7.60 (0.99) <0.001
TWO-HOURS POST
LUNCH 4.62 (0.72) 6.30 (1.12) <0.0005
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TABLE 3.4 COMPARISON OF GLYCATED HAEMOGLOBIN  
AND FASTING/TWO-HOUR BLOOD GLUCOSE LEVELS WITH 
THOSE OBTAINED AT RECALL ON THE ORIGINAL 
SCREENING SURVEY IN THE HIGH AND LOW GLYCATORS
MEASUREMENT SCREENING AFTER 4 YEARS SIGNIFICANCE
CF
DIFFERENCE(p)
FASTING BLOOD 4.43 (0.34) 4.59 (0.45) NS
GLUCOSE (mmol/l)
TWO-HOUR BLOOD 5.05 (1.33) 5.74 (2.12) NS
GLUCOSE (mmol/l)
GLYCATED
HAEMOGLOBIN(%) 6.89 (0,74) 7.08 (0.99) NS
a f f in i t y
chrom atography
GLYCATED
HAEMOGLOBIN((%) 5.84 (0.48) 5.06 (0.72) <0.005
is o e le c tr ic
focusing
GLYCATED
HAEMOGLOBIN (%) 7.63 (0.86) 7.67 (0.99) NS
e lectrophores is
- to ta l
GLYCATED
HAEMOGLOBIN (%) 7.06 (0.45) 6,99 (0.85) NS
e lectrophores is
-s ta b le
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3.5. DISCUSSION
The tolerance to a glucose load (2HBG) did not produce the clear 
separation of the low and high glycators as it did four years 
previously. Although the majority of the subjects still had some 
discrepancy between the GHb and 2HBG levels, most do not fall into 
the orig inal c lassification of high and low glycators, with the 
ranking for 2HBG and GHb differing by at least 30 centiles. This is 
probably not surprising as the blood glucose response to an oral 
glucose load is known to be highly variable in an individual. This is 
thought to be due to factors such as the absorption and distribution 
of glucose and the prevailing hepatic activity in glycolysis and 
gluconeogenesis. The insulin response is thought to exert a 
secondary modifying influence (Harding, Oakely and Wynn, 1973). 
Several studies have shown the poor reproducibility of the glucose 
tolerance test with increasing variability in fasting blood glucose, 
1-hour blood glucose and 2-hour blood glucose respectively (Harding, 
Oakley and Wynn, 1973; F o rres t,1987). The w ith in -sub ject 
coefficient of variation for 2 hour blood glucose has been shown to 
be 25% to 32% (Forrest,1987). The glucose tolerance test is known 
to be affected by a number of factors including diet and certain 
drugs. No change in medication was reported between screening and 
the present study, but three subjects had recently gone onto 
reducing diets. This would be expected to cause an exaggerated 
blood glucose response during the glucose tolerance test. One of the 
three subjects on the reducing diet was the new diabetic who 
despite a low fasting blood glucose did show a markedly raised two- 
hour blood glucose. The other two did not show any abnormal 
response to the glucose load.
Another factor that might result in a redistribution of the subjects 
in relation to their 2HBG and GHb level is the phenomenon known as 
‘the regression to the mean’ (Davis, 1976). This is a phrase used to 
describe the fact that a variable that is extreme on its first 
measurement will tend to be closer to the centre of distribution for 
a later measurement. This' variability can be attributed to both the 
inherent variation in the phenomenon being measured and the 
variability of the measurement itself.
The fasting blood glucose also did not produce the marked separation 
of the low and high glycators as the two-hour blood glucose did in 
the original study. However, this was also the finding in the original 
study. Although fasting glycaemia is less variable than the two-hour 
blood glucose (Harding, Oakley and Wynn, 1973), it is not always an
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accurate measurement as it is d ifficu lt to check whether the 
subjects are tritely fasted. The majority of the subjects had fasting 
blood glucpsfes which were increased from the original study which 
might explain why their GHb levels were not as discrepant as they 
had been previously and is possib ly due to a non-fasting 
measurement. It is unlikely that fasting glycaemia is the whole 
explanation for the disprepant GHblevels in these subjects as the 
fasting blood glucose levels were higher in the low glycators 
compared to the high glycators.
When the mean blood glucose levels calculated from the two profiles 
were plotted against GHb levels, all the subjects remained 
classified with the exception of the new diabetic. Although the two 
5-point blood glucose profiles may not accurately reflect 24 hour 
changes in blood glucose levels, the mean blood glucose calculated 
from the profiles is more representative of ambient blood glucose 
levels than the response to an unphysiological glucose load. The 
mean blood glucose may even be a more accurate measure of average 
glycaemia than fasting blood glucose if a number of the subjects 
were not truely fasting. Moreover, the mean blood glucose was 
significantly higher in the low compared to the high glycators. Also, 
the correlations between all the measures of glycaemia were much 
higher than the correlations between GHb and blood glucose levels. 
This would suggest that blood glucose levels are not the major 
determinant of GHb levels in these individuals. The high and low 
glycators demonstrate differences in absolute levels of GHb of 1 - 
2% at the same blood glucose levels (see Fig. 3.3(b)).
The high correlation found between the different assays for GHb in 
both groups suggests that the weak relationship found between GHb 
and levels of glycaemia is not random. Also, because the assays rely 
on d ifferent physiochemical properties, it is unlikely that method 
interferences are responsible for the low and high levels of GHb . 
The affin ity chromatography method separates only haemoglobin 
molecules with cis-dioi sugar residues attached to them (Gould et 
al.,1982), therefore it is unlikely that other m odifications of the 
haemoglobin molecule, such as occur in uraemia (Fluckiger et al.,
1981) during treatment with salicylates (Bridges et al., 1975), or 
with abnormal haemoglobins (Abraham et al., 1983) are responsible 
for the existence of low or high glycation levels. No subject 
reported regular salicylate use or excess alcohol consumption both 
of which can lead to falsely high GHb levels when measured by 
certain methods (Stevens et al., 1981). There was no significant 
differences in the methods for GHb measurement between screening 
and the present study except for isoelectric focusing. The poor
reproducibility of isoelectric focusing is probably due to technical 
difficulties with the method itself. The lack of individual variation 
in GHb as measured by the other methods suggests that the small 
differences found between screening and the present study in the 
relationship between GHb and blood glucose levels are due to 
changes in glycaemia and not GHb for reasons already described.
One other study has investigated the relationship between levels of 
GHb and measures of glycaemia on glucose tolerance testing in 
subjects with normal glucose tolerance (Modan et al., 1988). They 
reported wide differences in levels of GHb which were poorly 
explained by fasting or 2 hour blood glucose levels. They also 
demonstrated the stability of high and low levels of GHb over a 
period of more than three years. This would suggest that biological 
and assay variability were not responsible for the discrepancy. 
However, th is  study em ployed only a s ing le  ion-exchange 
chromatography method for the assay of GHb, so it is possible that 
other modifications of the haemoglobin moletule may be in part 
responsible for their findings.
A recent study examined levels of post-load blood glucose and of 
GHb in 129 men (Starkman et al.,1987). They showed that 22% of the 
subjects had discordant elevation of one or other value to a level 
above the 97% centile of a normal population. The group of subjects 
with abnorm alities in glucose tolerance but normal GHb levels 
dem onstra ted hyperinsu linaem ia  with' insulin resistance; most 
would probably be defined as having impaired glucose tolerance by 
WHO criteria (1985) and most previous studies have reported normal 
levels of GHB in subjects with impaired glucose tolerance (Albutt et 
a!.,1985; Simon et al.,1985). This study did not look further at the 
determinants of discordant elevations. Both the glucose tolerance 
test and the GHb assay were performed on a single occasion, 
therefore the problems of assay and biological variability remain.
It is. likely that high and low glycation rates will be less obvious in 
d iabetic subjects, where the high glucose levels may mask the 
effects of other factors on glycation. However, Gonen et al.(1979) 
found that in a mixed group of 230 diabetic subjects, 19% (24 
subjects) had discrepancies between GHb and random blood glucose 
levels and 15% (18 subjects) had discrepancies between GHb and 
fasting blood glucose levels. The majority of these discrepant 
results (85%) could not be explained by 24 hour blood glucose 
monitoring or by method interferences. Therefore, high and low 
rates of glycation of haemoglobin appear to occur in the diabetic as 
well as the normal population. No studies have as yet been
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undertaken to investigate possible determinants of high and low 
g lycation.
Thus, in conclusion, although the repeat glucose tolerance test 
failed to classify the high and low glycators as they were originally 
categorized in the Islington Diabetes Survey, the mean blood glucose 
calculated from the profiles clearly separates the high and low 
glycators into their original groups. The differednce in mean , blood 
glucose level between the two groups strongly suggests that other 
mechanisms, possibly unrelated to blood glucose levels must be at 
least partially responsible for determining the GHb level in these 
subjects and that these factors remain constant over a period of 4 
years of observation.
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PART B - B I O C H E M I C A L  AND H AEM A T Q L Q G I C  AL
INVESTIGATION OF THE LOW AND HIGH GLYCATORS
3.6. INTRODUCTION
Despite the fact that four years had elapsed between the original 
screening survey and the follow-up study described in Part 1, 
marked differences in the level of GHb' relative to the mean blood 
glucose level were still apparent in the majority of the subjects. 
92% were still classified as high and low glycators. One subject (a 
low glycator) had become diabetic in the interim and was omitted 
from further study. This consistent classification suggests that the 
phenomenon was not a transient occurrence and factors other than 
glucose were responsible for the differences in glycation levels of 
haemoglobin.
A number of physiological factors have been shown to directly 
affect the glycation reaction, both in v i t ro  and in v i v o . The 
glycation of haemoglobin might be affected by intra-erythrocyte pH 
(Lowry et ai.,1985), 2,3-diphosphoglycerate (Smith et ai.,1982; 
Lowry et al., 1985) and inorganic phosphate (Watkins, et al.,1985). 
There are also a number of compounds present in vivo that could 
compete with glucose for binding to haemoglobin, such as vitamin C 
(Stolba et ai., 1987) and pyridoxai-5’-phosphate (Srivastova et al., 
1972). High doses of aspirin and excess alcohol consumption can 
produce metabolites in v ivo  that have been shown to react with 
protein amino groups (Bridges et al., 1975; Stevens et al., 1981). 
Pathologically raised levels of urea, as occurs in renal disease, 
leads to the production of cyanate which can also react with amino 
groups (K ilmartin and Ross-Bernardi, 1971). Amino acids 
themselves can potentially react with glucose and therefore could 
compete with haemoglobin amino groups for binding of glucose.
The half-life of the erythrocyte also plays an important role in the 
extent of glycation of haemoglobin (Bunn et al., 1976). Therefore 
haemolytic diseases leading to decreased erythrocyte survival could 
lead to reduced levels of GHb (Starkman et al., 1983). Conversely, 
increased erythrocyte production leading to polycythaemia can 
produce increased GHb levels (Graham et al., 1980).
It is apparent that many other factors apart from blood glucose 
could potentially influence the glycation of haemoglobin. Therefore 
a detailed biochemical and haematological investigation of the high
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and low glycators may determine the cause(s) of their inappropriate 
level of glycation of haemoglobin.
Although the blood glucose level does not appear to be related to the 
level of glycation of haemoglobin in these subjects, the intra­
erythrocyte glucose levels to which haemoglobin is exposed may be 
different to plasma glucose levels and therefore will be measured.
GHb is the glycated protein most frequently used as a monitor of 
blood glucose control, but glycated plasma proteins, in particular 
glycated albumin, have also been used as short-term indices of 
glycaemia (see Chapter 1). It should be relevant to investigate 
whether the high and low levels of glycation of haemoglobin seen in 
our subjects are also true for other proteins and for this reason 
fructosam ine and specifica lly  g lycated albumin will also be
measured. Free fatty acids have been shown to bind to the same site
on albumin as the major site of glucose attachment (Merish et al., 
1982) in v i t ro . Therefore, the plasma level of free fatty acids will 
also be determined.
3.7. METHODS
3.7.1. SUBJECTS AND STUDY DESIGN
The 13 subjects (7 high and 5 low glycators) who took part in the 
glucose tolerance test agreed to donate a large fasting venous blood 
sample (30 ml) and a 24 hour urine specimen to carry out the 
biochemical and haematological analyses.'
3.7.2. SAMPLES AND METHODS
(Details of all methodology are given in. Chapter 2).
The blood collection and analyses for each subject is shown in
Scheme 1.
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SCHEME. 1. COLLECTION OF BLOOD AND ANALYSES 
ON EACH SUBJECT
30 mis WHOLE BLOOD
5 m ls  
LITHIUM HEPARIN
INTRAERYHROCYTE
pH
5 m ls  
POTASSIUM EDTA
15mls 
LITHIUM HEPARIN
■ 5 m ls  
POTASSIUM EDTA
HAEMATOLOGY
FULL BLOOD COUNT 
RETICULOCYTES 
COOMB'S TEST 
ABNORMAL 
HAEMOGLOBINS
GLYCATED
HAEMOGLOBIN
(see p a r t  A)
BIOCHEMH5TRY
HAEMATOCRIT
WHOLE BLOOD GLUCOSE
INORGANIC PHOSPHATE
2,3-DIPHOSPHOGLYCERATE
GLUCOSE
INORGANIC PHOSPHATE
FREE FATTY ACIDS
UREA
PLASMA INSULIN
VITAMIN C
AMINO ACIDS
FRUCTOSAMINE
GLYCATED ALBUMIN
VITAMIN C
AMINO ACIDS
ERYTHROCYTE GLUCOSE
INORGANIC PHOSPHATE
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The measurement of in tra-erythrocyte  pH was carried out 
immediately after the collection of the blood. Lithium heparin 
whole blood was deproteinised immediately for the measurement of 
glucose, inorganic phosphate and 2,3-diphosphoglycerate. The 
extracts for glucose and inorganic phosphate were stored at 4°C 
prior to analysis with in 24 hours. The extract for 2,3- 
diphosphoglycerate was stored at -80°C and analysed within 3 - 4 
months. The remaining lithium heparin whole blood was centrifuged 
for 10 minutes at 3000 g (room temperature). Plasma was 
deproteinised for the measurement of glucose, inorganic phosphate 
and vitamin C. The extracts for vitamin C was stored at -80°C and 
analysed within 3 months. The rest of the plasma was divided up 
into small aliquots (200 - 500 pi) and stored at -80°C for the 
analysis of the other plasma constituents (see schem el) 1 - 4 
months later. After centrifugation of the whole blood and removal 
of the plasma, the packed red biood cells were deproteinised for the 
measurement of erythrocyte vitamin C and amino acids. The 
extracts were stored at -80°C until analysis 3 months later.
The whole blood samples collected at 30 minutes, 1 hour and 2 hours 
during the glucose tolerance test were aiso deproteinised for the 
measurement of glucose. The remaining whole blood at each time 
point was centrifuged, for 10 minutes at 3000 g (room temperature). 
Some of the plasma was deproteinised for glucose analysis and the 
rest stored at ~80°C for the measurement of insulin. The extracts 
for glucose were stored at 4°C and analysed within 24 hours as for 
the fasting blood.
The 24 hour urine collection was preserved with 20 mg of 
th iomersal (BDH Chemicals Limited, Poole, Dorset). After 
measurement of the volume, the urine was divided up into 5 x 20 ml 
aliquots which were stored at -80°C. These were analysed for 
creatinine and amino acids 1 - 3 months later.
The haematological analyses were kindly performed by the 
Haematology Department at the Whittington Hospital in North 
London.
3.7.3. CALCULATED ANALYSES
Intra-erythrocyte glucose and inorganic phosphate were calculated 
from the whole blood and plasma measurements together with the 
haematocrit (see Chapter 2). The intra-erythrocyte inorganic 
phosphate was calculated for the fasting biood sample only. Intra­
erythrocyte glucose was. calculated for all the blood samples
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collected during the glucose tolerance test including the fasting 
sample.
3.7.4. STATISTICAL METHODS
The glycated albumin and fructosamine levels were expressed in 
centiles in order to compare them to glycated haemoglobin and to 
examine their relationship with blood glucose levels.
Pearson’s correlation coefficient(r) were used to examine the 
relationship between different glycated proteins and also between 
glycated proteins and the biochemical posters measured. Student’s t- 
tests were used to compare glycated proteins and all of the 
biochemical and haematological parameters measured between the 
high and low glycators. Paired Student’s t-tests were used to 
compare plasma and intra-erythrocyte glucose concentrations. 
Unless otherwise stated values are shown as mean (* SD)-
3.8. RESULTS
3.8.1. RELATIONSHIP OF GLYCATED ALBUMIN AND 
FRUCTOSAMINE WITH BLOOD GLUCOSE LEVELS COMPARED TO 
GHB AND BLOOD GLUCOSE LEVELS
3.8.1.1. Two-hour Blood Glucose
Both glycated albumin and fructosamine showed a poor correlation 
with 2FIBG (see Figs. 3 .6(a)(ii) and 3 .7(a)(ii)). The relationship 
between glycated albumin and 2HBG was marginally better than that 
of fructosamine (r = 0.38 and r = 0.14 respectively). However, both 
glycated albumin and fructosamine showed a markedly different 
relationship with 2HBG than GHb (see Figs. 3.6(a)(i) and 3.7(a)(i) 
compared to Fig. 3.3(a) + (b)). The high and low glycators were re­
distributed on both sides of the unity line. Although three high 
glycators still had fructosamine levels 30 centiles higher than the 
centile for 2HBG, the other four had crossed the line of unity, with 
one high glycator now having a fructosamine 30 centiles lower than 
the 2HBG centile. Glycated albumin showed a similar change as for 
fructosamine except that only one high glycator still had a glycated 
albumin 30 centiles higher than the 2HBG centile. One low glycator 
still had a fructosamine 30 centiles lower than the 2HBG centile, 
but another two low glycators had fructosamines 30 centiles higher 
than the 2HBG centile. Glycated aibumin in the low glycators 
showed a similar finding as fructosamine in relation to the 2HBG.
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(i) USING CENTILES
FIGURE.3.6(a) RELATIONSHIP BETWEEN GLYCATED ALBUMIN
AND TWO-HOUR BLOOD GLUCOSE IN THE HIGH AND LOW
GLYCATORS
CENTILE FOR TWO-HOUR BLOOD GLUCOSE
The line of agreement and the +30 and -30 centile lines are 
indicated.
High glycators are represented as (♦) and the low glycators as (□). 
(ii) WITHOUT THE USE OF CENTILES
TWO-HOUR BLOOD GLUCOSE 
(mmol/l)
The regression line and correlation coefficient (r) are indicated.
High glycators are represented as (■) and low glycators as (□).
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FIGURE.3.7(a) RELATIONSHIP BETWEEN FRUCTOSAMINE AND
TWO-HOUR BLOOD GLUCOSE IN THE HIGH AND LOW GLYCATORS
(i) USING CENTILES
CENTILE FOR TWO-HOUR BLOOD GLUCOSE
The line of agreement and the +30 and -30 centile lines are 
indicated.
High glycators are represented as (♦) and the low glycators as (□). 
(II) WITHOUT THE USE OF CENTILES
(mmol/l)
The regression line and correlation coefficient (r) are indicated.
High glycators are represented as (■) and low glycators as (□).
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3.8.1.2. Fasting Blood Glucose
A significant correlation (p < 0.05) was found between glycated 
albumin and FBG (r = 0.65) whereas no correlation was found 
between fructosamine and FBG (r = 0.093) (see Figures 3.6(b)(ii) 
and 3.7(b)(ii)). When expressed in centiles (see Figure 3.6(b)(i) and 
3.7(b)(i)) for glycated albumin, all the highs had crossed over the 
line of unity, although for fructosamine two highs remained on the 
original side of the line. The low glycators were distributed on both 
sides of the unity line for both glycated albumin and fructosamine 
(similarly to 2HBG). However, two low glycators still had very low 
glycated albumin and fructosamine levels in relation to their FBG 
level.
3.8.1.3. Mean Blood Glucose (Profiles)
As with FBG a significant correlation (p < 0.05) was found between 
glycated albumin and MBG (r = 0.53) whilst no apparent correlation 
was found between fructosamine and MBG (r = -0.07) (see Figures
3.6(c)(ii) and 3.7(c)(ii)). However, when expressed in centiles (see 
Figures 3.6(c)(i) and 3.7(c)(i) the distribution of the subjects was 
similar for both measures of plasma glycation in relation to the 
MBG. The high glycators were again distributed on both sides of the 
unity line, only .with fructosamine two high glycators still had 
relatively high fructosamine levels. These two subjects also had 
high fructosamine levels compared to their glycated albumin levels 
(see Figure 3.8(c) numbers 13 and 8). The low glycators were also 
distributed on both sides of the unity line. However, three of these 
subjects still had glycated albumin and fructosamine levels 30 
centiles lower than the MBG centile.
1 18
(i) USING CENTILES
FIGURE.3.6(b) RELATIONSHIP BETWEEN GLYCATED ALBUMIN
AND FASTING BLOOD GLUCOSE IN THE HIGH AND LOW
GLYCATORS
CENTILE FOR FASTING BLOOD GLUCOSE
The line of agreement and the +30 and -30 centile lines are 
indicated.
High glycators are represented as (♦) and the low glycators as (□). 
(ii) WITHOUT THE USE OF CENTILES
(mmol/l)
The regression line and correlation coefficient (r) are indicated.
High glycators are represented as (■) and low glycators as (□).
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FIGURE.L.7 .(b) RELATIONSHIP BETWEEN FRUCTOSAMINE AND
FASTING BLOOD GLUCOSE IN THE HIGH AND LOW GLYCATORS
(I) USING CENTILES
CENTILE FOR FASTING BLOOD GLUCOSE
The line of agreement and the +30 and -30 centile lines are 
indicated.
High glycators are represented as (O) and the low glycators as (□) . 
(ii) WITHOUT THE USE OF CENTILES
(mmol/l)
The regression line and correlation coefficient (r) are indicated.
High glycators are represented as (ffl) and low glycators as (□).
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(i) USING CENTILES
FIGURE.3.6.(c) RELATIONSHIP BETWEEN GLYCATED ALBUMIN
AND MEAN BLOOD GLUCOSE(PROFILES) IN THE HIGH AND LOW
GLYCATORS
CENTILE FOR MEAN BLOOD GLUCOSE 
(PROFILES)
The line of agreement and the +30 and -30 centile lines are 
indicated. High glycators are represented as (♦ and the low glycators 
as (□) .
(ii) WITHOUT THE USE OF CENTILES
(mmol/l)
The regression line and correlation coefficient (r) are indicated. 
High glycators are represented as (■) and low glycators as (□).
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(i) USING CENTILES
FIGURE.3.7.(c) RELATIONSHIP BETWEEN FRUCTOSAMINE AND
MEAN BLOOD GLUCOSE(PROFILES) IN THE HIGH AND LOW
GLYCATORS
CENTILE FOR MEAN BLOOD GLUCOSE(PROFILES)
The line of agreement and the +30 and -30 centile lines are 
indicated. High glycators are represented as (❖) and the low 
glycators as (□) .
(ii) WITHOUT THE USE OF CENTILES
2 .2  H  i    i —— r  i  - - i   i............... t ' ■ • i
4 5 6 7 8
MEAN BLOOD GLUCOSE(PROFILES)
(mmol/l)
The regression line and correlation coefficient (r) are indicated. 
High glycators are represented as (■) and low glycators as (□).
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3.8.2. CORRELATION OF GLYCATED ALBUMIN, FRUCTOSAMINE
AND GLYCATED HAEMOGLOBIN.
A weak negative correlation (r = -0.43) was found between glycated 
albumin and GHb (see Figure 3.8(a)), whilst no apparent correlation 
was found between fructosamine and GHb (r = -0.18)(see Figure 
3.8(b)). A weak positive correlation was found between glycated 
albumin and fructosamine (r = 0.46) (see Figure 3.8(c)). There was 
one high glycator who had a relatively high fructosamine level 
compared to the glycated albumin level (No. 8).
3.8.3. COMPARISON OF GLYCATED ALBUMIN, FRUCTOSAMINE 
AND GLYCATED HAEMOGLOBIN LEVELS IN THE HIGH AND LOW 
GLYCATORS
Although the GHb levels were higher in the high glycators and the 
glycated albumin levels were higher in the low glycators, none of 
the differences were significant (see Table 3.5). The fructosamine 
levels were virtually identical in both groups of subjects.
3 .8 .4 . P LA S M A  AND IN TR A -E R Y TH R O C Y TE  G LUCOSE 
CONCENTRATIONS IN THE LOW AND HIGH GLYCATORS
Although there were no significant differences in either plasma or 
intra-erythrocyte glucose concentrations between the low and high 
glycators (see Table 3.6), there were sign ificant d ifferences 
between the two blood compartments at d ifferent time points 
within each group of subjects (see Figure 3.9(a) and (b)). There was 
no significant difference between the fasting plasma and intra­
erythrocyte glucose concentrations in either the low or high 
glycators. However, following the glucose load, although no 
significant d ifferences were found between plasma and in tra­
erythrocyte glucose concentrations in the high glycators, there were 
highly significant differences between the two compartments in the 
low glycators (see Table 3.7(a) and (b)). The total plasma 
concentration during the OGTT (i.e. swing) was significantly greater 
than the total intra-erythrocyte glucose concentration in both the 
high (p<0.02) and low glycators (p<0.005)
1 23
FIGURE.3.8.(a) CORRELATION BETWEEN GLYCATED
ALBUMIN AND GLYCATED HAEMOGLOBIN IN THE HIGH
AND LOW GLYCATORS
GLYCATED ALBUMIN (%)
The regression line and correlation coefficient (r) are indicated.
High glycators are represented as (■) and low glycators as (□).
1  2 4
FIGURE.3.8.(b) CORRELATION BETWEEN GLYCATED 
HAEMOGLOBIN AND FRUCTOSAMINE
FRUCTOSAMINE (mmol/l)
The regression line and correlation coefficient (r) are indicated. 
High glycators are represented as (■) and low glycators as (□).
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FIGURE.3.8.(c) CORRELATION BETWEEN GLYCATED
ALBUMIN AND FRUCTOSAMINE
FRUCTOSAMINE (mmol/l)
The regression line and correlation coefficient (r) are indicated. 
High glycators are represented as (B) and low glycators as (□).
TABLE 3.5 COMPARISON OF GLYCATED PROTEINS IN
THE HIGH AND LOW GLYCATORS
GLYCATED LOW HIGH SIGNIFICANCE
PROTEIN GLYCATORS GLYCATORS OF DIFFERENCE
(P)
MEAN GLYCATED
HAEMOGLOBIN (%) 6.13 (0.97) 6.87 (0.97) NS
GLYCATED ALBUMIN 2.28 (0.57) 1.99 (0.43) NS
10/
FRUCTOSAMINE 2.55 (0.32) 2.53 (0.31) NS
(m m o l/ l)
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T A B L E  3 . 6  C O M P A R I S O N  O F  P L A S M A  A N D  I N T R A ­
E R Y T H R O C Y T E  G L U C O S E  C O N C E N T R A T I O N S  I N  T H E  H I G H  
AND L O W  G L Y C A T O R S  D U R I N G  T H E  G L U C O S E  T O L E R A N C E  
T E S T
GLUCOSE LEVEL LOW HIGH SIGNIFICANCE
GLYCATORS GLYCATORS OF DIFFERENCE
(P)
FASTING PLASMA 5.25 (0.58) 5.86 (0.66) NS
GLUCOSE(mmol/l)
FASTING INTRA­
ERYTHROCYTE 4.60 (1.38) 5.01 (1.14) NS
GLUCOSE (mmol/l)
TWO-HOUR PIASMA 7.05 (1.48) 6.15 (1.99) NS
GLUCOSE (mmol/l)
TWO-HOUR INTRA­
ERYTHROCYTE 5.01(1.73) 6.12(1.94) NS
GLUCOSE (mmol/l)
SUM PLASMA GLUCOSE 29.88 (4.35) 30.55 (5.57) NS
-OGTT(m mol/l)
SUM INTRA- 22.63 (6.52) 27.11 (5.97) NS
ERYTHROCYTE
GLUCOSE -
OGTT(mmo!/l)
1  2 8
F I G U R E . 3 . 9 .  C H A N G E S  I N  G L U C O S E  C O N C E N T R A T I O N
I N  T H E  P L A S M A  A N D  E R Y T H R O C Y T E S  D U R I N G  T H E  
G L U C O S E  T O L E R A N C E  T E S T
(a) LOW GLYCATORS
2 -|---,---,---,---1---,---,---,---j---,---1
0 1 2 3 4 5
1 -  BASAL (FASTING)
2 = 30 MINS POST-LOAD
3 = 1 HOUR POST-LOAD
4 = 2 HOURS POST-LOAD
The significance of difference between the plasma and erythrocyte 
glucose concentrations is indicated.
1  2 9
TABLE 3.7 (a) DIFFERENCES BETWEEN PLASiVtA AND
INTRA-ERYTHROCYTE GLUCOSE CONCENTRATIONS IN
THE LOW GLYCATORS
TIME
FASTING 
30 MINUTES
1-HOUR
2-HOURS 
SUM
PLASMA
GLUCOSE
(m m o l/ l)
5.25 (0.58)
9.11 (2.08)
8.49 (1.44)
7.05 (1.48)
29.88 (4.35)
INTRA- SIGNIFICANCE
ERYTHROCYTE OF DIFFERENCE 
GLUCOSE (p)
(m m o l/ l)
4.60 (1.38) NS
6.36 (1.49) <0.01
6.68 (2.26) <0.01
5.01 (1.73) <0.01
22.63 (6.52) <0.005
1 3 0
TABLE 3.7 (b) DIFFERENCES BETWEEN PLASMA AND
INTRA-ERYTHROCYTE GLUCOSE CONCENTRATIONS IN
THE HIGH GLYCATORS
TIME PLASMA INTRA- SIGNIFICANCE
GLUCOSE ERYTHROCYTE OF DIFFERENCE
(m m o l/ l)  GLUCOSE (p)
(m m o l/ l)
FASTING 5,86 (0.66) 5.01 (1.14) NS
30 MINUTES 9.67(1.45) 8.58(2.96) NS
1-HOUR 8.81 (2.35) 7.41 (1.91) NS
2-HOURS 6.15 (1.99) 6.12 (1.94) NS
SUM 30.55 (5.57) 27.11 (5.97) <0.02
1 3 1
The ratio of intra-erythrocyte to plasma glucose, known as the 
permeability of the erythrocyte to glucose (Higgins et al., 1982) was 
significantly lower (p<0.05) in the low compared to the high 
glycators two hours after the glucose load. There were no 
significant differences between the two groups of subjects in 
permeability at fasting or at any other time (except at two hours) 
during the OGTT (see Table 3.8).
There was a significant (p<0.001) correlation between plasma and 
intra-erythrocyte glucose concentration at two hours, with the 
correlation being greater for the high (r = 0.87) than the low 
glycators (r = 0.67) (see Figure 3.10(b)). At fasting, the correlation 
between intra-erythrocyte and plasma glucose levels was weaker (r 
= 0.54), although there was a slightly better correlation for the low 
(r -  0.70) than the high glycators (r = 0.62) (see Figure 3.10(a)). A 
highly significant (p<0.001) correlation was found between intra­
erythrocyte glucose concentration and the mean GHb level in the low 
glycators, particularly at fasting (r = 0.91) (see Figure 3.11(a) and
(b)). The co rre la tion  between in tra -e ry th ro cy te  g lucose 
concentration and mean GHb level was much weaker in the high 
glycators, particularly at two hours (r « 0.22). At similar intra­
erythrocyte glucose concentrations to the low glycators, the high 
glycators had sim ilar or higher GHb levels. Similarly, the 
relationship between erythrocyte permeability to glucose and mean 
GHb levels was much stronger for the low than the high glycators 
(see Figure 3.12(a) and (b)).
1  3 2
T A B L E  3 . 8  R A T I O  O F  I N T R A - E R Y T H R O C Y T E  T O  
P L A S M A  G L U C O S E  ( i e .  e r y t h r o c y t e  g l u c o s e  
p e r m e a b i l i t y  )  I N  T H E  H I G H  A N D  L O W  G L Y C A T O R S  
D U R I N G  T H E  G L U C O S E  T O L E R A N C E  T E S T
TIME LOW HIGH SIGNIFICANCE
GLYCATORS GLYCATORS OF DIFFERENCE
(P)
FASTING 0.87 (0.24) 0.86 (0.17) NS
30 MINUTES 0.71 (0.13) 0.88 (0.28) NS
1 HOUR 0.77 (0.16) 0.87 (0.29) NS
2 HOURS 0.70 (0.17) 1.01 (0.24) <0.05
1  3 3
FIGURE.3.10. RELATIONSHIP BETWEEN PLASMA AND
ERYTHROCYTE GLUCOSE CONCENTRATIONS IN THE
HIGH AND LOW GLYCATORS
(a) FASTING
r = 0.54 
(lows r=0.70) 
(highs r=0.62)
FAST ERYTHROCYTE GLUCOSE 
(mmol/l)
(b) TWO-HOURS POST-LOAD
UJ(/>Oo
o
< o
2 =5
3 I3  E
Du
DCDOX
r s 0.85 
(lows r=0.67) 
(highs r=0.87)
(mmol/l)
The regression lines and correlation coefficients (r) are indicated.
High glycators are represented as (■) and low glycators as (a).
1 3 4
FIGURE.3.11. RELATIONSHIP BETWEEN MEAN
GLYCATED HAEMOGLOBIN AND ERYTHROCYTE GLUCOSE
CONENTRATIONS IN THE HIGH AND LOW GLYCATORS
(a) FASTING
CDX
0
X<UJ
s
r = 0.66 
(lows r=0.91) 
(highs r=0.53)
FAST ERYTHROCYTE GLUCOSE 
(mmol/l)
(b) TWO-HOUR POST-LOAD
£D
X
0
X<LU
r = 0.47 
(lows r=0.75) 
(highs r=0.22)
TWO-HOUR ERYTHROCYTE GLUCOSE 
(mmol/l)
The regression lines and correlation coefficients (r) are indicated.
High glycators are represented as (B) and low glycators as (□).
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FIGURE.3.12. RELATIONSHIP BETWEEN ERYTHROCYTE
PERMEABILITY TO GLUCOSE AND MEAN GLYCATED
HAEMOGLOBIN IN THE HIGH AND LOW GLYCATORS
(a) FASTING
r = 0.57 
(lows r=0.97) 
(highs r=0.47)
FAST ERYTHROCYTE PERMEABILITY(%)
(b) TWO-HOUR POST-LOAD
m
x
z<
LL!
2
TWO-HOUR ERYTHROCYTE PERMEABlLITY(%)
The regression lines and correlation coefficients (r) are indicated.
High glycators are represented as (®) and low glycators as (□).
1  3 6
3.8.5. COMPARISON OF FACTORS DIRECTLY AFFECTING THE 
GLYCATION REACTION IN THE LOW AND HIGH GLYCATORS 
(Results are shown in Tables 3.9 and 3.10).
There was no significant difference in either plasma or intra­
erythrocyte inorganic phosphate concentrations between the two 
groups, although there was a weak negative correlation between 
intra-erythrocyte inorganic phosphate and mean GHb (r = -0.38). The 
e ry th ro c y te  2 ,3 -d ip h o s p h o g ly c e ra te  c o n c e n t ra t io n s  were  
significantly (p<0.001) greater in the high glycators compared to the 
low glycators. There was also a weak positive correlation between 
erythrocyte 2,3-diphosphoglycerate and mean GHb (r = 0.30).
There was no significant difference in intra-erythrocyte pH between 
the two groups. However, there was a significant (p<0.05) positive 
correlation (r = 0.55) between intra-erythrocyte pH and mean GHb.
3.8.6. COMPARISON OF COMPOUNDS COMPETING WITH 
GLUCOSE FOR BINDING TO PROTEINS IN THE LOW AND HIGH 
GLYCATORS
(Results are shown in Tables 3.10 and 3.11).
There was no significant difference in either plasma or intra­
erythrocyte vitamin C concentrations between the two groups, 
although there was a weak negative correlation (r = -0.40) between 
intra-erythrocyte vitamin C concentrations and mean GHb levels. 
Neither plasma urea nor free fatty acids were s ignificantly 
different between the two groups.
3.8.7. COMPARISON OF AMINO ACID LEVELS IN THE HIGH AND 
LOW GLYCATORS
There were no significant differences in plasma, erythrocyte or 
urine total amino acids between the two groups (see Tables 3.12, 
3.13and 3.14). The plasma threonine and lysine concentrations were 
significantly greater (p<0.01 and <0.05 respectively) in the low 
glycators. Only the taurine concentration in the erythrocyte was 
significantly (p<0.05) greater in the low compared to the high 
glycators. A significant negative correlation was found between 
plasma total amino acids and mean GHb whereas only a very weak 
negative correlation was found between erythrocyte total amino 
acids and mean GHb (see Table 3.10).
1  3 7
TABLE 3 . 9  C O M P A R I S O N  O F  F A C T O R S  D I R E C T L Y  A F F E C T I N G  
THE G L Y C A T I O N  R E A C T I O N  I N  T H E  L O W  A N D  H I G H  
G L Y C A T O R S
FACTOR AFFECTING LOW HIGH SIGNIFICANCE
GLYCATION GLYCATORS GLYCATORS OF DIFFERENCE
(P)
PLASMA INORGANIC 0.97 (0.19) 1.06 (0.07) NS
PHOSHATE (mmol/l)
INTRA-ERYTHROCYTE
INORGANIC PHOSHATE 0.46 (0.21) 0.36 (0.21) NS
(m m o l/ l)
ERYTHROCYTE 2,3-
DIPHOSPHOGLYCERATE 4.81 (0.24) 5.61 (0.26) <0.001
(m m o l/ l)
INTRA-ERYTHROCYTE pH 7.05 (0.19) 7.17 (0.11) NS
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T A B L E  3 . 1 0  C O R R E L A T I O N  ( r )  O F  M E A N  G L Y C A T E D  
H A E M O G L O B I N  W I T H  V A R I O U S  B I O C H E M I C A L  P A R A M E T E R S  
M E A S U R E D  I N  T H E  L O W  A N D  H I G H  G L Y C A T O R S
MEASUREMENT CORRELATION
COEFFICIENT (r)
INTRA-ERYTHROCYTE -0 .38
INORGANIC PHOSPHATE
ERYTHROCYTE 2,3- 0.30
DIPHOSPHGLYCERATE
INTRA-ERYTHROCYTE pH 0.55
INTRA-ERYTHROCYTE -0 .40
VITAMIN C
INTRA-ERYTHROCYTE TOTAL -0 .30  
AMINO ACIDS
PLASMA TOTAL AM I NO -0 .57
ACIDS
SIGNIFICANCE (p)
NS
NS
<0.05
NS
NS
<0.05
T A B L E  3 . 1 1  C O M P A R I S O N  O F  C O M P O U N D S  C O M P E T I N G  
W I T H N  G L U C O S E  F O R  B I N D I N G  T O  P R O T E I N S  I N  T H E  L O W  
A N D  H I G H  G L Y C A T O R S
COMPOUNDS LOW HIGH SIGNIFICANCE
COMPETING WITH GLYCATORS GLYCATORS CF
GLUCOSE DIFFERENCE(p)
PLASMA VITAMIN C
(n m o l/ l)  62.6 (36.8) 54.0 (22.4) NS
INTRA-ERYTHROCYTE
VITAMIN C (nmol/l) 50.1 (20.1) 37.8 (29.9) NS
PLASMA UREA 4.64 (0.69) 4.64 (1.28) NS
(m m o l/ l)
PLASMA FREE FATTY
ACIDS (mmol/l) 0.49 (0.18) 0.61 (0.14) NS
I
1  4 0
TABLE 3.12 PLASMA AMINO ACIDS IN THE HIGH AND LOW
GLYCATORS (FASTING)
AMINO ACID LOW
GLYCATORS
( l im o l/ l )
HIGH
GLYCATORS
( j im o l/ l)
SIGNIFICANCE 
OF DIFFERENCE
(P)
ASPARTIC ACID N.D. 2.19 (3.97) NS
GLUTAMIC ACID 34.3 (29.7) 40.0 (43.9) NS
SERINE 49.9 (14.7) 75.3 (49.6) NS
ASPARAGINE 47.8 (28.3) 29.0 (22.3) NS
GLYCINE 118.5 (56.8) 98.2 (51.9) NS
TAURINE 28.3 (47.4) 19.6 (13.8) NS
HISTIDINE 43.3 (25.4) 25.4 (25.5) NS
CITRULLINE 17.0 (11.0) 17.5 (.10.2) NS
THREONINE ■ 65.8 (16.3) 27.3 (22.9) <0.01
ALANINE 178.0 (32.6) 166.3 (92.0) NS
ARGININE 48.7 (10.1) 49.9 (27.8) NS
PROLINE 108.1 (65.1) 71.7 (59.1) NS
TYROSINE 35.7 (21.8) 46.1 (15.1) NS
VALINE 114.4 (24.4) 129.4 (39.9) NS
METHIONINE 15.3 (2.6) 16.3 (13.1) NS
ISOLEUCINE 28.5 (15.3) 42.2 (18.0) NS
LEUCINE 88.5 (72.1) 102.8 (60.4) NS
PHENYLALANINE 50.4 (21.0) 34.1 (19.7) NS
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TRYPTOPHAN 40.4 (20.4) 28.1 (10.8) NS
ORNITHINE 33.5 (26.8) 37.8 (26.8) NS
LYSINE 105.6 (16.4 ) 84.0 (14.8) <0.05
T O T A L  A M IN O  1280 (160) 1090 (160) NS
ACIDS
N.D. = NOT DETECTED
1  4 2
TABLE 3.13 INTRA-ERYTHROCYTE AMINO ACIDS IN
THE HIGH AND LOW GLYCATORS (FASTING)
AMINO ACID LOW
GLYCATORS
( j im o l/ I )
HIGH
GLYCATORS
(jamol/l)
SIGNIFICANCE 
OF DIFFERENCE 
(P)
SERINE 66.0 (15.7) 56.9 (11.5) NS
ASPARAGINE 126.4 (19.5) 109.6 (19.5) NS
GLYCINE 186.8 (66.2 ) 183.0 (58.1) NS
TAURINE 32.4 (7.8 ) 9.6 (16.5 ) <0.02
CITRULLINE 7.5 (10.4 ) 7.2 (13.0) NS
THREONINE N.D. 8.7 (22.9) NS
ALANINE 179.9 (29.6) 191.0 (26.4) NS
PROLINE 50.8 (32.6 ) 28.2 (42.3 ) NS
VALINE 63.0 (18.5) 42.6 (11.8) NS
METHIONINE 5.5 (12.3) N.D. NS
ISOLEUCINE 285.0 (108.0) 160.9 (65.7) NS
LEUCINE 28.4 (24.1) 38.1 (49.9) NS
ORNITHINE 45.0 (11.9) 35.9 (21.3) . NS
LYSINE 75.3 (42.5) 48.8 (9.7) NS
TOTAL AMINO 1120 (170) 980 (120) NS
ACIDS
N.D. = NOT DETECTED
1 43
TABLE 3.14 TOTAL URINE AMINO ACIDS IN THE HIGH AND
LOW GLYCATORS
LOW GLYCATORS
(m m o l/24hours /m m o l
crea tin ine
0.29 (0.14)
HIGH GLYCATORS
(m m o!/24hours /m m ol
c rea tin ine
0.23 (0.11)
SIGNIFICANCE OF 
DIFFERENCE (p)
NS
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3.8.8. COMPARISON OF PLASMA INSULIN LEVELS IN THE LOW 
AND HIGH GLYCATORS
Although the plasma levels of insulin were higher in the high 
glycators than the low glycators at all time points except two- 
hours, the differences failed to reach significance (see Table 3.15).
3.8.9. COMPARISON OF HAEMATOLOGICAL VARIABLES IN THE 
LOW AND HIGH GLYCATORS
No abnormality in haematology was detected in any of the subjects. 
None of the tests suggested any differences in erythrocyte survival 
between the low and high glycators and no abnormal haemoglobins 
were detected in the subjects (see Table 3.16). All the subjects had 
a negative Coombs7 test indicating that antibodies to erythrocytes 
as a cause of haemolysis were not present.
3.8.10. COMPARISON OF TWO LOW G LYCATORS WITH 
RELATIVELY LOW GLYCATED ALBUMIN LEVELS WITH THE 
OTHER LOW GLYCATORS
None of the biochemical parameters measured were significantly 
different between the subgroup of low glycators who had relatively 
low glycated albumin levels as well as low GHb levels compared to 
the other low glycators who despite having relatively low GHb levels 
had appropriate levels of glycated albumin (see Table 3.17).
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TABLE 3.15 COMPARISON OF PLASMA INSULIN
LEVELS DURING THE GLUCOSE TOLERANCE TEST IN
THE LOW AND HIGH GLYCATORS
TIME OF LOW HIGH SIGNIFICANCE
SAMPLE GLYCATORS GLYCATORS OF DIFFERENCE
(m U /l)  (m U /l)  (p)
FASTING 11.0 (3.8) 12.5 (3.3) NS
30 MINUTES 64.1 (29.6) 93.2 (43.5) NS
1 HOUR 76.5 (55.7) 116.1 (71.8) NS
2 HOURS 77.7 (42.2) 65.8 (60.9) NS
SUM 235 (136) 289 (153) NS
1 46
TABLE 3 . 1 6  C O M P A R I S O N  O F  H A E M A T O L O G I C A L  
VARIABLES I N  T H E  LOW A N D  H I G H  G L Y C A T O R S
HAEMATOLOGICAL LOW HIGH SIGNIFICANCE
VARIABLE GLYCATORS GLYCATORS OF DIFFERENCE
(P)
ERYTHROCYTE COUNT 4.36 (0.37) 4.30 (0.42) NS
(x 1 0 1 2 / 1)
HAEMOGLOBIN 13.9 (0.9) 13.5 (0.9) NS
(g /1 0 0 m l)
PACKED CELL VOLUME 41 (4) 40 (4) NS
(%)
MEAN CELL 31.9 (1.2) 31.8 (2.1) NS
HAEMOGLOBIN (pg)
MEAN CELL
HAEMOGLOBIN 33.5 (2.1) 33.1 (1.4) NS
CONCENTRATION
(g/1 00m l)
RETICULOCYTES (%) 1.6 (0.6) 1.8 (0.5) NS
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TABLE 3.17 COMPARISON OF THE TWO LOW GLYCATORS (LL) WITH 
RELATIVELY LOW GLYCATED ALBUMIN TO THE OTHER LOW 
GLYCATORS (L)WHO HAVE APPROPRIATE LEVELS OF GLYCATED 
ALBUMIN
BIOCHEMICAL MEASUREMENT LOW GLYCATORS 
(LL)
FAST PLASMA GLUCOSE (mmol/l) 5.64 (0.48) 
2HOUR PLASMA GLUCOSE (mmol/l) 6.39
SUM OF PLASMA GLUCOSE-OGTT 31.20
(m m o l/l)
FAST INTRA-ERYTHROCYTE 3.84
GLUCOSE (mmol/l)
2HOUR INTRA-ERYTHROCYTE 3.44
GLUCOSE (mmol/l)
SUM OF INTRA-ERYTHROCYTE 
GLUCOSE -OGTT (mmol/l) 1 6.45
FAST PLASMA INSULIN (mU/l) 14.9
PLASMA INORGANIC PHOSPHATE 1.06
(m m o l/l)
INTRA-ERYTHROCYTE INORGANIC 
PHOSPHATE (mmol/l) 0.37
ERYTHROCYTE
2.3-DIPHOSPHOGLYCERATE 4.77
(m m o l/l)
INTRA-ERYTHROCYTE pH 7.14
PLASMA VITAMIN C (pmol/l) 34.5
INTRA-ERYTHROCYTE VITAMIN C 39.7
( jim o l/ l)
MEAN GLYCATED HAEMOGLOBIN 6.58
(%)
GLYCATED ALBUMIN (%) 1.70
FRUCTOSAMINE (mmol/l) 2.26
0.74)
(4.67)
0.79)
0.34)
(0.50)
2 .2 )
0.04)
0.09)
0.28)
0 .21 )
44.2)
12 .0 )
0.70)
0 . 10 )
0.03)
LOW GLYCATORS 
(L)
4.99 (0.54) 
7.49 (1.84)
29.00 (4.91)
2.44 (0.99) 
2.92 (1.46)
12.89 (5.17) 
8.4 (1.1)
0.91 (0.24)
0.53 (0.26) 
4.84 (0.27)
7.00 (0.19)
38.2 (28.0) 
77.6 (42.0)
5.83 (1.14)
2.67 (0.17) 
2/94 (0.23)
SIGNIFICANCE 
DIFFERENCE (p)
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
<0.05
NS
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MEAN BLOOD GLUCOSE-PROFILES 6.67 (0.46) 6.85 (0.75) NS
(m m o l/l)
PLASMA TOTAL AMINO ACIDS 1.34 (0.11) 1.24 (0.20) NS
(m m o l/l)
INTRA-ERYTHROCYTE TOTAL AMINO
ACIDS (mmol/l) 1.27 (0.06) 1.02 (0.14) NS
URINE TOTAL AMINO ACIDS
(mmol/24hrs/mmoi creatinine) 0.29 (0.19) 0.31 (0.15) NS
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DISCUSSION
The majority of the subjects studied in Part 1 who had inappropriate 
levels of GHb relative to their blood glucose levels did not have 
glycated albumin levels that were inappropriate relative to their 
levels of glycaemia. All of the so-called high glycators and most of 
the so-called low glycators had appropriate levels of glycated
albumin in relation to their blood glucose levels. The fructosamine 
levels followed a similar pattern to the glycated albumin levels, but 
in general there was a much weaker re lationship between 
fructosamine and blood glucose levels compared to glycated albumin 
and glycaemia. This probably reflects the non-specific nature of the 
fructosamine reaction which has a number of known interferences 
(Schleicher et al., 1988). These will also be more obvious in normal 
subjects where they probably make a larger contribution to the 
overall fructosamine activity measured. Albumin makes up at least 
60% of the total plasma proteins (Peters, 1985) and its specific 
measurement is a more accurate reflection of blood glucose levels 
than fructosamine, which is a measure of all plasma glycated
proteins, a heterogeneous mixture with different half-lives (Seng 
and Staiey, 1986). In general, the high and low glycators for. 
haemoglobin did not also show high and low glycation of albumin. 
This indicates that the glycation of haemoglobin and albumin were 
occurring at different levels.
Although albumin and haemoglobin are both found in the blood, they 
are located in different compartments. Albumin is free to circulate 
in the plasma and extravascular spaces, whilst haemoglobin is 
confined to the erythrocyte . Albumin has a half-l ife  of
approximately 19 days (Peters, 1985). There is no specific site for 
its metabolism. It is thought to be taken up by cells throughout the 
body and degraded in iysosomes (Baynes and Thorpe, 1981; Henderson 
et al., 1982). Haemoglobin c ircu la tes with in the mature
erythrocytes for 120 days, after which they are taken up and 
destroyed mainly by the spleen (Harris and Kellermeyer, 1970).
Both albumin and haemoglobin are glycated in vivo and have been 
shown to reflect blood glucose levels over the previous 2 - 3 weeks 
and 4 - 6 weeks respectively (Kennedy et al., 1981; Bunn et al., 
1978). Haemoglobin is glycated at both the N-termini of the a -  and 
p-chains and also at various e-amino groups of. lysine residues 
throughout the molecule. The major sites of glycation of 
haemoglobin in vivo are in order of prevalence, p-val-1, p - iys-66,
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oc-lys-61,. |3-lys-17 and a-val-1 (Shapiro et ai., 1980). Albumin on 
the other hand has been shown to be glycated mainly at the e-amino 
groups of lysine residues, although the end terminal amino acids 
have recently been shown to be glycated in vivo ( Robb et al.,1989). 
Lys-525 has been shown to be the major site of glycation of albumin 
in v ivo  (Garlick and Mazer, 1983; Iberg and Fluckiger, 1985). At 
least nine other lysine residues in albumin have been shown to be 
glycated in v ivo dbera and Fluckiger, 1986). These are lys 439, 199, 
281, 233, 317, 351, 534 and 12. The specificity of glycation of both 
albumin and haemoglobin has been suggested to be partially due to 
the pKa of the amino group but appears to be predominantly due to 
the location of the Schiff base within the microstructure of the 
protein (Watkins et al., 1988). Acid-base catalysis of the Amadori 
rearrangement by acidic or basic amino acids in close proximity to 
the Schiff base is thought to be the main factor in directing the 
specificity of glycation of albumin (Olufemi et al., 1987). With 
haemoglobin, although neighbouring amino acids may also play a role 
catalysing the rearrangement, the specific glycation of the (3-chain 
terminal valine residue is thought to be due to its location within 
the 2,3-diphosphoglycerate binding pocket. It is thought that the 
anionic phosphate groups catalyse the glycation reaction at this site 
(Watkins et al., 1987). Approximately 4 - 5% of haemoglobin is 
glycated at the p-chain termini in normal subjects whereas another 
9 - 10% of haemoglobin is thought to be glycated at lysine residues 
(Bunn et al., 1979).
The percentage of glycation of albumin in normal subjects has been 
shown to be 2 - 12%. The inconsistency in its measurement appears 
to be due to differences in the methodology (Yatscoff et al., 1984; 
Ziel and Davidson, 1987). With the methodology used in the present 
study (affin ity chrom atography and im munoelectrophoresis) a 
normal range of 1 - 3% was found.
Several studies have been carried out to investigate the relative 
merits of using glycated haemoglobin and/or glycated albumin in the 
monitoring of blood glucose levels (Yue et al., 1979; Schleicher et 
al., 1984; Ross .et ai., 1986). Although in general both glycated 
proteins have been shown to correlate well with measures of 
glycaemia in diabetic subjects, evidence does appear to suggest that 
haemoglobin and albumin are glycated at d ifferent levels. For 
example, the correlation of the two glycated proteins with various 
glycaemic indices is often different in the same subject. Schleicher 
et ai., (1984) found that in a group of diabetic subjects followed 
over several months, the correlation- between glycated plasma
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proteins with the mean blood glucose was significantly greater than 
for glycated haemoglobin. Quite poor correlations are also often 
found between glycated plasma proteins and glycated haemoglobin 
(Guthrow et al., 1979; Kennedy et al., 1981; Yatscoff et al., 1984; 
Ross et al., 1986). Guthrow et al., (1979) found that whilst glycated 
haemoglobin levels were in the norma! range in a group of diabetic 
subjects, glycated albumin levels were much higher in the same 
ind iv iduals.
This difference between the level of glycation of haemoglobin and 
albumin has been mainly attributed to the different half-lives of the 
two proteins, therefore reflecting different periods of glycaemia. 
This may be true in diabetics, particularly insu lin-dependent 
diabetics where large fluctuations in blood glucose occur, but it is 
unlikely to provide an explanation for the discrepancy found in the 
non-diabetic subjects between glycated albumin and glycated 
haemoglobin in this study. Significant correlations were found 
between the different measures of glycaemia with both the . high and 
low glycators.
The glucose concentration within the erythrocyte has been shown to 
be 60 - 80% of the plasma concentration (Somogyi, 1933; Higgins et 
al., 1982). In the present study, the erythrocyte glucose 
concentration was found to be approximately 80% (mean) of the 
plasma glucose concentration. However, there was a large 
variability in the -ratio of glucose in the erythrocyte to glucose in 
the plasma between individuals and at different time points during 
the giucose tolerance test.The low glycators had significantly lower 
intra-erythrocyte glucose concentrations compared to plasma at all 
time points during the glucose tolerance test (except at fasting). 
This may be a contributory factor in determining the low GHb levels 
relative to their plasma glucose levels in these subjects.
Although no significant difference was found between the fasting or 
two-hour intra-erythrocyte glucose concentrations between the low 
and high glycators, a much stronger correlation was found between 
the intra-erythrocyte glucose concentrations and the GHb levels in 
the low compared to the high glycators. This would suggest that 
differences between plasma and erythrocyte glucose concentrations 
might be responsible for the discrepancy found between glycated 
albumin and GHb in most of the low glycators. The high glycators 
had similar intra-erythrocyte glucose concentrations to the low 
glycators whilst having significantly higher GHb levels. This would 
therefore suggest that some other additional factor within the
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erythrocyte was causing a higher rate of glycation of haemoglobin 
relative to their erythrocyte glucose concentrations.
Any difference between plasma and erythrocyte glucose levels must 
be determined by transport of glucose into or out of the erythrocyte 
and/or metabolism of glucose within the erythrocyte. The principal 
route for the consumption of glucose in the erythrocyte is the 
Embden-Meyerhof pathway and more than 95% of glucose utilized by 
the cells pass through it (Grimes, 1980). The remainder passes 
through the hexose monophosphate shunt. However, metabolism of 
glucose via either of these pathways is unlikely to be the main 
explanation of the relatively low erythrocyte glucose levels because 
the transport of glucose into the erythrocyte has been shown to be 
250 times the rate of glucose utilization (Widdas, 1954). No
relationship has been found between the transport of glucose into 
the erythrocyte and the rate of glycolysis (Somogyi, 1933; Laris,
1958).
Glucose is taken up by the erythrocyte by facilitated diffusion 
(Grimes, 1980). Brahm (1983) studied the kinetics of glucose 
transport into the human erythrocyte in vitro and found it to be both 
concentration and pH dependent. The maximal transport occurred at 
pH 7.2 and decreased progressively with an increase in acidic or 
alkaline conditions.- Therefore at a physiological whole blood pH of
7.4, the transport system is not working at its maximal rate. This
may contribute to the difference found between plasma and
erythrocyte glucose levels. Glucose may be transported in either 
direction, with the influx depending on the extracellular pH and the 
efflux from the cell depending on the intra-erythrocyte pH. The 
weak relationship found between plasma and erythrocyte glucose 
levels in the low glycators compared to the high glycators could be 
explained by a failure of the transport system to work at a maximal 
rate, perhaps due to a pH effect. The intra-erythrocyte pH was found 
to be very close to the pH causing maximal transport in the high 
glycators but was lower in the low glycators. The extracellular pH ( 
in the calculation of intra-erythrocyte pH) was higher in the high 
glycators and was nearer the maximal rate in the low glycators. 
Therefore, if there is a difference in the rate of transport into the 
erythrocyte between the low and high glycators it is not explained 
by pH differences.
There is also some evidence for the conversion of glucose to 
glycogen within the erythrocyte. Guarner & Alvarez-Buylla (1989) 
studied glucose homeostasis in rats in vitro and in v ivo . They found 
that the erythrocytes incorporated glucose into their glycogen
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stores when plasma glucose was high and released it when the 
plasma glucose was low. Therefore, once the enzymes for the 
Em bden-M eyerhof and hexose monophosphate pathways are 
saturated, increased conversion of glucose to glycogen might provide 
part of the explanation of the relatively low erythrocyte glucose 
levels compared to plasma levels.
The permeability of the erythrocyte to glucose has been shown to 
play an important role in determining the extent of glycation of 
haemoglobin in different species (Higgins et al., 1982). They found 
strong positive association between permeability and the GHb level. 
A better correlation between permeability and GHb levels was found 
in the low compared to the high glycators who had higher GHb levels 
with similar permeabilities (and erythrocyte glucose levels) to the 
low glycators. This suggests that the perm eability of the 
erythrocyte to glucose may play a major role in determining the 
extent of glycation of haemoglobin in the low glycators. The weak 
relationship found between plasma and erythrocyte glucose levels in 
the low glycators would suggest some transport defect. This would 
also explain the discrepancy between GHb and glycated albumin 
levels in the low glycators as the swings in plasma glucose were 
significantly greater than those occurring in th-e erythrocyte.
The weak relationship found between intra-erythrocyte glucose and 
GHb levels in the high glycators would suggest that erythrocyte
glucose was not the major determinant of the GHb levels. One of the
major m etabolites of g lucose within the erythrocyte , 2,3-
diphosphoglycerate has been shown to be a potent catalyst of 
haemoglobin glycation (Smith et al., 1982; Lowrey et al., 1985). The
2.3-diphosphoglycerate levels were significantly higher in the high 
glycators and may be the additional factor stimulating glycation of 
haemoglobin resulting in high GHb levels, relative to both the plasma 
and erythrocyte glucose levels. 2,3-diphosphoglycerate is produced 
along with 3-phosphoglycerate from the common substrate 1,3- 
diphosphoglycerate (see Figure 3.13). It undergoes conversion to 3- 
phosphoglycerate  and therefore acts as a bypass to the
phosphoglycerate kinase step. The two pathways compete for their 
substrate and- form e ither adenosine tr iphosphate  or 2,3- 
diphosphoglycerate. This section of the Embden-Meyerhof pathway 
is called the Rapoport-Luebering Shuttle and the regulation between 
the two branches is complex (Grimes, 1980). The two steps in the
2.3-diphosphoglycerate branch are catalysed by two different 
e n z y m e s ,  2 ,3 -d ip h o s p h o g ly c e ra te  m u ta s e  and 2 ,3 -  
diphosphoglycerate phosphatase (Rose and Liebowitz, 1970). 2,3- 
diphosphoglycerate like adenosine triphosphate is an inhibitor of its
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F IG U R E .3.13. T H E  FORMATION OF 2,3
D IP H O S P H O G L Y C E R A T E  V IA  T H E  RAPOPORT 
LUEBERSNG S H U T T L E
GLUCOSE
1,3-D  I PHOSPbioGLYCERATE
muta3e
2,3-DIPHOSPHOGLYCERATE
y f  phosphatase
3-PH0SPH0GLYCERATE
J,
2-PH0SPH0GLYCERATE
v>
LACTATE
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own synthesis because of its action on the mutase. In addition to 
changes in 2 ,3-d iphosphog lycera te  levels brought about by 
modulations within the shuttle, 2,3-diphosphoglycerate levels may 
be affected secondarily to direct effects upon overall glycolysis. 
Glycolysis is very pH sensitive, with a fall in pH decreasing the rate 
of glycolysis, leading to a reduction in 2,3-diphosphoglycerate. The 
level of 2,3-diphosphoglycerate is further decreased by an increase 
in phosphatase activity mediated by a fall in pH. An increase in pH 
leads to an increase in glycolytic activity and therefore an increase 
in 2,3-diphosphoglycerate levels. Astrup (1969) showed that a 
change of pH of 0.01 units corresponded to a change in 2,3-
diphosphoglycerate of 4% in v iv o . Inorganic phosphate can also 
stimulate glycolysis independently of pH increasing levels of 2,3- 
diphosphoglycerate (Grimes, 1980).
The importance of 2,3-diphosphoglycerate in the erythrocyte lies in 
its ability to alter the extent to which haemoglobin binds oxygen. 
This was discovered by two independent groups of workers, Benesch 
and Benesch and Chanutin and Curnish in 1967 (Grimes, 1980).
Arnone (1972) carried out x-ray studies which indicated that 2,3- 
phosphoglycerate binds in the central cavity of deoxyhaemoglobin 
between the two p-chains by salt bridges. At the entrance to the 
central cavity there are p-chain cationic groups, and 2,3- 
diphosphoglycerate which is anionic is believed to form seven salt
bridges with val-1, his-2 and iys-43 of the two p-chains together
with one of the lys-82 residues. Oxygenation leads to a 
con fo rm a tiona l change leading to the expu ls ion  of 2,3- 
diphosphoglycerate from the central cavity (Grimes, 1980). Changes 
in the 2,3-d iphosphogiycerate level permit adjustment of the 
d issociation of oxygen from haemoglobin according to ' the 
physiological conditions.
Hypoxia which may arise due to pulmonary disease, circulatory 
d isease,. high altitude or severe exercise leads to an increase in 2,3- 
d iphosphoglycerate levels by two mechanisms. Firstly, the 
increased binding of 2,3-diphosphoglycerate to deoxyhaemoglobin 
leads to a fall in free 2,3-diphosphoglycerate, removing the 
inhibition of the mutase in the shuttle, which results in increased 
formation of 2,3-diphosphoglycerate. This leads to an increase in 
total levels of both free and bound. Secondly, hypoxia may stimulate 
glycolysis by a pH. effect because deoxyhaemoglobin is more alkaline 
than oxyhaemoglobin, . leading to an increase in intra-erythrocyte pH. 
It is likely that the latter mechanism is the predominant one 
(Geriach and. Duhm, 1972). Anaemia also leads to a slight increase in
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pH due to tendency to hyperventilate and also because the ratio of 
deoxy- to oxyhaemoglobin increases which results in an increase in
2.3-diphosphoglycerate levels. An increase in plasma inorganic 
phosphate, as occurs in renal disease, also leads to an increase in
2.3-diphosphoglycerate synthesis (Grimes, 1980). There are at least 
two inborn errors, of metabolism that can affect the glycolytic 
process in the erythrocyte and therefore the 2,3-diphosphoglycerate 
level (Newsholme and Leech, 1985). Pyruvate kinase deficiency 
leads to an increase in 2,3-d iphosphoglycerate levels whilst 
hexok inase de fic iency  leads to a d ram atic  fall in 2,3- 
diphosphoglycerate levels. There is also some evidence that genetic 
factors may influence 2,3-diphosphoglycerate levels in individuals 
(Brewer et al., 1970). Several studies have shown a positive 
correlation between erythrocyte 2,3-diphosphoglycerate and GHb 
levels in vivo (Roberts et al., 1984; Story et al., 1986) and in v itro  
(Smith et al., 1972; Lowrey et al., 1985). It has also been suggested 
that the glycation of haemoglobin leads to a compensatory increase 
in 2,3-diphosphoglycerate levels in subjects with diabetes. Bunn 
and Briehi (1970) showed that GHb had an increased oxygen affinity 
in v i t ro . They suggested that this was due to the fact that in GHb 
glucose attaches to the end terminal valines of the p -c h a in s ,  
therefore inhibiting the binding of 2,3-diphosphoglycerate. This led 
to the proposal that in. diabetics, glycation of haemoglobin might 
lead, to tissue hypoxia and that 2,3-diphosphoglycerate synthesis is 
increased to prevent this from occurring (Ditzel et al., 1975). The 
levels of 2,3-diphosphoglycerate have been shown to be raised in 
diabetics (Ditzel et al., 1975; Roberts- et al., 1984), but there is no 
conclusive evidence ‘ tha t-the  increase in 2,3-diphosphoglycerate is 
due to the inability of 2,3-diphosphoglycerate to bind to GHb.
On the other hand, 2,3-diphosphoglycerate has been shown to 
catalyse the reaction of glucose with haemoglobin in vitro (Smith et 
al., 19-72; Lowry et al., 1985; Watkins et al., 1987). It appears to 
enhance the glycation of both valine and lysine residues selectively 
by binding to basic micro-environments within the haemoglobin 
molecule and catalysing the conversion of the Schiff base to the 
ketoamine (see Figure 1.4). The s ign if icantly  higher 2,3- 
diphosphoglycerate levels found in the high glycators may be the 
additional factor responsible for the inappropriately high GHb levels 
in these subjects.
The mechanism for . the increased 2,3-diphosphoglycerate levels is 
unclear. The presence of an inborn error of metabolism is unlikely 
as the effect of an enzyme deficiency has a much more marked 
effect on the. 2,3-diphosphoglycerate levels. They rise to 10 mmol/l
1 57
in subjects with pyruvate kinase deficiency (Newsholme and Leech, 
1985). Also, giycation of haemoglobin is unlikely to be the cause of 
the increased 2,3-diphosphoglycerate levels as the high glycators 
only had 6 - 8% of their haemoglobin glycated. The plasma levels of 
inorganic phosphate and the in tra-erythrocyte  pH were not
significantly higher in the high compared to the low glycators.
However, the finding that a change in pH of only 0.01 units could 
result in a 4% increase in 2,3-diphosphoglycerate might be part of 
the explanation for the higher 2,3-diphosphoglycerate levels in the 
high glycators, who had a mean intra-erythrocytic pH 0.12 units 
higher than that of the low glycators. The cause of the slightly 
higher pH in the high glycators is not clear. None of the subjects had 
evidence of pulmonary or circulatory disease and no evidence for 
anaemia was suggested by the haematology results. It is possible 
that the higher 2,3-diphosphoglycerate levels in the high glycators 
is a genetic phenomenon.
Another explanation for a discrepancy between glycated haemoglobin 
and blood glucose levels is the competition of other substances with 
glucose for binding to haemoglobin. However, there was no 
s ign ificant differences in erythrocyte vitamin C concentrations
between the two groups., which has been shown to inhibit the 
glycation of plasma proteins (Stolba et ai., 1987, 1988). Also, no 
significant differences in plasma urea were found, which at high 
levels is converted to cyanate, which can subsequently react with 
protein amino groups (Fluckiger et al., 1981). The questionnaire
revealed no differences in the intake of alcohol or salicylates, 
whose m etabolites in v iv o  can also react with amino groups 
(Stevens et al., 1981; Bridges et al., 1975). Pyridoxal-5-phosphate 
is known to bind to protein amino groups covalently (Harding, 1985). 
However, due to technical difficulties this was not measured in the 
low and high glycators. Amino acids themselves can react with 
glucose (Sensi et al., 1989) and thereby reduce the amount available 
to react with protein amino groups. The total amino acid 
concentrations in the plasma, erythrocyte and urine were not 
s ign if icantly  d iffe ren t between the low and high g lycators. 
Although the erythrocyte taurine concentration was higher in the 
low glycators, it only represents approximately 3% of the total 
amino acid concentration in the erythrocyte and is therefore unlikely 
to contribute to the discrepancy found between the GHb and blood 
glucose levels in the low glycators.
There were two low glycators who as well as having inappropriately 
low GHb levels, also had glycated albumin levels that .were low 
compared to their blood glucose levels. None of the biochemical
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parameters measured were found to be significantly d ifferent 
between this small subgroup and the other low glycators who had 
appropriate levels of glycated albumin. It is possible that the 
factor(s) responsible for the relatively low glycated albumin levels 
were different to those causing the low GHb levels. One of the 
important roles of albumin is the transport of substances throughout 
the body (Peters, 1985), including endogenous and exogenous 
substances such as therapeutic drugs. The questionnaire revealed 
that one of the subgroup of low glycators was on naproxen, a non­
stero idal anti- in flam m atory drug, which has been shown to 
covalently bind to albumin (Peters, 1985) and the other subject with 
a low glycated albumin was on thyroxine and valium, both of which 
are known to bind to albumin (Peters, 1985). The binding of these 
drugs may influence the extent to which glucose can react with 
albumin. None of the other low glycators were on regular medication 
known to bind to albumin. Therefore, the relatively low glycated 
albumin levels in the subgroup of low glycators may be due to the 
inhibition of glycation by therapeutic drugs.
This study has shown that in normal, non-diabetic subjects, the 
levels of glycated albumin and in particularly GHb may not always be 
appropriate to the level of glycaemia. There are subjects with high 
levels of GHb relative to their blood glucose levels who have 
appropria te glycated albumin levels. At least part of this 
discrepancy appears to be due to increased levels of erythrocyte
2,3-diphosphoglycerate which may be due to relatively high intra- 
erythrocytic pH or perhaps genetically determined. There are also 
subjects with low levels of GHb relative to their blood glucose 
levels who have appropriate levels of glycated albumin. This may be 
at least partia lly due to the relatively low in tra-erythrocyte 
glucose levels compared to plasma and also the apparent ability of 
their erythrocytes to ‘damp out’ the swings in glucose occurring in 
the plasma post-prandially. There are also some subjects who have 
relatively low GHb and glycated albumin levels. The low GHb levels 
are probably due to the relatively low intra-erythrocyte glucose 
levels, whilst the low glycated albumin levels may be due to the 
presence of therapeutic drugs which compete with glucose for 
binding to albumin, thereby inhibiting glycation.
Therefore, in conclusion, GHb may not always accurately reflect 
mean blood glucose levels due to intra-individual differences in 
erythrocyte permeability and/or metabolism. In general, glycated 
albumin appears to provide a more accurate reflection of mean blood 
glucose levels, except when certain drugs are being taken which 
interfere with the reaction of glucose, and albumin. The possibility
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that sim ilar factors could affect the glycation 
diabetic subjects needs to be investigated.
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proteins in
C H A P T E R  4
THE EFFECT OF DIET ON THE GLYCATION OF PROTEINS
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4.1. INTRODUCTION
By affecting blood glucose levels, diet may indirectly influence the 
glycation of proteins in v iv o .
The blood glucose concentration depends on the balance between the 
glucose inflow and outflow (Marks and Rose, 1981). The main source 
of glucose comes from the diet, which may be in the form of complex 
carbohydrates such as starch, disaccharides such as lactose or free 
in its monosaccharide form.
The rate of absorption of glucose from the gut and hence the post­
prandial rise in blood glucose concentration is dependent on the size 
and composition of the meal ingested (Newsholme and Leech,1983). 
Two major dietary components known to have marked effects on 
blood glucose levels in normal and d iabetic  subjects are 
carbohydrates (Brunzell et al., 1971; Simpson et al., 1979) and 
soluble fibre (Jenkins et al., 1976, 1977; Krotkiewski, 1984). The 
type of carbohydrate will affect the rate of absorption. For 
example, complex carbohydrates, such as starch are relatively 
slowly digested. Although digestion begins in the mouth, it is not 
completed until it reaches the duodenum, where the free glucose is 
then transported across the intestinal mucosa. In contrast, the 
ingestion of free glucose will result in a more rapid absorption and 
therefore a more rapid rise in blood glucose concentration (McMahon 
et al., 1989).
The amount of carbohydrate in the diet will also affect the blood 
glucose concentration occurring post-prandially. A- carbohydrate 
restricted diet causes an intolerance to a glucose load (Wilkerson et 
al., 1960) whilst causing a reduction in fasting blood glucose 
(Ktorza et al., 1985).
The effect of a high carbohydrate intake on blood glucose levels has 
also been investigated. Brunzell et al., (1971) found that a high 
carbohydrate diet led to a fall in fasting blood sugar and to an 
improvement in oral glucose tolerance in both normal and mildly 
diabetic subjects. However Bierman and Nalmin (1961) found that a 
high carbohydrate diet had no effect on blood glucose levels in 
diabetic subjects whilst Grey and Kipnis (1971) found a worsening 
of these glucose parameters on a high carbohydrate diet in obese 
subjects. These contradictory findings were probably partly due to
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the studies being carried out with different groups of subjects 
(normals, obese or diabetic), with in some instances no adequate 
control of calorie intake and body weight. Also, the diets utilized 
varied greatly in composition and duration, as did the type and 
consistency of the meal used as a test dose.
These conclusions were supported by Silva et al., (1987) who 
evaluated the short-term (3 weeks) and long-term (6 weeks) effects 
of a high carbohydrate diet on carbohydrate metabolism in normal, 
obese and diabetic subjects. Fasting blood glucose and insulin were 
measured twice weekly. The tolerance to carbohydrate was 
assessed by the blood glucose and insulin responses to oral and 
intravenous glucose loads and to a standard liquid meal. It was 
found that the long-term diet improved the tolerance to oral glucose 
in the obese and diabetic subjects whilst having no effect on their 
fasting glucose or insulin levels. In the normal subjects, the long­
term diet had no significant effects on tolerance to oral glucose or 
on fasting blood glucose, although it did increase both the fasting 
and post-load insulin levels significantly. However, in response to 
the liquid test meal, both the blood glucose and insulin levels were 
significantly increased in all the subjects. The response to the
intravenous glucose load was also different. There were no
significant differences in blood giucose or insulin levels following
the intravenous glucose bolus after the high carbohydrate diet in any 
of the subjects. These contradictory results found between the 
different methods of glucose tolerance assessment were probably 
due to differences in the rate of entry of glucose into the blood and 
therefore of the insulin response.
The fibre content of a meal will also have a major influence on the 
rate of absorption of glucose from the gut and therefore on the post­
prandial blood glucose levels (Newsholme and Leech,1983). Fibre is 
a general term used to describe a range of different substances
including cellulose, hemi-cellulose, lignin, pectin and gums and 
mucilages. The metabolic effects of different types of fibre may
vary. Gel-forming fibres such as guar gum have been shown to
reduce post-prandial glucose and insulin levels in healthy subjects 
(Jenkins et al.,1978) and in diabetic subjects (Jenkins et al., 1976). 
Likely reasons for this are a reduced rate of carbohydrate absorption 
due to a slower gastric-emptying rate (Wilmshurst and Crawley, 
1980) as well as a reduced secretion of insulin secretagogues like 
gastric inhibitory polypeptide.
Krotkiewski (1984) investigated the acute and long-term effects of
guar-gum on post-prandial glucose levels in obese non-diabetic
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subjects. Both acute and long-term treatment (8 weeks) with guar 
resulted in a decrease in mean post-prandial blood glucose level 
(following a standard test meal containing guar). However, in the 
long term study this reduction in mean post-prandial blood glucose
was due to two particular patients who had higher initial post­
prandial blood glucose levels than the rest of the group. After the 
long-term treatment with guar the post-prandial blood glucose level 
decreased by 26% in these two subjects but was not significantly
different in the rest of the group. The mean fasting blood glucose
was not s ign ificantly  d ifferent after the acute or long-term
treatment with guar.
It is apparent that the effects of a high carbohydrate or high fibre 
diet on blood glucose levels depends on whether normal, obese or 
diabetic subjects are studied and particularly on the type of test 
used to assess glucose tolerance. The difference between the 
subjects is probably due to differences in insulin secretion and 
tissue sensitivity to insulin.
The effect of a long-term high carbohydrate or high fibre diet on 
blood glucose levels is probably better assessed by measuring 
glycated protein levels which are a reflection of ambient blood 
glucose levels (Bunn et al., 1976). If the carbohydrate and fibre 
content of the diet primarily affect the post-prandial changes in 
blood glucose levels, glycated albumin in the plasma is more likely 
to indicate these changes than GHb in the erythrocyte. Glycated 
haemoglobin appears to be less sensitive to small changes in blood 
glucose concentration partly due to its longer half-life and also 
because albumin appears to be glycated at a faster rate compared to 
haemoglobin (Olufemi et al., 1987).
In the high and low glycators described in Chapter 3, the 
carbohydrate and fibre content of their diets (calculated from 7-day 
food diary) did not explain the discrepancy found between their GHb 
and blood glucose levels. Also, the glucose profiles showed that the 
ambient blood glucose level was not the main determinant of the GHb 
levels. However, the dietary survey as a method of assessing 
nutrient intake has been criticised for its imprecision and poor 
reproducibility (Burke, 1947; James et al., 1980). Therefore, the 
effect of di.et, specifically a high glucose/low soluble fibre and a 
high soluble fibre/low glucose diet on the glycation of both albumin 
and haemoglobin in a group of normal subjects was investigated. 
Glucose-tolerance at the start and following each dietary period was 
assessed by a 75 g oral glucose load. Plasma glucose and insulin
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levels were measured at fasting, one hour and two hours after the 
load.
4.2. METHODS
4.2.1. SUBJECTS AND STUDY DESIGN
11 non-diabetic subjects, 7 male and 4 female, aged 22 - 45
participated in the study. This comprised a six week period on a
high glucose/low soluble fibre diet (A) and six weeks on a low 
giucose/high soluble fibre diet (B) in random sequence.
Each subject was instructed to follow a baseline diet which was low 
in both sugar and soluble fibre. During the period of diet A subjects 
had their diets supplemented with 100 g glucose/day taken in the 
form of a high glucose drink (Lucozade, Beecham Laboratories p.I.e., 
Slough, Buckinghamshire, U.K.). Diet B was supplemented with a guar 
preparation (Guarem, Rybar Laboratories Limited, Amersham, 
Buckinghamshire, U.K.) initially in a dose of 5 g/day and increasing 
to 5 g three times a day over two weeks. This was taken either 
mixed into or sprinkled over food or in a drink just before or during 
the meal.
Subjects had their usual dietary intake assessed by a dietitian and 
were advised on any caloric intake changes required for either diet 
to ensure that an isocaloric intake was maintained throughout the 
study. All participants were provided with low sugar/low fibre food 
and drinks to encourage compliance throughout the twelve week 
period.
Subjects were instructed to avoid any drugs such as aspirin, or
vitamin supplements such as vitamin C or B6 which are known to
affect glycation. Alcohol intake, smoking and exercise were 
continued as habitual for each individual.
Height and weight were measured at the beginning of the study and 
at the end of each dietary period. Compliance with the glucose drink 
and guar preparation were estimated by counting the number of 
unfinished bottles and sachets respectively.
4.2.2. SAMPLE COLLECTION
At the beginning of the study and at the end of each six week period, 
each subject had a glucose tolerance test with venous blood being 
taken fasting, 1 hour and 2 hours after a 75 g glucose load. For the
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fasting sample 10 ml of blood was collected into a lithium heparin 
container and 5 mi into a potassium EDTA container. At 1 hour and 2 
hours after the glucose load 5 ml blood samples were collected into 
lithium heparin containers. Some of the lithium heparin whole blood 
at each time point was deproteinised and the extracts stored at 4°C 
for 24 hours prior to glucose analysis. Fasting lithium heparin 
whole blood was also deproteinised for the measurement of 2,3- 
d iphosphoglycerate. The extracts were stored at -80°C until 
analysis up to 3 months later. The rest of the whole blood at each 
time point was centrifuged (at room temperature) for 10 minutes at 
3000 g. Some of the plasma at each time point was deproteinised 
and the extracts stored at 4°C for 24 hours prior to glucose analysis. 
The rest of the plasma was stored at -80°C for up to 3 months prior 
to the measurement of insulin and glycated albumin (on the fasting 
plasma only). Haematocrits were measured on the potassium EDTA 
whole blood samples, the rest of which were stored at 4°C for 1 
week prior to the analysis of GHb by agar-ge! electrophoresis (with 
and w ith o u t the rem oval of the S ch if f  base), a ff in ity  
chromatography and iso-electric focusing.
The intra-erythrocyte glucose concentration was calculated from 
the whole blood and plasma measurements together with the 
haematocrit (see Chapter 2).
4.2.3. ASSAY METHODS
The full details of all the methods are given in Chapter 2.
4.2.4. STATISTICAL METHODS
Unless o therw ise  stated, all the p lasma and erythrocyte  
measurements are expressed as the mean (* SD). The measurements 
after each dietary period were compared to the basal measurements 
using paired Student’s t-tests.
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4.3. RESULTS
4.3 .2 . P LA S M A  AND IN TR A-ER Y TH R O C Y TE G LUCO SE 
CONCENTRATIONS BEFORE AND FOLLOWING THE TWO DIETARY 
PERIODS
4.3.2.1. Post - H igh So lub le  F ibre /Low G lucose Diet
There were no significant changes from the basal concentrations in 
fasting or two-hour plasma or intra-erythrocyte glucose levels 
following the high soluble fibre/iow glucose diet (see Table 4.1). 
However, the one-hour and total plasma glucose concentrations were 
significantly increased from the basal concentrations (p < 0.025 and 
p < 0.01 respectively). The intra-erythrocyte one-hour and total 
glucose concentrations, on the other hand remained unchanged
following the high soluble fibre/low glucose diet.
4.3.2.2. Post - H igh G lucose /Low  So lub le  Fibre Diet
There were no significant changes from the basal concentrations in 
plasma glucose at any time point during the glucose tolerance test 
following the high glucose/low soluble fibre diet (see Table 4.1). 
Although there were no sign ificant changes from the basal
concentrations in intra-erythrocyte glucose at fasting and two- 
hours post-glucose load, the one-hour intra-erythrocyte glucose 
concentration was significantly (p < 0.005) decreased following the 
high glucose/low soluble fibre diet.
4.3.2. COMPARISON OF PLASMA AND INTRA-ERYTHROCYTE
GLUCOSE CONCENTRATIONS BASALLY AND AFTER EACH 
DIETARY PERIOD
There was no significant difference between the plasma and intra­
erythrocyte glucose concentrations at the different time points of 
the glucose tolerance test performed at the start of the study.
However, following both dietary periods, the differences in glucose 
concentration between the two compartments was markedly 
significant at all time points including fasting (see Table 4.2.). The 
mean intra-erythrocyte glucose concentration was 80 - 90% of the 
mean plasma glucose concentration.
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TABLE 4.1 PLASMA AND INTRA-ERYTHROCYTE GLUCOSE 
CONCENTRATIONS DURING THE GLUCOSE TOLERANCE TEST 
BASALLY AND AFTER EACH DIETARY PERIOD
GLYCAEMIC
PARAMETER
BASAL
MEASUREMENT
HIGH GLUCOSE 
/LOW SOLUBLE 
FIBRE
HIGH SOLUBLE 
FIBRE/LOW GLl
PLASMA
GLUCOSE
(m m o l/ l)
FASTING 5.70 (1.00) 6.12 (0.96) 6.00 (0.88)
1HOUR 5.73 (1.15) 5.51 (1.83) 7.23 (2.49)*
2HOURS 5.85 (1.39) 5.65 (1.53) 6.39 (1.51)
SUM 17.58 (2.88) 18.04 (4.06) 20.10 (3.95)*
INTRA­
ERYTHROCYTE
GLUCOSE
(m m o l/ l)
FASTING 5.37 (1.25) 5.21 (1.16) 5.65 (1.05)
1HOUR 5.47 (1.10) 4.40 (0.81)*** 6.28 (1.95)
2HOURS 5.78 (1.55) 5.19 (1.00) 5.67 (1.43)
SUM 16.6 (3.20) 14.81 (2.69) 17.69 (3.67)
The glucose concentrations following each dietary period were 
compared to the basal concentrations.
p < 0.025
** . p < 0.01
*** p < 0.005
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TABLE 4.2 COMPARISON OF PLASMA AND INTRA- 
ERYTHROCYTE GLUCOSE CONCENTRATIONS DURING THE 
GLUCOSE TOLERANCE TESTS BASALLY AND AFTER EACH 
DIETARY PERIOD
TIME OF SAMPLE PLASMA GLUCOSE INTRA-ERYTHROCYTE
(m m o l/l) GLUCOSE (mmol/l)
BASAL
FASTING 5.70 (1.00) 5.37 (1.25)
1HOUR 5.73 (1.15) 5.47 (1.10)
2HOURS 5.85 (1.39) 5.78 (1.55)
SUM 17.58 (2.88) 16.60 (3.20)***
HIGH GLUCOSE/LOW 
SOLUBLE FIBRE
FASTING
1HOUR
2HOURS
SUM
HIGH SOLUBLE 
FIBRE/LOW GLUCOSE
FASTING
1HOUR
2HOURS
SUM
6.12 (0.96) 5.21 (1.16)'
5.51 (1.83) 4.40 (0.81)*
5.65 (1.53) 5.19 (1.05)*
18.04 (4.06) 14.81 (2.69)’
6.00 (0.88) 5.65 (1.05)***
7.23 (2.49) 6.28 (1.95)****
6.39 (1.51) 5.67 (1.43)**
20.10 (3.95) 17.69 (3 .67)***’
The plasma and intra-erythrocyte glucose concentrations are compared at each time 
point during the three glucose tolerance tests.
p < 0.025
p < 0.01
p < 0.005 
p < 0.0025 
***** p < 0.0005
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The sum of the glucose concentrations measured at the different 
time points during each of the three glucose tolerance tests (total 
glucose) was significantly ( p <0.005) lower in the erythrocyte 
compared to the plasma.
4.3.3. PLASMA INSULIN LEVELS
There were no significant changes from the basal levels in fasting 
or post-load plasma insulin levels following either dietary period 
(see Table 4.3).
4.3.4. ERYTHROCYTE 2,3-DIPHOSPHOGLYCERATE LEVELS
The e ry th rocy te  2 ,3 -d iphosphog lyce ra te  leve ls s ign if ican tly  
decreased from the basal level after both the high soluble fibre/low 
glucose (p <0.001) and high glucose/low soluble fibre (p <0.05) 
diets (see Table 4.4).
4.3.5. GLYCATED PROTEIN LEVELS
There were no significant changes in GHb by any of the methods of 
measurement following either dietary period (see Table 4.5).
Glycated albumin significantly decreased following the high soluble 
f ib re /low  glucose diet (p = 0.01) and s ign if ican tly  increased 
following the high glucose/low soluble fibre diet (p = 0.02) (see 
Table 4.4). The individual changes in glycated albumin are shown in 
Figure 4.1, which shows that the level increased in all but one 
subject after the high glucose diet and fell in all but two subjects 
after the diet high in soluble fibre.
No s ign if icant changes were found in plasma fructosam ine 
concentration following either dietary period (see Table 4.5).
4.3.6. COMPLIANCE AND BODY WEIGHT
All the subjects completed both dietary periods. Compliance with 
the high soluble fibre diet, as evidenced by counting unconsumed 
sachets of guar gum was 89.7 ± 7.5% and with the high glucose diet, 
using counts of unconsumed Lucozade, 97.1 ± 3.5%.
There were no significant changes in BMI during either dietary 
period, 21.63 ±3.10 (Basal), 21.74 ± 3.38 (high glucose) and 21.61 ± 
3.10 (high soluble fibre).
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TABLE 4.3 PLASMA INSULIN LEVELS DURING THE 
GLUCOSE TOLERANCE TESTS BASALLY AND AFTER 
EACH DIETARY PERIOD
TIME BASAL HIGH HIGH SOLUBLE
GLUCOSE/LOW FIBRE/LOW 
SOLUBLE FIBRE GLUCOSE
FASTING
(m U /l)
6.4 (2.1) 7.7 (3.2) 6.7 (2.1)
1HOUR
(m U /l)
29.4 (22.6) 32.7 (26.7) 37.6 (24.2)
2HOURS
(m U /l)
20.2 (18.4) 21.7 (23.1) 22.2 (14.8)
SUM
(m U /l)
56.0 (40.7) 59.8 (49.5) 66.5 (33.9)
TABLE 4.4 FASTING ERYTHROCYTE 2,3- 
DIPHOSPHOGLYCERATE CONCENTRATIONS BASALLY 
AND FOLLOWING EACH DIETARY PERIOD
BASAL MEASUREMENT 
(m m o l/ l)
4.78 (0.49)
HIGH GLUCOSE/LOW 
SOLUBLE FIBRE DIET 
(m m o/l)
4.41 (0.34)**
HIGH SOLUBLE 
FIBRE/LOW GLUCOSE 
(m m o l/ l)
4.31 (0.34)****
** p < 0.05
**** p < 0.001
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TABLE 4.5 COMPARISON OF GLYCATED PROTEINS
BASALLY AND FOLLOWING EACH DIETARY PERIOD
GLYCATED
PROTEIN
BASAL HIGH HIGH SOLUBLE
GLUCOSE/LOW FIBRE/LOW 
SOLUBLE FIBRE GLUCOSE
GLYCATED 
HAEMOGLOBIN (%) 
(a f f in i ty  
chrom atography)
GLYCATED 
HAEMOGLOBIN (%) 
( is o e le c tr ic  
focusing)
GLYCATED 
HAEMOGLOBIN (%) 
(e le c tro p h o re s is - 
to ta l)
5.88 (0.47) 6.02 (0.44)
4.69 (0.24) 4.60 (0.48)
FRUCTOSAMINE
(m m o l/l)
GLYCATED ALBUMIN
5.82 (0.36)
4.48 (0.28)
7.19 (0.53) 6.94 (0.62) 6.73 (0.70)
GLYCATED
HAEMOGLOBIN (%) 6.42 (0.61) 6.16 (0.72) 6.16 (0.38)
(e le c tro p h o re s is -
s tab le )
2.05 (0.12) 2.12 (0.06) 2.10 (0.11)
1.71 (0.35) 1.95 (0.23)* 1.33 (0.30)**
p=0.02
p=0.01
172
FIGURE.4.1 . INDIVIDUAL CHANGES IN GLYCATED
ALBUMIN FOLLOWING THE TWO DIETARY PERIODS
1 . BASAL
2 = POST-HIGH GLUCOSE/LOW SOLUBLE FIBRE DIET
3 = POST-HIGH SOLUBLE FIBRE/LOW GLUCOSE DIET
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4.4. DISCUSSION
This study has shown that dietary supplementation with giucose or 
soluble fibre in normal subjects has a marked effect on albumin 
glycation, whilst having no apparent effect on the glycation of 
haemoglobin. The high glucose/low soluble fibre diet resulted in a 
14% increase in glycated albumin and the high soluble fibre/low 
glucose diet led to a 22% decrease in glycated albumin. These 
results suggest that the diets led to changes in plasma glucose 
levels, which subsequently resulted in alterations in the extent of 
glycation of albumin. These results are apparently at variance with 
the results for plasma glucose levels obtained during the glucose 
tolerance tests (Table 4.1). For the high glucose diet, no significant 
changes from the basal glucose levels were observed while for the 
high soluble fibre diet the observed significant increases at 1 hour
and for the total change in plasma giucose are contrary to the
decrease in glycated albumin that was found.
Most of the previous studies with guar (Jenkins et al., 1976, 1977) 
have shown a decrease in post-prandial blood glucose levels after 
long- or short-term treatment. However, in these studies, guar was 
given with or immediately before the test meal or glucose load. 
This would have the effect of decreasing post-prandial blood glucose 
levels by reducing the rate of absorption of glucose from the gut. in
the present study, the subjects were not only put on a high fibre
diet but also on one containing reduced amounts of glucose. Also, no 
guar was consumed before or during the glucose tolerance test. 
Therefore, following the ingestion of a 75 g glucose load after six 
weeks on a diet low in sugar and high in fibre, an increased glucose 
response would likely result.
The high glucose/low soluble fibre diet had no apparent effects on 
plasma glucose tolerance. However, during the glucose tolerance 
test performed at the start of the study (basal), in the majority of 
the subjects, the one-hour plasma glucose level had decreased to a 
level below that of fasting, suggesting that the peak in plasma 
glucose was occurring much earlier. Therefore, the ‘true’ tolerance 
to the glucose load was not measured. A blood sample taken at 30 
minutes after the glucose load may have given a better assessment 
of tolerance.
Following a long-term (6 weeks) high carbohydrate diet, Silva et al., 
(1987) sim ilarly found no effects on fasting blood glucose or 
tolerance to an oral glucose load in normal subjects. However they
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did find a significant increase in both fasting and post-load insulin 
levels following the high carbohydrate diet. No significant changes 
in fasting or post-load insulin levels occurred in the present study, 
although again the peak insulin response may have occurred earlier 
than the sample taken one-hour post dose. Most studies that have 
demonstrated an improvement in glucose tolerance have been with 
very high carbohydrate diets, such as 85% carbohydrate (Brunzell et 
al., 1971). In the present study, in order to maintain an iso-caloric 
diet, the main change was in the type of carbohydrate and not the 
total consumed. Anderson (1974) showed that in normal subjects, as 
dietary carbohydrate increased glucose tolerance improved, but the 
actual source of carbohydrate made no difference.
Glycated albumin has been shown to correlate the strongest with 
mean blood g lucose leve ls ca lcu la ted  from frequen t da ily 
measurements (Dolhofer and Wieland, 1980; Ziel and Davidson, 1987) 
as compared to both fasting and post-load blood glucose levels. 
Therefore alterations in the tolerance to an unphysiological glucose 
load after each diet are unlikely to be helpful in explaining the 
changes in glycated albumin that occurred during the diet. Glycated 
albumin is a very sensitive indicator of short-term changes in biood 
glucose level (Dolhofer & Wieland, 1980; Kennedy et al., 1981; Jones 
et al., 1983) due to its relatively short half-life and its greater 
tendency to become glycated (compared to haemoglobin) (Olufemi et 
ai., 1987). Therefore it is probably representative of the small 
changes in blood glucose level that occur throughout the day, 
including those occurring post-prandially. It has been shown that 
the proportion of time that a person is in a genuinely fasted state is 
fewer than nine hours (Marks and Rose, 1981). The proportion of 
time that a person is fasting depends on the frequency of feeding, 
the size and composition of the meals, the rate of gastric emptying 
and intestinal absorption. The last three factors are all affected by 
both the carbohydrate and fibre content of the meals. Therefore, by 
influencing the extent and duration of the post-prandial changes in 
blood glucose level, dietary carbohydrate and fibre are likely to 
affect the glycation of albumin. The effect of d ifferent types of 
carbohydrate and fibre on the blood glucose response can be defined 
in terms of a.glycaemic index (Gl) (Jenkins et a!., 1984; Chantelau et 
al., 1986; Riccardi and Rivellese, 1987). This is calculated as 
fo llo w s :
BLOOD GLUCOSE AREA OF TEST FOOD X 100
BLOOD GLUCOSE AREA OF REFERENCE FOOD
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where the available carbohydrate content of the test and reference 
foods is the same. The glycaemic index of different foods depends 
on the rate at which they are digested, the presence of other types 
of food (e.g. fats, proteins) and on the metabolic response to the 
absorbed glucose (Jenkins et al., 1984). Thus, free glucose has a 
high glycaemic index whilst guar has a low glycaemic index.
Unfortunately no daily glucose profiles were collected during the 
study which might have been useful in explaining the changes in 
glycated albumin. However, the increase in glycated albumin during 
the high giucose/low soluble fibre and the decrease in glycated 
albumin on the high soluble fibre/low glucose diets can probably be 
explained by the theoretical glycaemic indexes of the two diets 
(high soluble fibre - low glycaem ic index, high glucose - high 
glycaemic index).
In con trast to g lyca ted a lbum in, the p lasm a fructosam ine  
concentration did not s ign ificantly  change after e ither d ietary 
period. This is probably due partly to the fact that fructosamine is 
measuring the glycation of a wide variety of proteins, which may be 
affected to different extents (Seng and Staley, 1986; Austin et ai., 
1987). Also, the variable contribution of non-specific components 
to the fructosamine reaction (Schleicher et al., 1988) thought to 
partly account for the variability of the measurement (Howey et al.,
1987) may mask the effect of small changes in blood glucose level 
on glycation.
Glycated haemoglobin was also not significantly altered by either 
diet. Although, GHb has a longer half-life than glycated albumin, due 
to the slight reversibility of the glycation reaction (Mortensen and 
Christophersen, 1983; Mortensen et al., 1984) GHb reflects blood 
glucose levels over the previous 4 - 6 weeks (Berstein, 1987). 
Therefore any changes in blood glucose levels occurring within each 
dietary period of six weeks would be expected to be reflected in 
changes in the GHb level. GHb has previously been shown to increase 
on a carbohydrate-rich diet (Serog et al., 1982) and decrease during 
ca lo ric  restriction (K torza et al., 1985), in normal subjects. 
However, this increase was explained by an increase or decrease in 
fasting blood glucose respectively and was associated with a gain or 
loss in weight. No measurement of intra-erythrocyte glucose or 
glycated plasma proteins were obtained, but the results suggest that 
an increase or decrease in basal intra-erythrocyte glucose was 
responsible for the increase or decrease in GHb respectively.
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There were no significant changes in fasting or two-hour intra­
erythrocyte giucose levels similarly to plasma following either diet. 
However, daily post-prandial changes in intra-erythrocyte glucose 
levels were not measured and may have provided a possible 
explanation for the lack of alteration in GHb compared to glycated 
albumin. In Chapter 3, it was shown that plasma changes in glucose 
concentration are not always mirrored by similar changes in glucose 
concentration in the erythrocyte. In the present study, the total 
change in intra-erythrocyte glucose was found to be consistently, 
s ign ifican tly  lower than the to ta l change in plasma glucose 
occurring during the glucose tolerance tests. The fasting intra­
erythrocyte glucose levels were 80 - 100% of the fasting plasma 
glucose levels, but during the glucose tolerance tests, the intra­
erythrocyte glucose levels varied from 60 - 140% of the plasma 
glucose levels. This would suggest that albumin and haemoglobin 
are not only exposed to different basal giucose concentrations but 
also different post-prandia! swings in glucose concentration. The 
lack of alteration of GHb following each diet would suggest that any 
changes occurring in daily post-prandial plasma glucose were not 
m irro red  . by s im ila r changes in in tra -e ry th ro cy te  g lucose 
concentration. This apparent difference in the glucose concentration 
between plasma and erythrocytes is probably due to the rate of 
glucose transport to the erythrocyte and/or metabolism within the 
erythrocyte as discussed in Chapter 3.
Apart from the glucose concentration within the erythrocyte, other 
factors may influence the glycation of haemoglobin. In Chapter 3,
2 ,3-d iphosphog lycera te ' was found to be an im portant factor 
affecting haemoglobin glycation. In the present study, although 
erythrocyte 2,3-d iphosphoglycerate levels decreased sign ificantly 
after both diets there were no significant changes in GHb. The 
percent changes in 2,3-diphosphoglycerate were small for both diets 
but were significant because of the small individual variation. With 
most methods for measuring GHb there was a trend to a decreased 
value with both diets but the individual variation was much greater.
In conclusion, the changes in glycated albumin following dietary 
supplementation with glucose or guar were probably the result of 
small changes in daily post-prandial plasma glucose levels. The lack 
of alteration of GHb is probably due to its location within the 
erythrocyte, where the changes in glucose concentration do not 
mirror those occurring in the plasma at the same time. This may 
also explain why the dietary patterns in the high and low glycators 
failed to explain the discrepancy found between GHb and blood 
glucose levels.
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This study substantiates current literature that glycated albumin is 
a more sensitive indicator of short-term changes in blood- glucose 
than GHb. This is not only because of the difference in half-life of 
the two proteins and the apparent increased rate of glycation of 
albumin , but also because of their different locations within the 
blood, where they are exposed to d iffe rent concentrations of 
glucose. This compartmental difference in glucose concentration 
may partly explain the large variation found in the relationship 
between different glycated proteins and between different glycated 
proteins and blood glucose levels.
Further work needs to be carried out to investigate whether 
differences in intra-erythrocyte and plasma glucose concentration 
occur post-prandia lly after ‘norm al’ meals in both normal and 
diabetic subjects and how variable the differences are in individuals 
and between individuals.
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CHAPTER 5
PROTEINS
THE EFFECT OF VITAMIN C ON THE GLYCATION OF
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5.1. INTRODUCTION
Vitam in C has recently been shown to affect the glycation of 
proteins (Stoiba et al., 1987; Khatami et ai., 1988). However, the 
effects found are confusing and conflicting. Stoiba et al., (1987,
1988) investigated the e ffect of ascorbic acid (AA) and its 
metabolite dehydroascorbic acid (DHAA) on the glycation of bovine 
serum  album in and co llagen in the presence of vary ing  
concentrations of glucose in v i t r o . It was found that whilst AA 
inhibited glycation, DHAA apparently enhanced glycation. Khatami et 
al., (1988) also studied the effect of AA and DHAA on the glycation 
of bovine serum albumin in v it ro , but found that both compounds 
inhibited glycation. The only apparent difference between the two 
studies was the concentration of vitamin C used. Stoiba et al., 
(1987) used concentrations up to I mM, whilst Khatami et al., (1988) 
used 5 mM AA and DHAA. Stoiba et al., (1987) also performed an j_n 
v ivo  study in which ten insulin-dependent diabetic subjects were 
supplemented with 1.5 g of vitamin C daily for three weeks. A 
significant fall in fructosamine concentration was found to occur, 
thus suggesting . an inhibition of glycation of plasma proteins by 
vitamin C as no change in glycaemia was observed.
In the study described in Chapter 3, vitamin C was not found to be a 
s ign ificant contributory factor in reducing haemoglobin glycation, 
although a weak negative correlation was found between erythrocyte 
vitamin C levels and GHb levels. Differences in erythrocyte vitamin 
C levels in the high and low glycators might have helped to explain 
the discrepancies found between GHb and blood glucose levels. 
However, the effects of vitamin C on glycation have so far been 
shown to occur only at unphysio logically high levels that are 
produced in vivo by supplementation with large doses of vitamin C. 
So it would have been unlikely that at the physiological levels of 
vitamin C found in low and high glycators effects on glycation 
would be apparent. Vitamin C, in particular .DHAA has long been 
known to food chemists to react with amino groups of both amino 
acids and proteins (Kurata et al., 1973; Ranganna and Setty, 1974; 
Kurata and Fujimaki, 1976). Benesch (1981) using eiectron-spin- 
resonance studies showed that AA could bind to proteins via an ionic 
interaction. In physiological fluids it is likely that DHAA can form a 
reversible Schiff base with amino groups (Tolbert and Ward, 1982), 
but cannot undergo the Amadori rearrangement to form a ketoamine 
because it lacks the two hydrogens corresponding to the carbon-2 on 
glucose which are needed for the reaction (see Figure 5.1). It is also
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possible that the carbonyl groups of ascorbic acid and the further 
oxidation product of DHAA, diketogulonic acid (DKG) could also react 
with amino groups to. form Schiff bases. DKG may be able to undergo 
the Amadori rearrangement due to the location of two hydrogens on 
carbon-4 next to the carboxyl group, (see Fig. 5.1). Thus, all three 
compounds AA, DHAA and DKG could compete with glucose for 
binding to proteins and thereby inhibit glycation.
There are, however, three indirect mechanisms by which vitamin C 
could affect glycation. AA has been shown to influence glucose 
tolerance by affecting the production and/or secretion of insulin 
(Sylvest et al., 1942; Arendt and Patee, 1956; Scarlett et al., 1970). 
AA is also involved in the catalysis of many enzyme reactions, 
including those involved in carbohydrate metabolism (Mapson,1967). 
Therefore, ascorb ic acid may ind irectly  a ffec t g lyca tion  by 
influencing the blood glucose levels. The second indirect mechanism 
is the effect of AA and DHAA on the glycation of intracellular 
proteins. By affecting the transport of glucose into cells, AA and 
DHAA could influence the intracellu lar glucose concentration to 
which proteins are exposed. Bigley et al., (1983) suggested that 
DHAA transport into human neutrophils and fibroblasts is mediated 
by glucose transport systems. Similarly to glucose, uptake may be 
dependent on insulin in certain tissues. This would suggest that 
AA/DHAA may com pete with glucose for uptake into cells. 
.Mooradian (1987) found that DHAA (but not AA) competed with 
glucose for uptake into the brain but not into muscle in v it ro . The 
effect appears to be tissue specific.
The third mechanism by which AA and DHAA could affect glycation is 
a specific effect on haemoglobin. Both in vitro (Wood and Beutler, 
1973) and in vivo (Moore et al., 1977) studies have shown that AA 
appears to increase the levels of 2 ,3-d iphosphog lycera te  in 
erythrocytes. This is thought to be due to some effect of vitamin C 
on the metabolism of glucose within the erythrocyte. As 2,3- 
diphosphoglycerate is known to catalyse glycation (Smith et al., 
1982; Lowrey et al., 1985) vitamin C could in this way indirectly 
lead to an increase of glycation of haemoglobin.
The effect of AA and its metabolites on the glycation of proteins is 
therefore likely to be very complex in v iv o . Different proteins may 
be affected in different ways depending on their location. However, 
if the overall effect of vitam in C is to inhibit the glycation of 
proteins, it could have the potential of being used therapeutically to 
ameliorate or prevent the chronic complications of diabetes and
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perhaps even the normal process of ageing. Although Stolba et al., 
(1987) showed a significant decrease in fructosamine concentration 
in v ivo  with vitamin C supplementation, the effect on glycation of 
intracellular proteins such as haemoglobin was not determined and 
no attempt was made to try and elucidate the mechanisms involved. 
The fructosamine assay is also known to be unreliable with many 
un iden tified  non-spec ific  in te rfe rences (Howey et a l., 1987; 
Schleicher et al., 1988). Therefore, to study the mechanisms in 
more detail, the effect of ora! vitamin C in a group of healthy 
volunteers on the glycation of proteins was investigated.
Before describ ing th is study, .the absorption, d is tribution  and 
metabolism of vitamin C in normal subjects will be discussed.
5.1.1. ABSORPTION, DISTRIBUTION AND M ETABOLISM  OF 
VITAMIN C.
Vitamin C from the diet is rapidly absorbed through the buccal 
mucosa, from the stomach and the small intestine. The rate of 
absorption from the small intestine depends on the local pH and the 
vitamin C concentration. Quantitatively absorption from the small 
intestine is most important. AA dissociates, in aqueous solution to 
the ascorbate radical which is not absorbed as the charge on the 
molecule interferes with its transport (Hornig- et al., 1971). DHAA 
is electrically neutral and is therefore the more suitable ligand for 
transport (Bigley et al., 1983). V itam in 'G  transport has been shown 
to fo llow  saturation k inetics and exhibits a high degree of 
specificity for the L-isomer suggesting a .carrier mediated process. 
Evidence would suggest vitamin C transport occurs by facilitated 
diffusion (Hornig et al., 1971).
The. metabolism of AA is illustrated in Fig. 5.2. The principal 
pathway involves the loss of two successive e lectrons. The 
intermediate free radical immediately and reversibly forms DHAA. 
Subsequent irreversible hydrolysis yields the b io logically inactive 
DKG which undergoes degradation  by a lte rna te  pathways; 
decarboxylation to carbon dioxide and five-carbon fragments such as 
L-xylose, and the form ation of oxalic acid and four-carbon 
fragments, such as threonic acid (Jaffe, 1984). The formation of 
.ascorbic acid 2-hydrogen sulphate has also been demonstrated as a 
m etabolic product in humans, but has no known b io log ica l 
s ign ificance .
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The plasma level of vitamin C of an individual will depend on the 
dietary intake, the rate of absorption through the gastrointestinal 
tract, transport between plasma and tissues and the rate of renal 
excretion. The relative proportions of AA and its metabolites will 
depend on rates of release and.uptake by blood cells and tissues 
together with the rate of oxidation. It has been found that AA makes 
up a major proportion, of total vitamin C in plasma (approximately 
75%) of normal subjects, DHAA contributes only 5 - 10% of total 
vitamin C whilst DKG makes up at least 20% of the total. (Cox and 
Whichelow, 1975). Supplementation with vitam in C produced a 
d ifferent picture, with plasma DHAA rising 100-fold, whilst AA 
levels remained unchanged such that the concentration of DHAA 
exceeds that of AA by two-fold. The DKG levels were not 
quantitated in this case (Chatterjee et al., 1973).
The distribution of vitamin C between various cellu lar components 
of blood in normal individuals and its relation to the plasma 
concentration has been investigated by Barkhan and Howard (1958) 
and again by Evans et al., (1982). It is found that although the 
leucocytes and platelets have the highest concentration of AA in the 
blood (40 to 80-fold greater than plasma concentration) the 
erythrocytes and plasma make up approximately 70% of the total 
blood AA due to their relatively greater proportion. Erythrocytes 
and plasma have approximately the same concentration of AA, which 
suggests that erythrocytes do not concentrate AA to any appreciable 
extent. Daily supplementation of normal individuals with 2 g of 
vitamin C results in a more than two and a half fold increase in 
plasma AA concentration whilst smaller increases are seen in the 
cellu lar components of the blood. The AA content of platelets 
increases by 78%, erythrocytes by 50% and leucocytes by 33% (Evans 
et al., 1982).
All the metabolites (as well as AA) are excreted in the urine. The 
relative proportions vary from species to species and the amount 
ingested. In humans, with physiological doses of 60-100 mg/day 
urinary oxalate is the major metabolite, with 30-50 mg/day being 
formed. But when vitamin C is given in larger doses up to 10 g/day, 
the urinary oxalate is increased by only 10-30 mg/day and the 
vitamin is largely excreted unmetabolized in the faeces (Hornig and 
Moser, 1981). Substantial quantities of AA are excreted in the urine 
after the plasma concentration exceeds its renal threshold of 1.4 
mg/100 ml (79 pmol/l). The half-life of ascorbic acid is inversely 
related to the daily intake and is 13-40 days in humans (Jaffe, 
1984).
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Very little  is known of the factors which control the rate of 
turnover of AA. Studies by Bates et al., (1981) showed that the rate 
of turnover in healthy male subjects was related to the pool of AA 
and for a given pool size was remarkably constant between 
individuals. It seems to vary depending on daily intake but may also 
be influenced by external factors such as smoking and stress (Jaffe, 
1984).
It is likely that the extent of the effect of vitam in C on the 
g lycation of prote ins in v iv o  w ill vary considerab ly  between 
sub jects due to in tra -ind iv idua l d iffe rences in absorption, 
d istribution, metabolism and renal excretion of the vitamin. To 
inves tiga te  the e ffec t of v itam in  C on g lyca tion , during 
supplementation plasma and erythrocyte levels of total vitamin C 
were monitored and related to both glycated albumin and GHb levels. 
Plasma and in tra-erythrocyte glucose concentrations were also 
measured to monitor any changes in glycaemia occurring during 
supplem entation with vitam in C. Plasma insulin levels were 
measured and also erythrocyte 2,3-diphosphoglycerate due to the 
evidence that the levels within the erythrocyte may be affected by 
vitamin C.
5.2. METHODS
5.2.1. SUBJECTS AND STUDY DESIGN
Twelve healthy volunteers agreed to participate in the study. These 
were seven males and five females aged 22 - 50. Ascorbic acid in 
the form of 500 mg tablets were supplied by Roche (Roche Products 
Limited, Welwyn Garden City, Hertfordshire). The subjects were 
asked to take 1g (2 x 500 mg) of vitamin C daily for three months. 
15 ml fasting venous blood samples were collected at the start of 
the study and at the end of each month. Two further samples were 
obtained at one month (15 mis) and two months (5 mis) after 
cessation of the vitamin C supplement (6 samples in total). The 
subjects were asked to follow their usual diet, but to refrain from 
the consumption of excess alcohol and the ingestion of aspirin and 
dietary supplements (other than the vitamin C).
5.2.2. BLOOD SAMPLES
The 15 ml blood samples were each divided up into two aliquots. 10 
mis was transferred into a lithium heparin tube and 5 mis into a 
potassium EDTA tube. Some of the lithium heparin whole blood was 
deproteinised immediately for the measurement of glucose and 2,3-
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diphosphoglycerate. The remaining lithium heparin whole blood was 
centrifuged at 3000 g (room temperature) for 10 minutes. Some of 
the resulting plasma was deproteinised for measurement of glucose 
and vitamin C. The remaining plasma was stored at -80°C  in 
aliquots for the analysis of insulin, fructosam ine and glycated 
albumin three months later. The packed red cells were also 
deproteinised for the measurement of vitamin C. The whole blood 
and plasma extracts for glucose were stored at 4°C and analysed 
within six hours of collection. The plasma and red blood cell 
extracts for measurement of vitamin C were stored at -80°C and 
analysed within one week. A very small amount of the potassium 
EDTA whole blood was used im m ediate ly to measure the 
haematocrit. The rest was stored at 4°C for one week prior to the 
ana lys is  of GHb by a ffin ity  chrom atography and agar-ge l 
electrophoresis (with removal of the Schiff base). The 5 ml blood 
sample collected two months after cessation of the vitamin C 
supplement was transferred into a potassium EDTA container. It 
was stored at 4°C and analysed for glycated haemoglobin by affinity 
chromatography and electrophoresis within one week of collection.
The intra-erythrocyte glucose was calculated from the whole biood 
and plasma m easurements together with the haem atocrit (see 
Chapter 2).
5.2.3. ASSAY METHODS
The full details of alt the methods are given in Chapter 2.
5.2.4. STATISTICAL METHODS
All the plasma and erythrocyte measurements are expressed as the 
mean (± SD). The measurements at d ifferent time points were 
compared to the basal levels using paired Student’s t-tests.
5.2.5. IN VITRO EXPERIMENT TO INVESTIGATE THE EFFECT OF 
VITAMIN C ON GLYCATED HAEMOGLOBIN METHODOLOGIES
Haemoglobin obtained from freshly haemolyzed human red blood 
cells was incubated with AA or DHAA in the presence or absence of 
glucose. Following dialysis GHb was measured on each of the 
incuba tes  by both a ffin ity  ch rom a tog raphy and agar-ge l 
electrophoresis (with removal of Schiff base).
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5.2.5.1. Reagents
All the reagents were of “Analar” grade and obtained from BDH (BDH 
Products Limited, Poole, Dorset).
A 0.1 M phosphate buffer with 0.001% sodium azide was prepared and 
adjusted to pH 7.4. This buffer was then used to prepare five other 
solutions as follows:
(i) Glucose, 25 mmol/l.
(ii) Glucose, 25 mmol/l and AA, 1 mmol/l
(iii) Glucose, 25 mmol/l and DHAA, 1 mmol/l
(iv) AA, 1 mmol/l
(v) DHAA, 1 mmol/l
The pH of each solution was re-adjusted to pH 7.4 if necessary.
A 0.9% saline solution was prepared for dialysis.
The reagents for the affin ity chromatography and electrophoresis 
methods for GHb are as described in Chapter 2.
5.2.5.2. Procedure
10 mis fasting whole blood was obtained from a healthy volunteer 
and transfe rred  into a lith ium  heparin conta iner. It was 
im m edia te ly cen trifuged  fo r 10 m inutes at 3000 g (room 
temperature) and the plasma discarded. 500 pi of the packed red 
blood cells were diluted in 3 .5 .mis of each of the five incubation 
solutions containing glucose and/or vitamin C. A further 500 pi of
packed red blood cells were diluted in the phosphate buffer alone.
After vortexing thoroughly, the six samples were incubated at 37°C 
for 3 days. This was followed by dialysis of al! of the samples 
against 25 I of 0.9% saline over 48 hours.
The dialysates containing the modified haemoglobin were then 
subjected to affin ity chromatography and electrophoresis for the 
remeasurement of GHb. The procedures for the latter two methods 
were followed as described in Chapter 2.
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5.3. RESULTS
5.3.1. FASTING PLASMA AND ERYTHROCYTE VITAMIN C 
LEVELS BEFORE, DURING AND AFTER SUPPLEMENTATION
The total plasma vitamin C levels increased by 49% after one month 
and remained elevated during supplementation. The percentage by 
which the vitamin C levels were elevated above the basal level 
varied from month to month. After cessation of the vitamin C 
supplement the plasma levels of vitamin C were lower than the 
original basal level (see Fig. 5,3).
The erythrocyte levels of vitamin C followed a different pattern to 
the plasma levels with supplementation. After one month there was 
no significant change in levels, but after two months it rose by 21% 
and by 40% after three months. After one month’ cessation of 
vitamin C the levels of vitamin C within the erythrocyte were lower 
than the basal level (see Fig. 5.3).
Comparison of the piasma and the erythrocyte levels of vitamin C 
(see table .5.1) show that in itia lly the plasma levels were 23% 
higher than the erythrocyte levels of vitamin C. However, after one 
month of supplem entation because there was no change in 
erythrocyte levels, the piasma vitamin C level was -85% higher than 
the erythrocyte level (p <0.0005). After 2 months supplementation 
there was less difference between plasma and erythrocyte vitamin C 
levels because the erythrocyte vitamin C level had also increased, 
but the difference still remained significant (p <0.0005). After 3 
months there was no longer a significant difference between the 
two compartments (p >0.05). One month following the cessation of 
supplementation, the difference between the plasma and erythrocyte 
vitamin C levels became significant again (p <0.01).
5.3.2. EFFECT OF VITAMIN C ON FASTING GLYCAEMIA 
(PLASMA AND ERYTHROCYTE)
There were no significant changes in either fasting plasma or 
erythrocyte glucose concentration throughout the study (see Table
5.2 and Table 5.3).
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FIGURE.5.3. CHANGES IN VITAMIN C CONCENTRATION  
IN THE PLASMA AND ERYTHROCYTES DURING 
SUPPLEMENTATION
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TABLE 5.1 FASTING PLASMA AND ERYTHROCYTE VITAMIN 
C LEVELS BEFORE, DURING AND AFTER SUPPLEMENTATION  
WITH VITAMIN C
SAMPLE PLASMA ERYTHROCYTE
VITAMIN C VITAMIN C
CONCENTRATION CONCENTRATION 
(p m o l/ l)  (p m o l/l)
BASAL 73.3 (13.9) 59.5 (17.3)
1 MONTH
SUPPLEMENTATION 109.2 (18.6) 59.1 (9.5)
2 MONTHS
SUPPLEMENTATION 119.1 (19.9) 73.8 (17.1)
3 MONTHS
SUPPLEMENTATION 93.3 (16.8) 83.6 (10.8)
1 MONTH AFTER 
CESSATION OF
SUPPLEMENTATION 59.2 (12.9) 43.3 (16.8)
SIGNIFICANCE 
OF DIFFERENCE
(P)
<0.01
<0.0005
<0.0005
NS
< 0.01
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TABLE 5.2 EFFECT OF VITAMIN C ON FASTING PLASMA
GLUCOSE LEVELS
BASAL 1 MONTH 2 MONTHS 3 MONTHS 1 MONTH
ON VITAMIN ON VITAMIN ON VITAMIN POST 
C C C VITAMIN C
PLASMA
GLUCOSE 5.05 (0.34) 4.94 (0.24) 5.01 (0.29) 4.86 (0.47) 4.82 (0.40) 
(m m o l/ l)
SIG. OF
DIFFERENCE NS NS NS NS
(P) .
T A B L E  5 . 3  E F F E C T  O F  V I T A M I N  C  O N  F A S T I N G  I N T R A ­
E R Y T H R O C Y T E  G L U C O S E  L E V E L S
BASAL 1 MONTH ON 2 MONTHS 3 MONTHS 1 MONTH
VITAMIN C ON VITAMIN ON VITAMIN POST
C C VITAMIN C
INTRA­
ERYTHROCYTE 4.07(0.60) 4.23 (0.61) 4.32 (0.60) 3.96 (0.97) 3.78 (0.55)
GLUCOSE 
(m m o l/l)
SIG. OF
DIFFERENCE NS NS NS NS
(P)
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5.3.3. EFFECT OF VITAMIN C ON FASTING PLASMA INSULIN 
LEVELS
There was no s ign ificant d ifference in plasma insulin levels, 
although there was a slight increase initially after two and three 
months (not significant) (see Table 5.4).
5 .3.4. EFFECT OF VITAM IN C ON ERYTHROCYTE 2,3- 
DIPHOSPHOGLYCERATE LEVELS
Although at one and two months following supplementation the 2,3- 
d iphosphog lycera te  levels increased, it was not s ta tis tica lly  
s ign ificant (see Table 5.5). However, after three months, the 
increase in 2,3-diphosphoglycerate was significant (p <0.05). After 
cessation of the vitamin C, the 2,3-diphosphoglycerate returned to 
the basal level.
5.3.5. EFFECT OF VITAMIN C ON GLYCATED PROTEINS
5.3.5.1. F ru c to sa m in e
Supplem entation with vitam in C produced a small percentage 
decrease in fructosamine concentration. At one and three months 
the decrease was significant (p <0.005 and p <0.01 respectively) 
but at two months the decrease was not statistically significant. A 
month after cessation of vitamin C, the fructosamine concentration 
returned to the basal level (see Fig. 5.4).
5.3.5.2. G lycated A lbum in
The glycated albumin decreased by 33% after one month and 
remained at this level during supplementation with vitamin C. After 
one month cessation of vitam in C the glycated albumin level 
increased by 12% (see Fig. 5.5).
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TABLE 5.4 EFFECT OF VITAMIN C ON FASTING PLASMA
INSULIN LEVELS
BASAL 1 MONTH ON 2 MONTHS ON 3 MONTHS ON 1 MONTH
VITAMIN C VITAMIN C VITAMIN C POST
VITAMIN C
PLASMA
INSULIN 6.98(2.82) 7.68 (3.28) 8.18 (3.29) 6.49 (2.40) 7.93 (2.94)
(m U /l)
SIG. OF
DIFF. (p) NS NS NS NS
TABLE 5.5 EFFECT OF VITAMIN C ON ERYTHROCYTE 2,3- 
DIPHOSPHOGLYCERATE(DPG) LEVELS
BASAL 1 MONTH 2 MONTHS 3 MONTHS 1 MONTH 
CN CN CN POST
VITAMIN C VITAMIN C VITAMIN C VITAMIN C
ERYTHROCYTE
2,3 DPG 4.64(0.69) 4.80 (0.64) 4.87 (0.61) 5.12 (0.83) 4.61 (0.64)
(m m o l/l)
SIG. OF
DIFFERENCE NS NS <0.05 NS
(P)
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FIGURE.5.4. EFFECT OF VITAMIN C ON FRUCTOSAMINE
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FIGURE.5.5. EFFECT OF VITAMIN C ON GLYCATED
ALBUMIN
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The GHb level decreased by 18% at one month and remained at about 
this level during supplementation and even at one month after 
cessation of vitamin C. Two months after the end of vitamin C 
supplementation the GHb level had almost returned to. the basal level 
(see Fig. 5.6(a)).
5.3.5.3. G lycated  Haem og lob in  (A ff in ity Chrom atography )
5.3.5.4. Glycated Haemoglobin (Electrophoresis)
The GHb levels measured by electrophoresis initially fell after one 
month (by 11%) but after two and three months the levels increased 
progressively and remained raised even 1 month after vitamin C 
supplementation had finished. The GHb level had almost returned to 
the basal level two months following cessation of the vitamin C 
supplement (see Fig. 5.6(b)).
5.3.7. EFFECT OF VITAMIN C ON THE METHODOLOGIES FOR 
GLYCATED HAEMOGLOBIN (IN VITRO)
1 mM AA or DHAA had no significant effect on the glycation of 
haemoglobin in the absence or presence of glucose when affinity 
chrom atography was used (see Table 5.6). However, when 
electrophoresis was used to measure glycated haemoglobin, a 
significant increase was recorded in the presence of both AA and 
DHAA. In the presence of only AA or DHAA and no additional glucose 
a significant increase in glycated haemoglobin was still measured 
by electrophoresis. This increase was greater than that observed 
when haemoglobin was incubated with glucose alone.
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FIGURE.5.6 EFFECT OF VITAMIN C ON GLYCATED
HAEMOGLOBIN
(a) AFFINITY CHROMATOGRAPHY
(b) ELECTROPHORESIS
1 = BASAL
2 =1 MONTH SUPPLEMENTATION
3 = 2 MONTHS SUPPLEMENTATION
4 = 3 MONTHS SUPPLEMENTATION
5 = 1 MONTH CESSATION SUPPLEMENTATION
6 = 2 MONTHS CESSATION SUPPLEMENTATION
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TABLE 5.6 EFFECT OF VITAMIN C ON THE METHODOLOGIES
FOR GLYCATED HAEMOGLOBIN (IN VITRO)
PHOSPHATE GLUCOSE GLUCOSE 
BUFFER 
(0.1 M)
GHb(%) 5.50 
(E)
(%)
CHANGE
GHb(%) 5.76 
(A.C.)
%
CHANGE
(25mM) (25mM)
+AA 
(1 mM)
8.00 16.90
45 114
9.00 9.00
56 56
GLUCOSE AA 
(25mM) (1 mM)
+DHAA 
(1 mM)
16.80 12.80
113 73
9.30 6.16
61 7
E = ELECTROPHORESIS (WITH LABILE REMOVED)
A.C. = AFFINITY CHROMATOGRAPHY
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DHAA 
(1 mM)
17.10
116
6.36
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5.4. DISCUSSION
This study has confirmed previous work that vitamin C affects the 
glycation of proteins. It has also provided a better insight into the 
possib le  m echanism s involved in v iv o  and shown that the 
methodology used for the measurement of glycated proteins has 
important consequences on the interpretation of the results.
The in v itro  experim ent showed that when haemoiysates were 
incubated with vitamin C in the absence or presence of glucose, 
measurement of GHb by electrophoresis and affinity chromatography 
produced very different results. AA and DHAA had no apparent effect 
on the g lyca tion  of haem oglobin as m easured by a ffin ity  
chrom atography, but apparen tly  increased the g lyca tion  of 
haemoglobin by more than 100% when electrophoresis was used to 
measure it. This discrepancy between electrophoresis and affinity 
chromatography is probably due to the two methods relying on 
completely different properties of GHb for their measurement. The 
a ffin ity  chrom atography method relies on the structure of the 
carbohydra te  m oiety attached to the protein amino groups, 
specifica lly the presence of cis-diols (Gould and Hall, 1987) to 
separate glycated from unglycated haemoglobin. The electrophoresis 
method on the other hand depends on the small charge difference 
between glycated and unglycated haemoglobin to separate them. 
Vitamin C (AA or DHAA) in the absence of glucose resulted in an 
increase in GHb when measured by electrophoresis suggesting that 
vitamin C in one form or another was reacting with haemoglobin to 
produce a charge change sim ilar to the addition of glucose to 
haemoglobin. For the electrophoresis method, the Schiff base is 
removed prior to the assay of GHb. Therefore, the increase in GHb 
measured in the presence of vitamin C must be the result of vitamin 
C reacting with haemoglobin to form a stable linkage, analogous to 
the ke toam ine  fo rm ed w ith  g lucose . W ith the a ff in ity  
chromatography method no change in GHb in the presence of vitamin 
C was found. This suggests that if vitamin C is reacting with 
haemoglobin it does not have the correct structure or configuration 
for binding to the boronate gel. Therefore, it is apparent that 
affin ity chromatography is measuring ‘true ’ glycated haemoglobin 
whilst electrophoresis is measuring vitamin C bound to haemoglobin 
in addition to ‘true’ glycated haemoglobin. Vitamin C did not appear 
to inhibit the addition of glucose to haemoglobin in this in v itro  
situation, unlike the inhibition of glycation of albumin by AA shown 
by Stolba et al.(1987) and Khatami et al.(1988). This may be partly
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due to differences in the relative concentrations of vitam in C, 
giucose and the proteins used in the experiments.
Supplementation of the subjects diet with vitamin C during the j_n 
v ivo  study produced a significant decrease in GHb when it was 
measured by a ffin ity  chrom atography, whereas e lectrophoresis 
measured a significant increase in GHb (except at one month after 
supplementation). The in vitro study showing the different effect of 
vitam in C on the two methods for GHb provides the likely 
explanation for this finding. Affinity chromatography is therefore 
measuring a true decrease in GHb. Plasma glycated proteins were 
also significantly decreased during vitamin C supplementation as 
m easured by fructosam ine and specifica lly  g lycated albumin 
(affinity chromatography). The decrease in fructosamine was much 
less marked than for glycated albumin. This is probably due partly 
to the fact that fructosamine is measuring the glycation of a wide 
variety of proteins, which may be affected to different extents 
(Seng and Staley, 1986; Mosca et al., 1987). Also, the variable 
con tribu tion  of non-specific  com ponents to the fructosam ine 
reaction (Schleicher et al., 1988) thought to partly account for the 
variability of the measurement (Howey et al., 1987) may mask the 
effect of vitamin C on glycation. The decrease in glycated albumin 
and GHb during supplementation would suggest that by some 
mechanism vitamin C was inhibiting glycation. The decrease in 
glycated albumin was approximately twice that of GHb. This may be 
due in part to structura l d ifferences of the two proteins and 
ava ilab ility  of sites for glycation or vitam in C binding, but is 
probably mainly due to the higher concentration of vitamin C in the 
plasma compared to the erythrocyte during supplementation.
Following one month cessation of vitamin C glycated albumin (and 
fructosamine) had returned to their basal levels. However, GHb 
(measured by both techniques) did not return to the basal level after 
one month, but had done so two months after finishing the vitamin C 
supplement. This is probably due to the relatively stow turnover of 
haemoglobin in the erythrocytes compared to the more rapid 
turnover of albumin.
The mechanism for the effect of vitamin C on glycation is complex. 
The in v itro  experiment suggested that vitamin C could react with 
haemoglobin to form a stable linkage. Therefore the most likely 
explanation for the decrease in glycated proteins measured during 
supplem entation w ith vitam in C in v iv o  is the competition of 
vitamin C with glucose for reaction with the protein amino groups, 
thereby inhibiting glycation. Vitamin C has previously been shown
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to react with amino groups on proteins, possibly via an ionic 
interaction (Benesch, 1987). The structure of DHAA (and AA) would 
suggest that they could only form a Schiff base, whereas the 
structure of DKG may allow it not only to form a Schiff base, but 
also to undergo the Amadori rearrangement to form a ketoamine. 
Cox and Whichelow (1974) found that in normal subjects DKG made 
up a surprising 20% of the total plasma vitamin C, whilst DHAA 
made up only 5% of the total. Furthermore, Chatterjee et al., (1973) 
found that supplementation with 2-4 g vitamin C produced a much 
greater increase in plasma levels of DHAA than AA. DKG was not 
measured in that study, but it is possible that DKG levels may 
increase similarly to DHAA. No measurement of erythrocyte levels 
of DKG or DHAA during supplementation have been carried out. The 
binding of DKG to haemoglobin and to other proteins would not only 
explain most of the in v ivo  findings, but also the in v itro  increase 
when measured by electrophoresis in GHb. Although the incubation 
solutions only contained AA or DHAA at the start, it is likely that 
further oxidation occurred during the three-day incubation, resulting 
in a substantially greater proportion of DKG compared to AA and 
DHAA. The absence of the cis-diol group in DKG would explain why if 
it reacted with haemoglobin it would not interact with the boronate 
gel during affinity chromatography, thus explaining the fact that no 
change in GHb was measured in the presence of vitamin C in v itro .
However, the com petitive reaction of vitamin C with glucose for 
reaction with protein amino groups does not explain all the results 
found in either the in vivo or in vitro  study. This .is reflected by the 
fact that at one month fo llow ing the start of the vitam in C 
supplement, the fall in GHb measured by affinity chromatography 
was m irrored by a s im ila r decrease in GHb measured by 
e lectrophoresis. A fter this GHb measured by electrophoresis 
progressive ly increased until at three months the percentage 
increase was equivalent to the percentage decrease measured by 
a ffin ity  chrom atography. From the results of the in v i t r o  
experiment, reaction of vitam in C with haemoglobin produced a 
falsely elevated GHb when measured by electrophoresis. This is in 
conflict with the initial fall in GHb measured by electrophoresis at 
one month. This would suggest that the decrease in GHb (also 
measured by affinity chromatography) at one month was not due to 
the reaction of vitamin C with haemoglobin, but due to some other' 
effect. In keeping with this is the fact that the erythrocyte vitamin 
C level did not increase after the firs t month, but did so 
progressively at two and three months. Although no change in 
fasting plasm a or erythrocyte glucose or plasm a insulin was 
observed during the study, no measurements were made closely
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following the ingestion of the vitamin C. Therefore, an acute effect 
of vitamin C on glucose metabolism or on the transport of glucose 
into the erythrocyte cannot be ruled out.
Therefore, the decrease in GHb found in v ivo  may be due to a 
combined effect of vitamin C. It may directly inhibit glycation by 
competition with glucose, but an indirect effect possibly on glucose 
metabolism or glucose transport into the erythrocyte also appears 
to occur. The decrease in glycated albumin may also be due to an 
effect of vitamin C on glucose tolerance as well as a direct effect 
on glycation by competition with glucose.
An unexpected finding was the increase in erythrocyte 2,3- 
d iphosphog lycera te  leve ls found to occur w ith v itam in  C 
supplementation. This would have the opposite effect on GHb levels 
as it is a known catalyst of glycation (Smith et al., 1982; Lowrey et 
al., 1985). It may be a contributory factor explaining why GHb levels 
did not decrease as much as the glycated albumin levels. However,
2,3-diphosphoglycerate may also catalyse the reaction of vitamin C 
as well as glucose with haemoglobin.
If vitamin C does react with proteins to produce a stable linkage, it 
may have deleterious effects similar to glucose. It has been shown 
in v itro  that ascorbic acid appears to react with lens crystallin 
proteins eventually producing extensive cross-linking analogous to 
glucose in non-enzymic glycation (Benesch et al., 1985; Ortwerth 
and Olesen, 1988). It has therefore been suggested that ascorbic 
acid is involved in the development of senile cataract. However, 
these in v itro  experim ents used very high concentrations of 
ascorb ic acid (20 - 100 mM) com pared to normal plasm a
concentrations, 40 - 90 pM and an in vivo experiment in which mice 
were fed a diet high in vitamin C for a year was found to have no 
effect (Benesch et al., 1985). However, further work is required to 
investigate the long-term effects of high doses of vitamin C, in v ivo  
on both short-lived and long-lived proteins.
If vitamin C can inhibit the glycation of proteins at levels unlikely 
to cause deleterious effects, it may be of use in the treatment of 
diabetics. Some of the chronic complications occurring in diabetes 
are thought to be due mainly to the further reactions of glycated 
proteins (Brownlee et al., 1984), therefore the adm inistration of 
vitamin C may be a simple way of slowing their progression, if 
glycation is also involved in the normal process of ageing (Cerami et 
al., 1987), long term vitamin C supplementation may even slow down 
this natural process.
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In conclusion, this study has shown that in normal subjects vitamin 
C can reduce the glycation of short-lived proteins such as albumin 
and haemoglobin in v iv o . Competition of vitamin C with glucose for 
reaction with protein amino groups does not appear to be the sole 
explanation for the inhibition effect. Further work is required to 
investigate the acute changes in glycaemia occurring following 
ingestion of vitamin C. Monitoring piasma and intra-erythrocyte 
glucose levels every hour for 6 - 12 hours after vitamin C intake 
might provide a more accurate indication of glucose tolerance than 
just the fasting glycaemia. The relative levels of AA, DHAA and DKG 
in the plasm a and erythrocyte  in normal subjects fo llow ing 
supplementation would also be useful to quantitate. The reaction of 
AA, DHAA and DKG with protein amino groups also needs to be 
studied to determine whether they bind irreversibly or reversibly. 
This may have important consequences on whether vitamin C could 
be used th e ra p e u tica lly  to de lay or p revent the chron ic  
complications occurring in diabetes.
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CHAPTER 6 
GENERAL DISCUSSION
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The main conclusion that can be drawn from the studies described in 
this thesis is that the location of a protein in v ivo  appears to have 
an important affect on the extent of its non-enzymatic modification 
by glucose (glycation).
A lthough the two proteins studied were both in the vascular 
compartment, albumin is free to circulate in the plasma whilst 
haemoglobin is confined to the erythrocyte. Chapter 3 showed that 
this difference in location resulted in albumin and haemoglobin 
being glycated to markedly different extents, s u c h . that in general 
only albumin was appropriately glycated in relation to the blood 
glucose level. In Chapter 4, changes in dietary fibre or carbohydrate 
in normal subjects resulted in changes in glycated albumin, with no 
apparent effect on GHb. This effect also appears to be a direct 
result of the different locations of albumin and haemoglobin in the 
blood. In Chapter 5, supplementation with oral vitamin C in normal 
subjects resulted in the inhibition of the glycation of both albumin 
and haemoglobin. However, albumin was inhibited to a much greater 
extent than haemoglobin, which appears to be at least in part due to 
the different concentrations of vitamin C reached in the plasma and 
erythrocytes during supplementation. In all of the studies the 
differences in the half-life of the two proteins did not explain their 
differences in glycation level.
As discussed in Chapter 1, the main factors affecting the glycation 
of proteins in v ivo  are the glucose concentrations to which it is 
exposed and its half-life (Bunn et al., 1976). As albumin and
haemoglobin are both present in the blood, it is assumed that they 
are exposed to the same basal and post-prandial concentrations of 
giucose. However, the results presented in Chapters 3 and 4 would 
suggest that not only is there sometimes a difference between the 
basal concentrations o f' glucose between the plasma and the 
erythrocyte, but also the total change in glucose concentration that 
occurs in the plasma following a glucose load is not mirrored in 
most cases, by the same change in glucose concentration in the 
erythrocyte. In general, the total change in erythrocyte glucose
concentration was substantially lower compared to that occurring in
the plasma. Not only is albumin in the plasma exposed to higher
concentrations and greater swings in glucose concentration than 
haemoglobin in the erythrocyte, but it is also more readily glycated 
than haemoglobin (Olufemi et al., 1987). Therefore, glycated 
albumin is likely to reflect changes in blood (plasma) glucose more
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accurately than GHb in the erythrocyte. The daiiy post-prandiai 
changes in plasma glucose concentration occurring in response to 
standard meals, in normal subjects are probably not as great as 
those occurring fo llow ing an un-physio !og ica l g lucose load. 
However, because albumin is more reactive, even small changes in 
the blood glucose concentration will be reflected by changes in 
glycated albumin. GHb on the other hand, may be unchanged because 
small changes, in plasma glucose may not be mirrored by similar 
changes in erythrocyte glucose and because haemoglobin is less 
reactive. These differences would account for the results presented 
in Chapter 4, where changes in dietary carbohydrate or fibre 
resulted in marked changes in glycated albumin whilst having no 
significant effect on GHb.
This d iffe re nce  betw een p lasm a and e ry th rocy te  g lucose 
concentrations is discussed in Chapter 3. it may be partly due to the 
rate of transport of glucose into the erythrocyte, which is affected 
by pH-dependent carriers in the membrane and also by metabolism of 
glucose inside the erythrocyte.
Although albumin and haemoglobin have markedly different half- 
lives and therefore reflect d ifferent periods of glycaemia, all the 
subjects studied in this thesis were non-diabetics. Therefore, day 
to day and week to week fluctuations in blood glucose levels 
comparable to those that occur particularly in IDD subjects are 
unlikely. Therefore, in normal subjects albumin and haemoglobin 
should in theory be exposed to consistent, relatively small daily 
changes in blood glucose levels.
If these d iffe rences between erythrocyte and plasma glucose 
concentrations also occurred in diabetic subjects, it might explain 
why GHb tends to correlate most strongly with fasting biood glucose 
levels (Dunn et al., 1979; Dods et al., 1979) and glycated albumin 
with mean blood glucose levels (ambient) (Dolhofer and Wieland, 
1980; Ziel and Davidson, 1987). In diabetics, particularly IDD 
sub jec ts  w here  the rapid  flu c tu a tio n s  in b lood g lucose  
concentrations result in random or fasting blood glucose levels 
being of little use in their management and a poor reflection of mean 
blood glucose levels, glycated albumin should be a much better 
indicator of short-term changes in blood glucose levels than GHb. 
Further work needs to be carried out to investigate how plasma and 
erythrocyte glucose concentrations change in response to glucose 
loads in diabetic subjects.
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In Chapter 4, despite the subjects being on the different diets for 6 
weeks, no changes in GHb occurred. However, glycated albumin 
increased significantly on the high glucose/low soluble fibre diet 
and decreased significantly on the high soluble fibre/low glucose 
diet. As no changes in fasting or post-load blood glucose levels 
were apparent, it was concluded that the changes in glycated 
albumin were probably the result of small changes in post-prandial 
glucose levels during each dietary period. The lack of alteration of 
GHb would suggest that haemoglobin in the erythrocyte was not 
exposed to comparable changes in glucose concentration. These 
results again suggest that glycated albumin might be a more 
accurate monitor of daily changes in blood glucose.
It was apparent in Chapter 3 that factors other than the glucose 
concentration and the half-iife of the protein may influence the 
g lycation of proteins. The erythrocyte 2,3-d iphosphoglycerate 
concentration was found to be significantly . greater in the high 
com pared to the low glycators and may account for the 
inappropriately high GHb levels in these subjects in. relation to both 
their plasma and intra-erythrocyte glucose concentrations. 2,3- 
D iphosphogiycerate has been shown to be a potent catalyst of 
glycation in v itro  (Smith et al., 1982; Lowrey et al., 1985), but the 
mechanism for the comparatively raised levels in the high glycators 
was unclear. There was no evidence for metabolic changes such as 
hypoxia to account for the raised levels of 2,3-diphosphoglycerate, 
but genetic factors have been suggested to play a role in determining 
the erythrocyte 2,3-diphosphoglycerate level (Brewer et al., 1970) 
in v ivo  and thus may be the cause of the relatively high levels in 
these subjects.
This independent effect of 2,3-diphosphoglycerate on the glycation 
of haemoglobin may have important implications in the use of GHb as 
a reliable and accurate monitor of blood glucose control in diabetic 
subjects. It may explain why GHb does not always correlate very 
well with glycated albumin (Guthrow et al., 1979; Kennedy et a t, 
1981; Yatscoff et al., 1984; Ross et al., 1986) in diabetic subjects.
In all three studies described in th is thesis, the plasm a 
fructosamine concentration showed a poor correlation with other 
glycated protein levels and with blood glucose levels, whether 
fasting, in response to glucose l o a d  or calculated from daily blood 
glucose profiles. In Chapter 3 fructosamine correlated weakly with 
glycated albumin, but whilst the latter showed a good relationship 
with blood glucose levels (especially ambient blood glucose levels), 
fructosam ine showed no relationship with any of the glycaemic
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parameters measured. In Chapter 4, despite significant changes in 
glycated albumin during each diet, no s ign ificant changes in 
fructosamine occurred. In Chapter 5, supplementation with vitamin 
C resulted in both s ign ificantly reduced glycated albumin and 
glycated haem oglobin, w h ils t having little  or no e ffect on 
fruc tosam ine .
These findings may be partly due to the fact that only non-diabetics 
were studied. The narrow reference range for both fructosamine and 
blood glucose levels in non-diabetic subjects may partly account for 
their poor correlation. However, the fructosamine assay has been 
shown not to be specific for glycated proteins. Schleicher et 
a l.(1988) found that at least 50% of the fructosamine activity was 
ascribable to non-specific reducing components. The nature of the 
other 50% is unclear but does not appear to be albumin associated 
and differs from patient to patient (Howey et al., 1987). Fluckiger 
et al., (1987) showed that there was v a s t ' intra-individual variation 
in fructosam ine concentration that was not accounted for by 
correction for protein concentration, suggesting that other factors 
must be responsible for this variability. It is likely that there is a 
g re a te r co n trib u tio n  of these u n iden tified  fac to rs  to the 
fructosamine concentration measured in non-diabetic subjects, such 
that they are able to mask the effect of small changes in blood 
glucose or other factors (e.g. vitamin C) on glycation. This may 
account for the lack of change in fructosamine during the diet study 
and the sm all change in fruc tosam ine  during  v itam in C 
supplementation. .A longitudinal study was recently carried out by 
Suhonen et al., (1989) in pregnant IDD diabetic subjects comparing 
the relative merits of using different glycated proteins to monitor 
blood glucose levels (measured every fortn ight for two months). 
They showed that whilst GHb, glycated total proteins and glycated 
albumin correlated significantly with ambient blood glucose levels, 
no correlation was found between fructosamine and ambient blood 
glucose levels. Also, whilst the changes in GHb, glycated total 
proteins and glycated albumin paralleled each other, the changes in 
fructosam ine were much smaller and were often opposite to the 
changes in the other assays. These findings support those found 
with fructosamine measurement in the non-diabetics studied in this 
thesis, which suggest that the measurement of a specific glycated 
protein is a more accurate indicator of blood glucose levels than is 
the measurement of fructosamine.
In Chapter 3 there were also two low glycators who not only had 
inappropriately low GHb levels, but who also had inappropriately low 
glycated albumin levels. This was explained by the presence of
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therapeutic levels of thyroxine and valium in one of the subjects and 
naproxen in the other subject. These therapeutic drugs are all known 
to bind to albumin (Peters, 1985) and are therefore able to compete 
w ith g lucose for b ind ing, reducing g lycation  if com parable 
concentrations are reached. Many therapeutic drugs bind to albumin 
in v iv o . Some of these are tightly but reversibly bound by 
hydrophobic or ionic interactions (such as thyroxine, diazepam), 
whilst others interact irreversibly by forming a covalent bond (such 
as aspirin, penicillin and possibly naproxen) (Peters, 1985). Further 
work is required to investigate the effect of drugs on the glycation 
of albumin in vitro and in v iv o . The effect of drugs on the glycation 
of haemoglobin will depend on whether they are able to cross the 
erythrocyte membrane and also on whether the binding to albumin is 
specific. Also, some drugs are rapidly metabolised in the liver and 
blood to compounds which either are no longer able to cross the 
erythrocyte membrane or no longer react with protein amino groups. 
For example, aspirin (acety Isal icy lie acid) is rapidly metabolised to 
salicylic acid which no longer reacts with proteins. The glycation of 
haemoglobin has been shown to be far less susceptible to inhibition 
by aspirin than albumin (Rendell et al., 1986). This is because the 
conversion to salicylic acid occurs during its transport across the 
erythrocyte membrane, such that haemoglobin is exposed to much 
lower concentrations of acetylsal icy lie acid than albumin in the 
plasma. As the major site of glycation on haemoglobin is the amino 
terminus of the [3-chains, it will probably be less affected by drugs 
which mainly bind to e-amino groups. It is likely that naproxen, 
diazepam and thyroxine are able to cross the erythrocyte membrane 
and may have contributed to the inappropriate ly low glycated 
haemoglobin in the low glycators. A better knowledge of drug 
interference is therefore needed for the correct interpretation of 
glycated protein results.
Although drugs may affect the glycation of proteins, it is less likely 
that the fructosamine measurement will be affected by drugs, as it 
appears to be less sensitive to small changes in glycation than the 
measurement of specific glycated proteins.
The fact that GHb and glycated albumin do not always reflect mean 
blood glucose levels accurately, due to other factors influencing the 
glycation process, suggests that the glycation of other proteins 
particularly those that are intracellular may not occur at the same 
level as those in the blood. The glycation of these proteins may be 
dependent not only on the extracellu lar or in tracellu lar glucose 
concen tra tion  (which w ill gene ra lly  d iffe r to the g lucose
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concentration in the blood), but also on the presence of other factors 
influencing the glycation process.
The identification of this locational difference in the individual 
level of g lycation of proteins may be im portant in helping to 
determine the rate of development of the complications occurring in 
diabetes in tissues such as the eye and the kidney.
The results in Chapter 5 showed that supplementation with oral 
vitam in C resulted in a plasm a and erythrocyte  vitam in C 
concentrations which reduced the glycation of both albumin and 
haem oglobin. V itam in C concentra tions in the plasm a and 
erythrocyte are known to be one of the lowest compared to other 
cells and organs of the body (Jaffe, 1984). Therefore, the effect of 
vitamin C on glycation may be more profound with other proteins 
located extravasculariy. There is also the possibility that vitamin C 
may react further with proteins to produce complex, cross-linked 
compounds sim ilar to the AGE-products that occur with glucose 
(Brownlee et al., 1984; Pongor et al., 1984). However, at present the 
evidence for these vitam in C/protein cross-linked products has 
come from in v itro  experiments using very high concentrations of 
vitamin C (Benesch et al., 1985; Ortwerth and Oiesen, 1988). Further 
work needs to be carried out to investigate the reaction of vitamin C 
and proteins both in v itro  and in v iv o  (in normal and diabetic 
subjects). Furth and Harding (1989) have recently reviewed 
g lyca tion  and post-am adori product fo rm a tion , p a rticu la rly  
substances that may be used to block either the initial glycation 
process or the formation of the AGE-products. They discuss the use 
of vitamin C in its anti-oxidant capacity to act as an anti-glycation 
agent. However, this is assuming that the damage to proteins occurs 
through free radicles which are produced from the reaction of 
glucose and oxygen and not by the glycation of proteins.
in conclusion, the m easurement of a specific glycated protein 
provides a more accurate indication of blood glucose control than 
the m easurem ent of fructosam ine concentration, with glycated 
albumin probably being a more reliable indicator of blood glucose 
control than GHb. More work is required to assess the validity of 
using glycated albumin as a general indicator of the level of protein 
glycation throughout the body. Vitamin C was shown to reduce the 
glycation of albumin and haemoglobin in v ivo , but again more work is 
needed to determine whether it should be used therapeutically in 
diabetic subjects to delay the. onset of complications.
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